1 | WELCOME TO THE WHO VACCINE TRIAL TRACKER | |||||||
|---|---|---|---|---|---|---|---|---|
2 | ||||||||
3 | For an overview of the vaccine pipeline, please see the WHO Global R&D Observatory at http://www.who.int/research-observatory/monitoring/processes/health_products/en/ | |||||||
4 | ||||||||
5 | The following pages provide publically available information on vaccine clinical trials since 2007. The sources on information for these trials are clinicaltrials.gov and who.int/ictrp, which includes clinical trial registries from 17 countries. | |||||||
6 | Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. | |||||||
7 | ||||||||
8 | If you have any questions or corrections to the WHO vaccine trial tracker, please contact us at moorthyv@who.int | |||||||
9 | ||||||||
10 | We make an effort to update the trial list and results reporting on a regular basis. Below please find the most recent updates for each page: | |||||||
11 | ||||||||
12 | Pathogen | Month of most recent update | Updating Partner | Further Information | ||||
13 | HIV | May 2018 | HVTN, IAVI | |||||
14 | Malaria | May 2018 | Schwartz Consulting | |||||
15 | TB | May 2018 | Aeras | |||||
16 | Dengue | May 2018 | WHO Secretariat | |||||
17 | RSV | May 2018 | PATH | |||||
18 | Rotavirus | May 2018 | PATH | |||||
19 | Shigella and ETEC | May 2018 | PATH | |||||
20 | Zika | January 2019 | WHO Secretariat | |||||
21 | Lassa, MERS-CoV, Nipah | May 2018 | CEPI | http://cepi.net/pipeline-dataset | ||||
22 | Ebola/Marburg | May 2018 | Oxford | |||||
23 | Pneumococcal infections | May 2018 | MSF Epicentre | |||||
24 | ||||||||
25 | FREQUENTLY ASKED QUESTIONS | |||||||
26 | What qualifies as results reporting? | |||||||
27 | The results made publicaly available should be of sufficient detail for the reader to understand the trial design, participants characteristics and flow, and primary and secondary endpoint results to an approximate level of detail that meets results submitted to a clinical trial registry. | |||||||
28 | A conference abstract or press release, for example, are unlikely to provide sufficient information to assess the quality and results of a trial. | |||||||
29 | The results must also be available for future consumption; thus, an oral presentation would not be considered making results available. |
1 | Disease & Pathogen | Vaccine Candidate | Publication Information | Other | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||
3 | HIV-1 | HIV | DNA multiclade + rAd5 multiclade | Active candidate / in development | Recombinant viral vector; Other: DNA | Conjugate | None | NCT00955006 | Completed | DAIDS | Government | Phase 2b | 9/1/2011 | 11/21/2017 | Adult | 17 | US | Results not yet reported | HVTN 076 | ||||||||||||||
4 | HIV-1 | HIV | rAd35 clade A + rAd5 clade A + rAd clade B | Active candidate / in development | Recombinant viral vector | Conjugate | env; rAd | None | NCT01095224 | Completed | DAIDS | Government | Phase 1 | 10/1/2010 | 4/4/2017 | Adult | 180 | US | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 15/02/16 | http://www.ncbi.nlm.nih.gov/pubmed/26475930 | clinicaltrials.gov | HVTN 083 | |||||||||
5 | HIV-1 | HIV | rAd5 multiclade + rAd5 clade B | Active candidate / in development | Recombinant viral vector | Conjugate | gag-pol, env gag-pol; rAd5 | None | NCT01159990 | Completed | DAIDS | Government | Phase 1b | 3/1/2011 | 5/30/2017 | Adult | 100 | US, Brazil, Peru, Switzerland | Results not yet reported | HVTN 084 | |||||||||||||
6 | HIV-1 | HIV | gp145 | Active candidate / in development | Subunit from target organism | Protein | Env | Aluminum salts (alum) | Not registered | Not yet recruiting | DAIDS | Government | Phase 1 | 11/1/2017 | Adult | 24 | US | Results not yet reported | HVTN 122 | ||||||||||||||
7 | HIV-1 | HIV | DNA clade B + rVSVIN clade B | Active candidate / in development | Recombinant viral vector DNA | Protein | None | NCT01578889 | Completed | DAIDS/NIAID/NIH | Government | Phase 1 | 5/1/2012 | 9/5/2016 | Adult | 100 | US | Results not yet reported | HVTN 087 | ||||||||||||||
8 | HIV-1 | HIV | AIDSVAX® B/E + DNA clade C +NYVAC clade C | Active candidate / registered | Subunit from target organism; DNA; Recombinant viral vector | Protein | Aluminum salts (alum) | NCT01799954 | Completed | EuroVacc Foundation | Other: non-profit | Phase 1 | 8/1/2012 | 7/5/2018 | Adult | 96 | Switzerland | Results not yet reported | HVTN 096 | ||||||||||||||
9 | HIV-1 | HIV | Env (A, B, C, E)/Gag DNA plasmids + Recombinant gp120 (A, B, C, E) protein | Active candidate / in development | Other: DNA Subunit from target organism | Other | GLA-SE | Not registered | Not yet recruiting | DAIDS | Government | Phase 1 | 12/1/2017 | Adult | 60 | US | Results not yet reported | HVTN 124 | |||||||||||||||
10 | HIV-1 | HIV | ALVAC-HIV (vCP 2438) + Bivalent Subtype C gp120 with MF59 (2 schedules) | Active candidate / in development | Recombinant protein from target organism; Recombinant viral vector with genes from target organism | Protein | ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env and 1086.C gp120 Env | Licensed other | alum or MF59 | NCT03284710 | Recruiting | DAIDS | Government | Phase 1/2a | 3/1/2017 | 5/1/2019 | Adult | 132 | Mozambique, South Africa, Zimbabwe | Results not yet reported | HVTN 107 | ||||||||||||
11 | HIV-1 | HIV | VRC01 mAb | Active candidate / in development | Other: monoclonal antibody | Protein | VRC01 mAb | None | NCT02165267 | Completed | DAIDS/NIAID/NIH | Government | Phase 1 | 9/1/2014 | 3/5/2016 | Adult | 88 | US | Results not yet reported | HVTN 104 | |||||||||||||
12 | HIV-1 | HIV | DNA clade C + AIDSVAX® B/E (Subtypes B, E gp120) | Active candidate / registered | Other | NCT02207920 | Completed | DAIDS | Government | Phase 1b | 7/1/2014 | Adult | 104 | US | Results not yet reported | HVTN 105 | |||||||||||||||||
13 | HIV-1 | HIV | p24CE 1/2 DNA + p55 Gag DNA | Active candidate / in development | Other: DNA | Other | DNA | Novel other | IL-12 DNA | NCT03181789 | Not yet recruiting | DAIDS | Government | Phase 1 | 10/1/2017 | 9/1/2019 | Adult | 56 | US | Results not yet reported | HVTN 119 | ||||||||||||
14 | HIV-1 | HIV | DNA Clade C + Bivalent Subtype C gp120/MF59 | Active candidate / in development | Subunit from target organism; Other: DNA | Other | Licensed other | MF59 | NCT02997969 | Ongoing | DAIDS | Government | Phase 1 | 6/1/2016 | 7/1/2018 | Adult | 132 | South Africa, Zambia, Tanzania | Results not yet reported | HVTN 111 | |||||||||||||
15 | HIV-1 | HIV | ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 | Active candidate / in development | Recombinant protein from target organism; Recombinant viral vector with genes from target organism | Protein | ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env and 1086.C gp120 Env | Licensed other | MF59 | NCT02968849 | Recruiting | DAIDS | Government | Phase 2b/3 | 10/1/2016 | 8/24/2021 | Adult | 5400 | South Africa | Results not yet reported | HVTN 702 | ||||||||||||
16 | HIV-1 | HIV | DNA Clade C + Bivalent Subtype C gp120/MF59 + Bivalent Subtype C gp120/AS01B | Active candidate / in development | Other: DNA; Subunit from target organism | Other | Licensed other | MF59 | NCT02915016 | Recruiting | DAIDS | Government | Phase 1/2a | 12/1/2016 | 10/1/2019 | Adult | 334 | US, South Africa | Results not yet reported | HVTN 108 | |||||||||||||
17 | HIV-1 | HIV | AIDSVAX® B/E + MVA/HIV62B | Active candidate / registered | Subunit from target organism; Recombinant viral vector | Protein | Aluminum salts (alum) | NCT02852005 | Recruiting | DAIDS | Government | Phase 1 | 1/1/2017 | 7/31/2019 | Adult | 30 | Peru, US | Results not yet reported | HVTN 114 | ||||||||||||||
18 | HIV-1 | HIV | VRC01 mAb + VRC01LS mAb | Active candidate / in development | Other: Monoclonal antiodies | Protein | VRC01, VRC01LS monoclonal antibodies | None | NCT02797171 | Recruiting | DAIDS | Government | Phase 1 | 3/1/2017 | 9/30/2019 | Adult | 101 | US, South Africa | Results not yet reported | HVTN 116 | |||||||||||||
19 | HIV-1 | HIV-1 | Ad26.Mos.HIV Trivalent; Ad26.Mos4.HIV; gp140 DP | Active candidate / in development | Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Protein gp140 C | None | None | NCT02788045 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 1 | 7/1/2016 | 12/1/2017 | 2018-05-01 | Adult | 198 | United States of America | Rwanda | Results not yet reported | CR108152 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
20 | HIV-1 | HIV | Ad4 + AIDSVAX® B/E + Substypes B, E, gp120 | Active candidate / registered | Recombinant viral vector; Subunit from target organism | Conjugate | Aluminum salts (alum) | NCT02771730 | Active, not recruiting | PaxVax | Industry | Phase 1 | 3/1/2015 | 2/25/2017 | Adult | 60 | US | Results not yet reported | HVTN 110 | ||||||||||||||
21 | HIV-1 | HIV-1 | FLSC-001 | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Env B | None | None | NCT02756208 | Open, recruiting | University of Maryland | Academic | Phase 1 | 11/1/2015 | 7/1/2017 | 2017-09-01 | Adult | 60 | United States of America | Results not yet reported | FLSC IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
22 | HIV-1 | HIV | VRC01 mAb | Active candidate / in development | Other: Monoclonal antibody | Protein | VRC01 mAb | None | NCT02716675 | Recruiting | DAIDS | Government | Phase 2b | 4/16/2016 | 7/1/2020 | Adult | 2700 | Brazil, Peru, US, Switzerland | Results not yet reported | HVTN 704/HPTN 085 | |||||||||||||
23 | HIV-1 | HIV-1 | Ad26.Mos.HIV Trivalent; gp140 DP | Active candidate / in development | Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Clade C gp140 | None | None | NCT02685020 | Completed | Janssen Vaccines & Prevention B.V. | Industry | Phase 1 | 3/1/2016 | 1/1/2018 | 1/1/2018 | Adult | 36 | US | Results not yet reported | IPCAVD010 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
24 | HIV-1 | HIV | HIV nef/tat/vif, env DNA + VSV envC | Active candidate / in development | Other: DNA; Recombinant viral vector | Other | None | NCT02654080 | Active, not recruiting | DAIDS | Government | Phase 1 | 4/16/2016 | 5/20/2019 | Adult | 14 | US | Results not yet reported | HVTN 112 | ||||||||||||||
25 | HIV-1 | HIV-1 | DNA-C CN54ENV; CN54gp140 | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | DNA Env C, Subunit Env C | None | None | NCT02589795 | Completed | Imperial College London | Academic | Phase 1 | 11/1/2015 | 7/1/2017 | 2017-12-01 | Adult | 24 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | CUTHIVAC002 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
26 | HIV-1 | HIV | VRC01 mAb | Active candidate / in development | Other: Monoclonal antibody | Protein | VRC01 mAb | None | NCT02568215 | Recruiting | DAIDS | Government | Phase 2b | 5/16/2016 | 6/1/2020 | Adult | 1500 | Botswana, South Africa, Zimbabwe, Kenya, Malawi, Mozambique,Tanzania | Results not yet reported | HVTN 703/HPTN 081 | |||||||||||||
27 | HIV-1 | HIV | PENNVAX-GP | Active candidate / in development | Other: DNA | Other | DNA | Novel other | IL-12 DNA | NCT02431767 | Completed | DAIDS | Government | Phase 1 | 9/1/2015 | 1/1/2018 | Adult | 94 | US | Results not yet reported | HVTN 098 | ||||||||||||
28 | HIV-1 | HIV-1 | PENNVAX-G DNA MVA CRF01_AE | Active candidate / in development | Recombinant viral vector DNA | Protein: specify | Env, gag-pol | Novel other: specify | Novel other: IL-15 DNA Plasmid for PENNVAX; None for MVA Boost | NCT01260727 | Completed | NIAID | Government | Phase 1 | 8/1/2014 | 2/1/2016 | 2016-02-01 | Adult | 88 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 9/2/2017 | 28968759 | RV 262 - HVTN | Indication: Prevention (active) infection/transmission | |||||||
29 | HIV-1 | HIV-1 | ALVAC-HIV (vCP1521) AIDSVAX® B/E | Active candidate / in development | Recombinant viral vector; Recombinant subunit (non VLP) | Protein: specify | Gag, protease, env | NCT01435135 | Completed | USAMRMC | Government | Phase 1 | 8/1/2015 | 11/1/2017 | 2017-11-01 | Adult | 94 | United States of America | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2017-02-24 | 28235027 | RV 305 MHRP | Indication: "Prevention (active) infection/transmission" | |||||||||
30 | HIV-1 | HIV | ALVAC-HIV(vCP2438) + Bivalent Subtype C + gp120/MF59 | Active candidate / in development | Recombinant protein from target organism; Recombinant viral vector with genes from target organism | Protein | ZM96 gp120 env, TM of LAI gp41, LAI gag-pro; TV1.C gp120 Env and 1086.C gp120 Env | Licensed other | MF59 | NCT02404311 | Active, not recruiting | DAIDS | Government | Phase 1/2 | 2/1/2015 | 8/13/2018 | Adult | 252 | South Africa | Results not yet reported | HVTN 100 | ||||||||||||
31 | HIV-1 | HIV-1 | AIDSVAX® B/E | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Env | Novel other: specify | AIDSVAX B/E: Alhydrogel | NCT01933685 | Completed | USAMRMC | Government | Phase 2 | 7/1/2014 | 12/1/2016 | 2017-02-01 | Adult | 40 | Thailand | Results not yet reported | RV 328 HVTN | Indication: "Prevention (passive) infection/transmission" | ||||||||||
32 | HIV-1 | HIV-1 | AIDSVAX® B/E | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Env | Novel other: specify | AIDSVAX B/E: Alhydrogel | NCT02165267 | Completed | USAMRMC | Government | Phase 2 | 7/1/2014 | 12/1/2016 | 2017-02-01 | Adult | 40 | Thailand | Results not yet reported | RV 328 HVTN | Indication: "Prevention (passive) infection/transmission" | ||||||||||
33 | HIV-1 | HIV-1 | ChAdV63.HIVconsv ; MVA.HIVconsv; AdCh3NSmut1; MVA-Nsmut | Active candidate / in development | Recombinant viral vector | Protein: specify | ChimpAd63 consensus; MVA consensus; 3NSmut1; | None | None | NCT02362217 | Ongoing | University of Oxford | Academic | Phase 1 | 10/1/2014 | 8/1/2016 | 2017-10-01 | Adult | 33 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | PEACHI-04 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
34 | HIV-1 | HIV-1 | Ad26.EnvA-01 | Active candidate / in development | Recombinant viral vector | Protein: specify | Env A | None | None | NCT00618605 | Completed | NIAID | Government | Phase 1 | 2/1/2008 | 7/1/2011 | 2015-10-01 | Adult | 60 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-11-02 | 23125443 | Ad26.ENVA.01 IAVI | Indiation: "Prevention (active) infection/transmission" | |||||||
35 | HIV-1 | HIV-1 | VRC-HIVADV038-00-VP; VRC-HIVADV027-00-VP | Active candidate / in development | Recombinant viral vector | Protein: specify | Ad35 Env A; Ad5 Env A | None | None | NCT00479999 | Completed | NIAID | Government | Phase 1 | 2/1/2009 | 5/1/2014 | Adult | 35 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-11-15 | 27846256 | VRC 012 (07-I-0167) IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||
36 | HIV-1 | HIV-1 | Ad26.EnvA-01 | Active candidate / in development | Recombinant viral vector | Protein: specify | Env A | None | None | NCT01103687 | Completed | NIAID | Government | Phase 1 | 7/1/2010 | 9/1/2012 | Adult | 24 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-08-26 | 25165165 | Ad26.ENVA.01 Mucosal/IPCAVD003 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||
37 | HIV-1 | HIV-1 | Ad5HVR48.ENVA.01 | Active candidate / in development | Recombinant viral vector | Protein: specify | Env A | None | None | NCT00695877 | Completed | NIAID | Government | Phase 1 | 2/1/2009 | 12/1/2012 | Adult | 48 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-04-08 | 24719474 | Ad5HVR48.ENVA.01 IAVI | Indication: Prevention (active) infection/transmission | ||||||||
38 | HIV-1 | HIV-1 | MVA Mosaic | Active candidate / in development | Recombinant viral vector | Protein: specify | gag/pol/env mosaics | None | None | NCT02218125 | Completed | Crucell Holand BV | Industry | Phase 1 | 9/1/2014 | 11/1/2015 | 2015-11-01 | Adult | 25 | United States of America | Results not yet reported | CR100965, IPCAVD006, HIV-V-A002 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
39 | HIV-1 | HIV-1 | GTU®-multiHIV B clade | Active candidate / in development | Other: DNA | Protein: specify | Rev, Nef, Tat, p17, p24 , Pro, RT, Env B | None | None | NCT02075983 | Unknown | Imperial College London | Academic | Phase 1 | 6/1/2013 | 6/1/2015 | 2015-12-01 | Adult | 30 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | CRO2049 CUTHIVAC001 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
40 | HIV-1 | HIV-1 | Ad26.ENVA.01 MVA Mosaic 1 and 2 gp140 DP | Active candidate / in development | Recombinant viral vector | Protein: specify | gag, pol, env | Novel other: specify | Ad26.ENVA.01: None MVA: None gp140 DP: Alum | NCT02315703 | Ongoing | Crucell Holand BV | Industry | Phase 2 | 12/1/2014 | 5/1/2016 | 2019-09-01 | Adult | 395 | United States of America | Rwanda | South Africa | Thailand | Uganda | Results not yet reported | A004 (HVTN 100) HVTN | Indication: "Prevention (active) infection/transmission" | ||||||||||
41 | HIV-1 | HIV-1 | pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | MVA consensus; DNA consensus; Ad35 Gag, RT, Integ, Nef A | None | None | NCT02099994 | Completed | University of Oxford | Academic | Phase 2 | 3/1/2014 | 8/1/2015 | 2015-08-01 | Adult | 72 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 07/08/15 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529153/ | IAVI N004/ HIVCORE004 IAVI | Indication: "Prevention (active) infection/transmission" | |||||||
42 | HIV-1 | HIV-1 | DNA - CN54ENV and ZM96GPN; CN54gp140; MVA-C | Active candidate / in development | DNA; Recombinant viral vector; Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | DNA Gag, Pol, Nef C; MVA Gag, Pol, Nef C; Protein Enc C | Novel other: specify | GLA-AF | NCT01922284 | Completed | Imperial College London | Academic | Phase 1 | 6/1/2013 | 1/1/2014 | 2015-12-01 | Adult | 40 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-02-22 | 28275375 | UKHVCSpoke003 IAVI | Secondary ID: EUDRACT TC 2012-003277-26; indication "Prevention (active) infection/transmission" | |||||||
43 | HIV-1 | HIV-1 | LIPO-5; MVA-B; GTU-MultiHIV | Active candidate / in development | DNA; Recombinant virall vector; Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Gag, Nef, Pol B; MVA Nef, Gag, Pol B; DNA Rev, Nef, Tat, Pol, Env B | None | None | NCT02038842 | Completed | Inserm. ANRS | Government | Phase 2 | 3/1/2014 | 10/1/2015 | 2016-03-01 | Adult | 92 | France | Results not yet reported | VRI01 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
44 | HIV-1 | HIV | DNA Nat-B env + DNA Consensus-S env + Trivalent DNA mosaic env + MVA-CMDR | Active candidate / in development | Recombinant viral vector; DNA | Congugate | MVA, env, gag, pol | None | NCT02296541 | Active, not recruiting | DAIDS | Government | Phase 1 | 1/15/2015 | 9/8/2020 | Adult | 105 | US, Switzerland | Results not yet reported | HVTN 106 | |||||||||||||
45 | HIV-1 | HIV-1 | gp140 | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Env | Aluminum salts (alum) | Aluminum salts (alum) | NCT02304185 | Completed | Crucell Holand BV | Industry | Phase 1 | 12/1/2014 | 4/1/2016 | 2016-04-01 | Adult | 50 | United States of America | Results not yet reported | IPCAVD008 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
46 | HIV-1 | HIV-1 | CN54gp140 | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | Env C | Novel other: specify | GLA-AF | NCT01966900 | Completed | Imperial College London | Academic | Phase 1 | 10/1/2013 | 11/1/2015 | 2015-11-01 | Adult | 14 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 24/05/17 | https://www.frontiersin.org/articles/10.3389/fimmu.2017.00595/full | X001 IAVI | Indication: "Prevention (active) infection/transmission" | |||||||
47 | HIV-1 | HIV-1 | Ad4-EnvC150; Ad4-mgag | Active candidate / in development | Recombinant viral vector | Protein: specify | mosaic Env | None | None | NCT01989533 | Open, recruiting | NIAID | Government | Phase 1 | 10/30/2013 | 1/1/2019 | 2020-01-01 | Adult | 440 | United States of America | Results not yet reported | PXVX-HIV-100-001/HVTN 110 IAVI | Indication: "Prevention (active) infection/transmission" | ||||||||||
48 | HIV-1 | HIV-1 | rcAd26.MOS1.HIV-Env | Active candidate / in development | Recombinant viral vector | Protein: specify | mosaic Env | None | None | NCT02366013 | Completed | IAVI | Product Development Partner | Phase 1 | 1/1/2015 | 6/1/2016 | 6/1/2016 | Adult | 22 | United States of America | Results not yet reported | R001 IAVI | Indication: ""Prevention (active) infection/transmission" | ||||||||||
49 | HIV-1 | HIV-1 | AAV1-PG9 | Active candidate / in development | Other: Vectored Immunoprophylaxis | Other: specify | NA | None | None | NCT01937455 | Open, recruiting | IAVI | Product Development Partner | Phase 1 | 9/1/2014 | 10/1/2017 | 2017-10-01 | Adult | 24 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | IAVI A003 IAVI | Indication: "Prevention (passive) infection/transmission" | ||||||||||
50 | HIV-1 | HIV-1 | ALVAC-HIV (vCP1521) AIDSVAX® B/E | Active candidate / in development | Recombinant viral vector; Recombinant subunit (non VLP) | Protein: specify | Gag, protease, env | NCT01931358 | Open, not recruiting | USAMRMC | Government | Phase 2 | 9/1/2013 | 11/1/2016 | 2017-02-01 | Adult | 360 | Thailand | Results not yet reported | RV 306 MHRP | Indication: "Prevention (active) infection/transmission" | ||||||||||||
51 | HIV-1 | HIV | rAd5 multiclade | Active candidate / in development | Recombinant viral vector | Conjugate | gag-pol/env; rAd5 | None | NCT01479296 | Active, not recruiting | DAIDS | Government | Phase 1b | 2/1/2012 | 1/17/2018 | Adult | 90 | US | Results not yet reported | HVTN 085 | |||||||||||||
52 | HIV-1 | HIV-1 | DNA multiclade + rAd5 multiclade | Active candidate / in development | Recombinant viral vector Other: DNA | Conjugate | gag-pol, env; rAD5 | None | NCT00865566 | Active, not recruiting | DAIDS | Government | Phase 2b | 6/1/2009 | 4/8/2018 | Adult | 2504 | US | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | http://www.ncbi.nlm.nih.gov/pubmed/24099601 | HVTN 505 | |||||||||||
53 | HIV-1 | HIV-1 | Full-Length Single Chain (FLSC); DNA CON-S env | active candidate | DNA; Subunit from target | Protein: specify | Env gp120 clade B fused to the N terminus of the two outer domains of CD4 by a flexible polypeptide linker; DNA consensus env | NCT03505060 | Ongoing | NIAID | Government | Phase 1 | 7/1/2018 | 11/30/2018 | Adult | 24 | USA | Results not yet reported | HVTN 125 | ||||||||||||||
54 | HIV-1 | HIV-1 | Radiolabeled 3BNC117 | Active candidate / in development | Other: Monoclonal antibody | Protein | 3BNC117 | NCT03468582 | Ongoing | University of Lausanne Hospitals | Academic | Phase 1 | 2/8/2018 | 2/7/2019 | Adult | 5 | Switzerland | Results not yet reported | |||||||||||||||
55 | HIV-1 | HIV-1 | env (A,B,C,A/E)/gag (C) DNA Vaccine; gp120 (A,B,C,A/E) Protein Vaccine | Active candidate / in development | DNA; Subunit from target | Protein: specify | env (A,B,C,A/E)/gag (C) DNA Vaccine ; gp120 (A,B,C,A/E) Protein Vaccine | GLA-SE | NCT03409276 | Ongoing | NIAID | Government | Phase 1 | 3/16/2018 | 10/1/2020 | Adult | 60 | USA | Results not yet reported | HVTN 124 | |||||||||||||
56 | HIV-1 | HIV-1 | Ad4HIV | Active candidate / in development | Recombinant viral vector | Protein: specify | CN54gp140/MPLA Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant; Ad4-EnvCN54 Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54 | MLA | NCT03408262 | Ongoing | Imperial College London | Academic | Phase 1 | 10/6/2017 | 12/20/2018 | Adult | 60 | UK | Results not yet reported | ||||||||||||||
57 | HIV-1 | HIV-1 | DNA-HIV-PT123; AIDSVAX B/E | Active candidate / in development | DNA; Subunit from target | Protein: specify | DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein | Aluminum salts (alum) | NCT03391375 | Ongoing | EuroVacc Foundation, IAVI | Product Development Partner | Phase 1 | 3/15/2017 | 1/31/2018 | 2018-31-01 | Adult | 49 | Uganda | Results not yet reported | EV07 | ||||||||||||
58 | HIV-1 | HIV-1 | gp145 C.6980 | Active candidate / in development | Subunit from target | Protein: specify | Env gp145 C.6980 recombinant oligomeric gp145 clade C Env protein | NCT03382418 | Ongoing | NIAID | Government | Phase 1 | 12/27/2017 | 5/5/2019 | 5/15/2019 | Adult | 45 | USA | Results not yet reported | HVTN 122 | |||||||||||||
59 | HIV-1 | HIV-1 | AAV8-VRC07 | Active candidate / in development | Other: Monoclonal antibody | Protein: specify | VRC07 | NCT03374202 | Ongoing | NIAID, NIH) | Government | Phase 1 | 1/11/2018 | 3/1/2019 | Adult | 25 | USA | Results not yet reported | VRC 603 | ||||||||||||||
60 | HIV-1 | HIV-1 | 3BNC117-LS | Active candidate / in development | Other: Monoclonal antibody | Protein: specify | 3BNC117-LS antibody | NCT03254277 | Ongoing | Rockefeller University | Academic | Phase 1 | 8/1/2017 | 10/1/2019 | 10/31/2019 | Adult | 30 | USA | Results not yet reported | ||||||||||||||
61 | HIV-1 | HIV-1 | CH505 sequenced Envs ; DNA Mosaic-Tre Env | Active candidate / in development | DNA; Subunit from target | Protein: specify | CH505 sequenced Envs Clade C; DNA mosaic env | NCT03220724 | Ongoing | NIAID | Government | Phase 1 | 8/1/2017 | 12/1/2020 | 12/1/2020 | Adult | 132 | USA | Results not yet reported | HVTN 115 | |||||||||||||
62 | HIV-1 | HIV-1 | PGDM1400; PGT121 | Active candidate / in development | Other: Monoclonal antibody | Protein | PGDM1400 & PGT121 antibodies | NCT03205917 | Ongoing | IAVI | Product Development Partner | Phase 1 | 7/1/2017 | 7/1/2019 | 7/1/2019 | Adult | 60 | USA | Results not yet reported | IAVI T002 | |||||||||||||
63 | HIV-1 | HIV-1 | ALVAC-HIV (vCP2438); gp120 | Active candidate / in development | Recombinant viral vector; Subunit from target organism | Conjugate | 96ZM651 gp120 (clade C strain) linked to transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain); protein clade C TV1.C gp120 Env and clade C 1086.C gp120 Env with MF59 OR AS01 | MF59 | AS01 | NCT03122223 | Ongoing | NIAID, Sanofi Pasteur, GlaxoSmithKline | Government, Industry | Phase 1/2 | 6/1/2017 | 9/30/2019 | 9/30/2019 | Adult | 320 | South Africa; Tanzania; Zambia; Zimbabwe | Results not yet reported | HVTN 120 | |||||||||||
64 | HIV-1 | HIV-1 | Ad26.Mos4.HIV; gp140 C | Active candidate / in development | Recombinant viral vector; Subunit from target organism | Conjugate | Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Protein gp140 C | aluminum phoshpate | NCT03060629 | Ongoing | Janssen Vaccines & Prevention B.V. | Industry | Phase 2B | 9/1/2017 | 11/2/2020 | 2/1/2022 | Adult | 2600 | South Africa | Results not yet reported | HVTN 705 | ||||||||||||
65 | HIV-1 | HIV-1 | VRC-HIVMAB075-00-AB | Active candidate / in development | Other: Monoclonal antibody | Protein: specify | VRC07-523LS antibody | NCT03015181 | Ongoing | NIAID | Government | Phase 1 | 1/6/2017 | 5/5/2018 | 5/5/2018 | Adult | 26 | USA | Results not yet reported | VRC 605 | |||||||||||||
66 | HIV-1 | HIV-1 | PGT121 | Active candidate / in development | Other: Monoclonal antibody | Protein: specify | PGT 121 | NCT02960581 | Ongoing | IAVI | Product Development Partner | Phase 1 | 11/1/2016 | 3/1/2018 | 3/1/2018 | Adult | 63 | USA | Results not yet reported | IAVI T001 | |||||||||||||
67 | HIV-1 | HIV-1 | Mosaic gp140; Ad26.Mos4.HIV; gp140 C | Active candidate / in development | Recombinant viral vector; Subunit from target organism | Conjugate | Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Protein gp140 C; Mosaic gp140 | aluminum phosphate | NCT02935686 | Ongoing | Janssen, NIAID | Government, Industry | Phase 2 | 12/1/2016 | 12/26/2018 | 3/26/2019 | Adult | 155 | USA; Kenya; Rwanda | Results not yet reported | HVTN 118 | ||||||||||||
68 | HIV-1 | HIV-1 | University of London P2G12 | Active candidate / in development | Other: Monoclonal antibody | Protein: specify | P2G12 antibody | NCT02923999 | Ongoing | St George's, University of London | Academic | Phase 1 | 3/1/2018 | 6/1/2019 | 12/1/2019 | Adult | 18 | UK | Results not yet reported | ||||||||||||||
69 | HIV-1 | HIV-1 | SAAVI DNA-C2; SAAVI MVA-C; gp140 Sub C | Active candidate / in development | Other: DNA | Protein | gag, RT, tat, nef, env; Env | Licensed other | MF59 | NCT01418235 | Completed | DAIDS | Government | Phase 1 | 11/28/2011 | 10/29/2013 | 10/27/2018 | Adult | 184 | South Africa | Results not yet reported | HVTN 086/SAAVI 103 | |||||||||||
70 | HIV-1 | HIV-1 | VRC07-523LS | Active candidate / in development | Other: monoclonal antibody | Protein | None | NCT03387150 | Recruiting | DAIDS | Government | Phase 1 | 2/28/2018 | 7/31/2021 | 7/31/2021 | Adult | 124 | US, Switzerland | Results not yet reported | HVTN 127/HPTN 087 | |||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||||
3 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01B/AS02A | NCT00443131 | Completed | GSK | Industry | Phase 2 | 2007-03-01 | 2007-07-01 | 2007-07-01 | Adult | 36 | Belgium | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-06-24 | 25424924 | |||||||||||
4 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01 | NCT00866619 | Completed | GSK | Industry | Phase 3 | 2009-03-01 | 2011-03-01 | 2014-01-01 | Child | 15459 | Burkina Faso | Gabon | Ghana | Kenya | Malawi |Mozambique | United Republic of Tanzania | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-11-17 | 22007715 | |||||||||||
5 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01 | NCT01323972 | Completed | GSK | Industry | Phase 3 | 2011-05-01 | 2012-04-01 | 2012-04-01 | Child | 327 | Nigeria | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-11-12 | 25077418 | |||||||||||
6 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01 | NCT01148459 | Completed | GSK | Industry | Phase 3 | 2010-07-01 | 2013-05-01 | 2013-05-01 | Child | 200 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-07-07 | 27394191 | |||||||||||
7 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01E | NCT00436007 | Completed | GSK | Industry | Phase 2b | 2007-04-01 | 2009-10-01 | 2009-10-01 | Child | 511 | Gabon | Ghana | United Republic of Tanzania | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-02-13 | 25885325 | clinicaltrials.gov | 2012-12-19 | |||||||||
8 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01E | NCT01231503 | Completed | GSK | Industry | Phase 2 | 2011-01-01 | 2014-04-01 | 2014-12-01 | Child | 480 | Malawi | Results reported in registry | ||||||||||||||
9 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01E | NCT02699099 | Not yet open | GSK | Industry | Phase 3 | 2017-01-01 | 2017-08-01 | 2020-03-01 | Child | 700 | Ghana | Results not yet reported | ||||||||||||||
10 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01E | NCT03276962 | Open, recruiting | GSK | Industry | Phase 2 | 2017-09-28 | 2020-04-15 | 2022-11-25 | Child | 1500 | Ghana | Results not yet reported | ||||||||||||||
11 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01B/AS01E | NCT01857869 | Completed | GSK | Industry | Phase 2 | 2013-05-01 | 2014-03-01 | 2014-12-01 | Adult | 64 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-09-01 | 27296848 | |||||||||||
12 | Malaria | P. falciparum | RTS,S/AS01 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01B/AS01E | NCT02992119 | Not yet open | University of Oxford | Academic | Phase 2 | 2017-02-01 | 2018-03-01 | 2018-03-01 | Adult | 190 | Thailand | Results not yet reported | ||||||||||||||
13 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT00890019 | Completed | University of Oxford | Academic | Phase 1 | 2007-07-01 | 2011-08-01 | 2011-09-01 | Adult | 54 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-03-01 | 22275401 | ||||||||||||
14 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT00890760 | Completed | University of Oxford | Academic | Phase 2 | 2009-03-01 | 2010-02-01 | 2011-02-01 | Adult | 55 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-11-28 | 24284865 | ||||||||||||
15 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01142765 | Completed | University of Oxford | Academic | Phase 2 | 2010-06-01 | 2011-03-01 | 2011-03-01 | Adult | 52 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-10-23 | 23089736 | ||||||||||||
16 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01364883 | Completed | University of Oxford | Academic | Phase 1 | 2011-07-01 | 2013-07-01 | 2013-07-01 | Adult | 39 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | |||||||||||||||
17 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01379430 | Completed | University of Oxford | Academic | Phase 1 | 2010-06-01 | 2011-05-01 | 2011-05-01 | Adult | 30 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-03-19 | 23526949 | ||||||||||||
18 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01373879 | Completed | University of Oxford | Academic | Phase 1 | 2010-06-01 | 2011-12-01 | 2011-12-01 | Child | Adult | 52 | Gambia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-03-19 | 23526949 | ||||||||||||
19 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01450293 | Completed | University of Oxford | Academic | Phase 1 | 2011-10-01 | 2013-03-01 | 2013-03-01 | Child | 72 | Gambia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-08-24 | 27109630 | ||||||||||||
20 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT02083887 | Completed | University of Oxford | Academic | Phase 1 | 2014-02-01 | 2015-11-01 | 2015-11-01 | Child | 65 | Gambia | Results not yet reported | |||||||||||||||
21 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01666925 | Completed | University of Oxford | Academic | Phase 2b | 2012-03-01 | 2012-08-01 | 2012-08-01 | Adult | 120 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-05-06 | 25947165 | ||||||||||||
22 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01658696 | Completed | University of Oxford | Academic | Phase 2b | 2012-08-01 | 2013-02-01 | 2013-02-01 | Adult | 120 | Senegal | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-12-15 | 27978537 | ||||||||||||
23 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | None | NCT01635647 | Completed | University of Oxford | Academic | Phase 2b | 2012-11-01 | 2014-08-01 | 2014-09-01 | Child | 730 | Burkina Faso | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-08-24 | 27109630 | ||||||||||||
24 | Malaria | P. falciparum | ChAd63/MVA ME-TRAP | Active candidate / in development | Recombinant viral vector | Protein: specify | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | Novel other: specify | Matrix M™ | NCT01669512 | Completed | University of Oxford | Academic | Phase 1 | 2012-08-01 | 2014-12-01 | 2014-12-01 | Adult | 23 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-10-27 | 28941620 | |||||||||||
25 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT01441167 | Completed | Sanaria | Industry | Phase 1 | 2011-09-14 | 2013-06-05 | 2013-06-05 | Adult | 64 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-08-08 | 23929949 | ||||||||||||||
26 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02015091 | Completed | Sanaria | Industry | Phase 1 | 2013-12-12 | 2015-05-01 | 2016-09-08 | Adult | 40 | United States of America | Results not yet reported | |||||||||||||||||
27 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT01988636 | Completed | Sanaria | Industry | Phase 1 | 2013-10-29 | 2015-08-20 | 2015-08-20 | Adult | 450 | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-02-16 | 28216244 | ||||||||||||||
28 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02132299 | Completed | Sanaria | Industry | Phase 1 | 2014-04-01 | 2015-07-01 | 2015-08-01 | Adult | 67 | United Republic of Tanzania | Results not yet reported | |||||||||||||||||
29 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02215707 | Completed | Sanaria | Industry | Phase 1 | 2014-06-01 | 2015-04-01 | 2015-06-01 | Adult | 67 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-01-12 | 28097230 | ||||||||||||||
30 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02418962 | Completed | Sanaria | Industry | Phase 1 | 2015-03-01 | 2015-09-01 | 2016-02-01 | Adult | 33 | Equitorial Guinea | Results not yet reported | |||||||||||||||||
31 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02613520 | Completed | Sanaria | Industry | Phase 1 | 2015-12-01 | 2016-08-01 | 2017-03-01 | Child | Adult | 99 | United Republic of Tanzania | Results not yet reported | |||||||||||||||||
32 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02627456 | Open, not recruiting | Sanaria | Industry | Phase 1 | 2015-10-08 | 2017-07-31 | 2017-07-31 | Adult | 500 | Mali | Results not yet reported | |||||||||||||||||
33 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02601716 | Open, recruiting | Sanaria | Industry | Phase 2 | 2016-01-01 | 2017-03-01 | 2017-06-01 | Adult | 84 | United States of America | Results not yet reported | |||||||||||||||||
34 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02663700 | Open, recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2016-04-07 | 2017-04-01 | 2017-10-03 | Adult | 112 | Burkina Faso | Results not yet reported | |||||||||||||||||
35 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02687373 | Open, recruiting | Sanaria | Industry | Phase 2 | 2016-07-01 | 2017-12-01 | 2018-11-01 | Child | 572 | Kenya | Results not yet reported | |||||||||||||||||
36 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT02859350 | Open, recruiting | Sanaria | Industry | Phase 1 | 2016-11-01 | 2017-07-01 | 2017-08-01 | Child | Adult | 135 | Equatorial Guinea | Results not yet reported | |||||||||||||||||
37 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT03503058 | Not yet open | Sanaria | Industry | Phase 2 | 2018-08-01 | 2019-07-01 | 2020-01-01 | Adult | 420 | Indonesia | Results not yet reported | |||||||||||||||||
38 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT03510481 | Open, recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2018-05-09 | 2019-06-30 | 2019-06-30 | Adult | 700 | Mali | Results not yet reported | |||||||||||||||||
39 | Malaria | P. falciparum | PfSPZ Vaccine | Active candidate / in development | Inactivated whole target organism | None | NCT03420053 | Open, recruiting | Sanaria | Industry | Phase 1 | 2018-02-07 | 2018-05-30 | 2018-09-30 | Adult | 21 | Tanzania | ||||||||||||||||||
40 | Malaria | P. falciparum | PfCelTOS FMP012 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CelTOS (cell-traversal protein for ookinetes and sporozoites) | Novel other: specify | AS01B | NCT02174978 | Open, not recruiting | Office of the Surgeon General, Department of the Army, USAMRMC | Government | Phase 1 | 2014-08-01 | 2019-08-01 | 2019-09-01 | Adult | 36 | United States of America | Results not yet reported | ||||||||||||||
41 | Malaria | P. falciparum | PfCelTOS FMP012 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CelTOS (cell-traversal protein for ookinetes and sporozoites) | Novel other: specify | GLA-SE | NCT01540474 | Completed | Office of the Surgeon General, Department of the Army, USAMRMC | Government | Phase 1 | 2012-02-01 | 2012-10-01 | 2012-12-01 | Adult | 30 | United States of America | Results not yet reported | ||||||||||||||
42 | Malaria | P. falciparum | CSVAC | Active candidate / in development | Recombinant viral vector | Protein: specify | CS | None | NCT01450280 | Completed | University of Oxford | Academic | Phase 1 | 2011-12-01 | 2012-10-01 | 2012-10-01 | Adult | 24 | Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-12-18 | 25522180 | ||||||||||||
43 | Malaria | P. falciparum | R21 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP less- HepBsA | Novel other: specify | AS01B | NCT02600975 | Open, recruiting | University of Oxford | Academic | Phase 1 | 2015-11-01 | 2017-03-01 | 2017-03-01 | Adult | 20 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||
44 | Malaria | P. falciparum | R21 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP less- HepBsA | Novel other: specify | Matrix-M1 | NCT02572388 | Open, recruiting | University of Oxford | Academic | Phase 1 | 2015-09-01 | 2017-03-01 | 2017-03-01 | Adult | 24 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||
45 | Malaria | P. falciparum | R21 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP less- HepBsA | Novel other: specify | Matrix-M1 | NCT02925403 | Open, recruiting | University of Oxford | Academic | Phase 1 | 2016-08-01 | 2017-02-01 | 2017-05-01 | Adult | 24 | Burkina Faso | Results not yet reported | ||||||||||||||
46 | Malaria | P. falciparum | R21 with ME-TRAP combined | Active candidate / in development | Recombinant viral vector | Protein: specify | 2 components: adjuv R21 + ChAd-MVA vectored ME-TRAP | Novel other: specify | Matrix-M1 | NCT02905019 | Open, recruiting | University of Oxford | Academic | Phase 2 | 2016-08-01 | 2017-03-01 | 2017-10-01 | Adult | 48 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||
47 | Malaria | P. falciparum | GMZ2 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | GLURP, MSP3 | Novel other: specify | Aluminium hydroxide, GLA-SE | Unknown | AMANET | Product Development Partner | Phase 1 | 2007-06-01 | 2008-07-01 | 2008-08-01 | Adult | 40 | Gabon | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2010-09-24 | 20696154 | ||||||||||||
48 | Malaria | P. falciparum | GMZ2 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | GLURP, MSP3 | Novel other: specify | Aluminium hydroxide, GLA-SE | Completed | Statens Serum Institut | Government | Phase 2b | 2010-11-01 | 2014-03-30 | 2014-03-30 | Child | 1840 | Gabon | Uganda | Burkina Faso | Ghana | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-07-28 | 27477844 | ||||||||||||
49 | Malaria | P. falciparum | GMZ2 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | GLURP, MSP3 | Novel other: specify | Aluminium hydroxide, GLA-SE | NCT00703066 | Unknown | AMANET | Product Development Partner | Phase 1 | 2008-06-01 | 2009-07-01 | 2009-08-01 | Child | 30 | Gabon | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-07-28 | 21829466 | |||||||||||
50 | Malaria | P. falciparum | pfAMA1-DiCo | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | AMA1-DiCo | Novel other: specify | Aluminium hydroxide, GLA-SE | NCT02014727 | Completed | Inserm | Government | Phase 1 | 2014-01-06 | 2015-03-01 | 2015-07-27 | Adult | 66 | France | Burkina Faso | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-10-27 | 28947345 | |||||||||||
51 | Malaria | P. falciparum | P27A | Active candidate / in development | Other: synthetic peptide | Protein: specify | P27A | Novel other: specify | Aluminium hydroxide, GLA-SE | NCT01949909 | Completed | Centre Hospitalier Universitaire Vaudois (CHUV) | Academic | Phase 1 | 2014-03-05 | 2015-07-01 | 2015-07-17 | Adult | 56 | Switzerland | Tanzania | Results not yet reported | Abstract / Poster / Conference proceedings | 2016-11-07 | Eight EDCTP Forum | |||||||||||
52 | Malaria | P. falciparum | MSP3 [181-276] field | Active candidate / in development | Other: synthetic peptide | Protein: specify | MSP3 | Aluminum salts (alum) | NCT00452088 | Completed | European Vaccine Initiative | Product Development Partner | Phase 1 | 2007-04-01 | 2008-05-01 | 2008-05-01 | Child | 45 | Burkina Faso | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2009-10-26 | 19855847 | ||||||||||||
53 | Malaria | P. falciparum | MSP3 [181-276] field | Active candidate / in development | Other: synthetic peptide | Protein: specify | MSP3 | Aluminum salts (alum) | NCT00469651 | Completed | AMANET | Product Development Partner | Phase 1 | 2007-10-01 | 2008-08-01 | 2008-08-01 | Child | 45 | United Republic of Tanzania | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2009-07-17 | 19607731 | ||||||||||||
54 | Malaria | P. falciparum | MSP3 [181-276] field | Active candidate / in development | Other: synthetic peptide | Protein: specify | MSP3 | Aluminum salts (alum) | NCT00652275 | Completed | AMANET | Product Development Partner | Phase 2b | 2008-05-01 | 2010-11-01 | 2010-12-01 | Child | 378 | Mali | Results not yet reported | |||||||||||||||
55 | Malaria | P. falciparum | SE36 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | N-terminal domain of serine repeat antigen (SERA5) | Aluminum salts (alum) | Completed | Research Foundation for Microbial Diseases of Osaka University, Japan | Academic | Phase 1 | 2009-09-22 | 2010-04-21 | 2010-04-21 | Child | Adult | 140 | Uganda | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-05-28 | 23724021 | |||||||||||||
56 | Malaria | P. falciparum | SE36 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | N-terminal domain of serine repeat antigen (SERA5) | Aluminum salts (alum) | Aluminum hydroxide gel | Completed | Nobelpharma Co Ltd, Japan | Industry | Phase 1 | 2015-06-24 | 2017-02-03 | 2017-02-08 | Child | 108 | Burkina Faso | Results not yet reported | Abstract / Poster / Conference proceedings | 2016-11-07 | Eight EDCTP Forum | ||||||||||||
57 | Malaria | P. falciparum | PfPEBS | Active candidate / in development | Other: synthetic protein | Protein: specify | PfPEBS | Novel other: specify | Aluminium hydroxide, GLA-SE | NCT01605786 | Unknown | Vac4All | Industry | Phase 2 | 2012-05-01 | 2013-05-01 | 2013-08-01 | Adult | 36 | Switzerland | Results not yet reported | ||||||||||||||
58 | Malaria | P. falciparum | ChAd63 RH5 +/- MVA RH5 | Active candidate / in development | Recombinant viral vector | Protein: specify | RH5 | None | NCT02181088 | Completed | University of Oxford | Academic | Phase 1 | 2014-08-01 | 2015-10-01 | 2015-10-01 | Adult | 26 | United Kingdom of Great Britain and Northern Ireland | Interim results reported | Abstract / Poster / Conference proceedings | 2016-11-13 | ASTMH Abstract | ||||||||||||
59 | Malaria | P. falciparum | ChAd63 RH5 +/- MVA RH5 | Active candidate / in development | Recombinant viral vector | Protein: specify | RH5 | None | NCT03435874 | Not yet open | University of Oxford | Academic | Phase 1 | 2018-02-19 | 2019-08-07 | 2020-08-07 | Child | Adult | 63 | Tanzania | Interim results reported | |||||||||||||||
60 | Malaria | P. falciparum | PRIMVAC | Active candidate / in development | Protein: specify | VAR2CSA fragment | Novel other: specify | Alhydrogel and GLA-SE | NCT02658253 | Open, recruiting | Inserm | Government | Phase 1 | 2016-05-09 | 2018-06-30 | 2019-03-31 | Adult | 68 | France | Burkina Faso | Results not yet reported | |||||||||||||||
61 | Malaria | P. falciparum | PAMVAC | Active candidate / in development | Protein: specify | VAR2CSA fragment | Novel other: specify | Alhydrogel, GLA-SE, GLA-LSQ | Open, recruiting | University Hospital Tuebingen | Academic | Phase 1 | 2016-05-09 | 2017-08-01 | 2017-12-01 | Adult | 66 | Germany | Benin | Results not yet reported | ||||||||||||||||
62 | Malaria | P. falciparum | Pfs25-VLP/Alhydrogel Fraunhofer | Active candidate / in development | Other: Pfs25 genetically fused to alfalfa mosiac virus coat protein | Pfs25 | Novel other: specify | Alhydrogel | NCT02013687 | Completed | Fraunhofer USA | Industry | Phase 2 | 2013-10-01 | 2014-08-01 | 2015-01-01 | Adult | 44 | United States of America | Results reported in registry | clinicaltrials.gov | 2016-11-21 | |||||||||||||
63 | Malaria | P. falciparum | Pfs25-EPA | Active candidate / in development | Other: Pfs25 conjugated with EPA | Pfs25 | None | NCT01867463 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2013-03-27 | 2015-12-22 | 2016-12-19 | Adult | 350 | United States of America | Mali | Results not yet reported | ||||||||||||||||
64 | Malaria | P. falciparum | Pfs25-EPA + Pfs230-EPA / Alhydrogel LMIV, NIAID, NIH | Active candidate / in development | Other: Pfs25M or Pf230D1M conjugated to EPA, respectively | Pfs25M, Pfs230D1M | Novel other: specify | Alhydrogel | NCT02334462 | Open, not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2014-12-10 | 2016-03-31 | 2017-09-30 | Adult | 54 | United States of America | Mali | Results not yet reported | |||||||||||||||
65 | Malaria | P. falciparum | Pfs25-EPA + Pfs230-EPA / AS01 LMIV, NIAID, NIH | Active candidate / in development | Other: Pfs25M or Pf230D1M conjugated to EPA, respectively | Pfs25M, Pfs230D1M | Novel other: specify | Alhydrogel, AS01 | NCT02942277 | Open, recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2016-10-06 | 2018-04-30 | 2018-04-30 | Adult | 900 | United States of America | Mali | Results not yet reported | |||||||||||||||
66 | Malaria | P. falciparum | ChAd63 Pfs25/MVA Pfs25 | Active candidate / in development | Other: Pfs25 fused to IMX313 | Pfs25 | None | NCT02532049 | Open, recruiting | University of Oxford | Academic | Phase 1 | 2015-10-01 | 2017-03-01 | 2017-03-01 | Adult | 24 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||||
67 | Malaria | P. vivax | ChAd63/MVA PvDBP | Active candidate / in development | Recombinant viral vector | Protein: specify | PvDBP_RII | None | NCT01816113 | Completed | University of Oxford | Academic | Phase 1 | 2013-04-01 | 2014-07-01 | 2014-07-01 | Adult | 24 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | Peer-reviewed publication or journal | 2017-06-15 | 28614791 | ||||||||||||
68 | Malaria | P. vivax | PvCS N+C+R/PvCS N+C | Unknown status | Novel other: specify | Montanide ISA-51 | NCT02083068 | Unknown | Malaria Vaccine and Drug Development Center | Industry | Phase 2 | 2014-05-01 | 2015-05-01 | 2015-08-01 | Adult | 32 | Colombia | Results not yet reported | |||||||||||||||||
69 | Malaria | P. falciparum | MSP3-LSP | Unknown status | Aluminum salts (alum) | NCT01341704 | Completed | Vac4All | Industry | Phase 2 | 2011-05-01 | 2011-12-01 | 2013-03-01 | Child | 800 | Mali | Results not yet reported | ||||||||||||||||||
70 | Malaria | P. falciparum | ChAd63-METRAP | Active candidate / in development | ME-TRAP | NCT03084289 | Open, recruiting | University of Oxford | Academic | Phase 1 | 2017-03-28 | 2017-09-01 | 2017-09-01 | Adult | 15 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||||||
71 | Malaria | P. falciparum | RH5.1/ ASO1 | Active candidate / in development | Novel other: specify | AS01 | NCT02927145 | Open, recruiting | University of Oxford | Academic | Phase 2 | 2016-09-01 | 2017-05-01 | 2018-01-01 | Adult | 78 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | |||||||||||||||||
72 | Malaria | P. falciparum | PfSPZ-GA1 | Active candidate / in development | Inactivated whole target organism | None | NCT03163121 | Open, recruiting | Sanaria | Industry | Phase 1 | 2017-05-30 | 2018-06-01 | 2018-10-01 | Adult | 67 | Netherlands | Results not yet reported | |||||||||||||||||
73 | Malaria | P. falciparum | D-CA/ChAd65-CA,D-CAT/ChAd63-CAT | Active candidate / in development | Other: prime with DNA vaccine and boost with recombinant viral vector | None | NCT03341754 | Open, recruiting | U.S. Army Medical Research and Materiel Command | Government | Phase 1 | 2017-11-20 | 2018-12-30 | 2019-11-01 | Adult | 52 | United States of America | Results not yet reported | |||||||||||||||||
74 | Malaria | P. falciparum | ChAdOx1, ChAdOx1/MVA LS2 | Active candidate / in development | Recombinant viral vector | Protein: specify | LS2 (LSA1 and LSAP2) | None | NCT03203421 | Open, recruiting | University of Oxford | Academic | Phase 2 | 2017-07-03 | 2018-09-01 | 2018-09-01 | Adult | 31 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | |||||||||||||||
75 | Malaria | P. falciparum | Pb(PfCS@UIS4)-infected mosquitoes | Active candidate / in development | Other: Genetically Modified Plasmodium Berghei | Other: specify | Whole parasite with CS protein | None | NCT03138096 | Open, not recruiting | Radboud University | Academic | Phase 2 | 2017-05-29 | 2018-07-01 | 2018-07-01 | Adult | 30 | Netherlands | Results not yet reported | |||||||||||||||
76 | Malaria | P. falciparum | 3D7-KAHRP-KO GAP parasite vaccine | Active candidate / in development | Other: Genetically attenuated | Other: specify | Whole parasite with CS protein | None | Open, not recruiting | National Health and Medical Research Council | Government | Phase 1 | 2017-08-22 | Adult | 6 | Australia | Results not yet reported | ||||||||||||||||||
77 | Malaria | P. falciparum | RTS,S/AS01E, RTS,S/AS01B | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01E | AS01B | NCT03162614 | Open, not recruiting | GSK | Industry | Phase 2 | 2017-05-23 | 2018-07-06 | 2018-09-03 | Adult | 150 | United States of America | Results not yet reported | ||||||||||||||
78 | Malaria | P. falciparum | AMA1-C1 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | AMA | C1 | Novel other: specify | CPG 7909 | NCT00427167 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2007-01-23 | 2008-11-05 | 2008-11-05 | Adult | 300 | United States of America | Results not yet reported | ||||||||||||||
79 | Malaria | P. falciparum | AMA1-C1 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | AMA | C1 | Novel other: specify | CPG 7909 | NCT00740090 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2008-08-11 | 2009-06-09 | 2009-06-09 | Child | 200 | Mali | Results not yet reported | ||||||||||||||
80 | Malaria | P. falciparum | AMA1-C1 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | AMA | C1 | Novel other: specify | CPG 7909 | NCT00984763 | Completed | University of Oxford | Academic | Phase 2 | 2010-01-01 | 2010-09-01 | 2010-09-01 | Adult | 8 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-07-22 | 21799809 | |||||||||||
81 | Malaria | P. falciparum | FMP010 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | MSP-1 | Novel other: specify | AS01B | NCT02458092 | Completed | U.S. Army Medical Research and Materiel Command | Government | Phase 1 | 2008-04-01 | 2008-12-01 | 2009-06-01 | Adult | 30 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-01-23 | 23342996 | |||||||||||
82 | Malaria | P. falciparum | FMP010 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | MSP-1 | Novel other: specify | AS01B | NCT00666380 | Completed | U.S. Army Medical Research and Materiel Command | Government | Phase 1 | 2008-04-01 | 2008-12-01 | 2009-06-01 | Adult | 26 | United States of America | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-01-23 | 23342996 | |||||||||||
83 | Malaria | P. falciparum | LSA-3-rec | Inactive / no longer in development | LSA3 | Novel other: specify | Montanide ISA 720 | NCT00509158 | Completed | Radboud University | Academic | Phase 2 | 2007-10-01 | 2008-10-01 | 2008-10-01 | Adult | 36 | Netherlands | Results not yet reported | ||||||||||||||||
84 | Malaria | P. falciparum | Adenovirus (Ad26) vectored CS; Adenovirus (Ad35) vectored CS | Inactive / no longer in development | Recombinant viral vector | Protein: specify | CSP | None | NCT01397227 | Completed | Crucell Holland BV | Industry | Phase 2 | 2011-06-01 | 2012-05-01 | 2012-05-01 | Adult | 36 | United States of America | Interim results reported | Abstract / Poster / Conference proceedings | 2012-11-14 | http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=cd94979d-5d70-43f4-bcc3-3e6d52c8cf33&cKey=d96c5f9f-1054-45ca-b31e-08a696aea12c&mKey=%7bC0DC51D1-29D3-44C6-BC0E-2069047A3801%7d | ||||||||||||
85 | Malaria | P. falciparum | Adenovirus (Ad35) vectored CS | Inactive / no longer in development | Recombinant viral vector | Protein: specify | CSP | None | NCT01018459 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2010-04-01 | 2011-12-01 | 2011-12-01 | Adult | 48 | Burkina Faso | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-11-11 | 24244339 | ||||||||||||
86 | Malaria | P. falciparum | ChAd63/MVA (monovalent CS or ME-TRAP) in prime boost regimen | Inactive / no longer in development | Recombinant viral vector | Protein: specify | CS | ME-TRAP | None | NCT01623557 | Completed | University of Oxford | Academic | Phase 2 | 2012-04-01 | 2012-11-01 | 2012-11-01 | Adult | 30 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | 25336730 | ||||||||||||
87 | Malaria | P. falciparum | ChAd63/MVA (multivalent CS, ME-TRAP or AMA-1) in prime-boost regimen | Inactive / no longer in development | Recombinant viral vector | Protein: specify | CS | ME-TRAP | AMA-1 | None | NCT01739036 | Completed | University of Oxford | Academic | Phase 2 | 2013-01-01 | 2013-10-01 | 2013-10-01 | Adult | 48 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | |||||||||||||||
88 | Malaria | P. falciparum | Adenovirus (Ad35) vectored CS and RTS,S-AS01 in heterologous prime-boost regimen | Inactive / no longer in development | Recombinant viral vector | Protein: specify | CSP | Novel other: specify | AS01 | NCT01366534 | Completed | GSK | Industry | Phase 2 | 2011-08-01 | 2012-02-01 | 2012-07-01 | Adult | 68 | United States of America | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-07-06 | 26148007 | |||||||||||
89 | Malaria | P. falciparum | PfSPZ Vaccine | Inactive / no longer in development | Inactivated whole target organism | None | NCT01001650 | Completed | Sanaria | Industry | Phase 1 | 2009-04-01 | 2010-07-01 | 2010-09-01 | Adult | 80 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-10-28 | 21903775 | ||||||||||||||
90 | Malaria | P. falciparum | RTS,S/AS01 + ChAd63 and MVA encoding ME-TRAP | Inactive / no longer in development | Recombinant subunit VLP (non-fusion) | Protein: specify | ME-TRAP | Novel other: specify | AS01B | NCT01883609 | Completed | University of Oxford | Academic | Phase 2 | 2013-09-01 | 2014-08-01 | 2014-08-01 | Adult | 48 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-09-01 | 27307573 | |||||||||||
91 | Malaria | P. falciparum | polyepitope DNA EP1300 | Inactive / no longer in development | Other: DNA vaccine | Protein: specify | CSP | SSP2 | TRAP | LSA-1 | EXP-1 | Novel other: specify | AS01B | NCT01169077 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2010-08-01 | 2012-07-01 | 2012-07-01 | Adult | 39 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-11-04 | 27697302 | |||||||||||
92 | Malaria | P. falciparum | ChAd63/MVA (ME-TRAP) co-administered with RTS,S/AS01 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | ME-TRAP | Novel other: specify | AS01B | NCT02252640 | Completed | University of Oxford | Academic | Phase 2 | 2015-01-01 | 2015-10-01 | 2015-10-01 | Adult | 48 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||
93 | Malaria | P. falciparum | NMRC-M3V-D/Ad- PfCA Prime/Boost | Inactive / no longer in development | Other: plasmid DNA and viral vector | Protein: specify | CPS | AMA-1 | None | NCT00870987 | Completed | U.S. Army Medical Research and Materiel Command | Government | Phase 2 | 2009-05-01 | 2016-11-01 | 2017-11-01 | Adult | 26 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-02-14 | 23457473 | ||||||||||||
94 | Malaria | P. falciparum | EBA175 RII | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | EBA175 RII, non-glycosylated | None | NCT01026246 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2010-06-01 | 2012-03-01 | 2012-03-01 | Adult | 60 | Ghana | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-09-19 | 27644034 | ||||||||||||
95 | Malaria | P. falciparum | AMA1-FVO [25-545] | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | AMA-1 | None | NCT00431808 | Unknown | African Malaria Network Trust | Product Development Partner | Phase 1 | 2007-05-01 | 2008-06-01 | 2008-06-01 | Adult | 40 | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-08-30 | 27577237 | ||||||||||||
96 | Malaria | P. falciparum | AMA1-C1/ ISA720 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | MSP-1 | Novel other: specify | ISA720 | NCT00487916 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2007-06-13 | 2009-02-05 | 2009-02-05 | Adult | 150 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-03-02 | 20051276 | |||||||||||
97 | Malaria | P. falciparum | FMP2.1/AS02A (AMA-1 3D7 E. coli-expressed in AS02 adjuvant) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | AMA-1 | Novel other: specify | AS01B | AS02A | NCT00460525 | Completed | U.S. Army Medical Research and Materiel Command | Government | Phase 2b | 2007-05-01 | 2009-07-01 | 2009-07-01 | Child | 400 | Mali | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2011-09-15 | 21916638 | |||||||||||
98 | Malaria | P. falciparum | ChAd63/MVA MSP1 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | MSP-1 | None | NCT01003314 | Completed | University of Oxford | Academic | Phase 2 | 2009-11-01 | 2010-09-01 | 2010-09-01 | Adult | 16 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-08-23 | 21862998 | ||||||||||||
99 | Malaria | P. falciparum | BSAM-2 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | BSAM-2 is a mixture of two MSP1 42 proteins, MSP1 42-FVO and MSP142-3D7; and two AMA1 proteins, AMA1-FVO and AMA1-3D7, mixed in a 1:1:1:1 ratio | Novel other: specify | Alhydrogel® + CPG 7909 | NCT00889616 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2009-04-23 | 2012-07-18 | 2012-07-18 | Adult | 400 | United States of America | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-10-04 | 23056238 | |||||||||||
100 | Malaria | P. falciparum | CSP, AMA1 virosomes (PEV 301,302) | Inactive / no longer in development | Other: virosomal | Other: specify | AMA-1 and CS mimotopes | None | NCT00513669 | Completed | Swiss Tropical & Public Health Institute | Academic | Phase 1 | 2008-01-01 | 2009-03-01 | 2009-03-01 | Child | Adult | 50 | United Republic of Tanzania | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-07-22 | 21799810 | ||||||||||||
101 | Malaria | P. falciparum | ChAd63 AMA1/MVA AMA1 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | AMA-1 | None | NCT01095055 | Completed | University of Oxford | Academic | Phase 1 | 2010-03-01 | 2010-10-01 | 2010-10-01 | Adult | 16 | United Kingdom of Great Britain and Northern Ireland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-02-21 | 22363582 | ||||||||||||
102 | Malaria | P. falciparum | ChAd63/AMA MVA/AMA1 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | AMA-1 | Novel other: specify | Alhydrogel® + CPG 7909 | NCT01351948 | Completed | University of Oxford | Academic | Phase 1 | 2011-06-01 | 2013-03-01 | 2013-03-01 | Adult | 35 | United Kingdom of Great Britain and Northern Ireland | Results not yet reported | ||||||||||||||
103 | Malaria | P. falciparum | Pfs25-EPA | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | Pfs25-EPA | Novel other: specify | Alhydrogel | NCT01434381 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Government | Phase 1 | 2011-08-01 | 2013-08-01 | 2013-08-01 | Adult | 30 | United States of America | Interim results reported | Abstract / Poster / Conference proceedings | 2012-11-15 | http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0130fb74-cf19-4ca4-8fdf-aec23ee8d680&cKey=9c96e9b4-2f63-42bb-9263-c0ce72e60c0a&mKey=%7bC0DC51D1-29D3-44C6-BC0E-2069047A3801%7d | |||||||||||
104 | Malaria | P. vivax | VMP001/AS01 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | CSP | Novel other: specify | AS01B | NCT01157897 | Completed | U.S. Army Medical Research and Materiel Command | Government | Phase 2 | 2010-07-01 | 2011-05-01 | 2011-12-01 | Adult | 48 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-02-26 | 26919472 | |||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | |
3 | Tuberculosis | Mycobacterium tuberculosis | Ad5-Ag85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT02337270 | Open, recruiting | McMaster University | Academic | Phase 1 | 9/5/2017 | 12/31/2019 | 4/30/2020 | Adult | 36 | Canada | Results not yet reported | Estimated primary and study completion dates listed | not yet complete | |||||||||
4 | Tuberculosis | Mycobacterium tuberculosis | Ad5-Ag85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00800670 | Completed | McMaster University | Academic | Phase 1 | 6/1/2009 | 12/1/2012 | 7/1/2013 | Adult | 48 | Canada | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-10-2 | 24089406 | https://clinicaltrials.gov/ct2/show/results/NCT00800670 | Dose escalation (study terminated after low dose cohort enrolled); Additional Publication - PMID 27703038 | ||||||
5 | Tuberculosis | Mycobacterium tuberculosis | AEC/BCO2 | Active candidate / in development | Inactivated whole target organism | Other: specify | Recombinant, freeze-dried whole Mtb | Novel other: specify | Mannitol + phosphate | NCT03026972 | Not yet open | AnHui Zhifei Longcom Biologic Pharmacy | Industry | Phase 1 | 4/1/2018 | 3/1/2019 | 3/1/2019 | Adult | 135 | China | Results not yet reported | Dose ranging (ag and adjuvant); ancitipated completion March 2019 | ||||||||||
6 | Tuberculosis | Mycobacterium tuberculosis | H4:IC31 (Aeras-404) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT01861730 | Completed | Aeras | Product Development Partner | Phase 2 | 7/1/2013 | 12/22/2017 | 12/22/2017 | Child | 243 | South Africa | Results not yet reported | Safety, immunogenicity in BCG-primed infants; Other Study ID Numbers: C-015-404/ IMPAACT P1113 U01AI068632 ( U.S. NIH Grant/Contract ) C-015-404 ( Other Identifier: Aeras ) | ||||||||||
7 | Tuberculosis | Mycobacterium tuberculosis | H4:IC31 (Aeras-404) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT02066428 | Completed | Aeras | Product Development Partner | Phase 1 | 11/1/2007 | 5/1/2009 | 5/1/2009 | Adult | 64 | Sweden | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-2-17 | 28216183 | Dose ranging (ag and adjuvant) | |||||||
8 | Tuberculosis | Mycobacterium tuberculosis | H4:IC31 (Aeras-404) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT02074956 | Completed | Aeras | Product Development Partner | Phase 1 | 5/1/2008 | 10/1/2009 | 10/1/2009 | Adult | 60 | Finland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-2-17 | 28216183 | Dose ranging (adjuvant) | |||||||
9 | Tuberculosis | Mycobacterium tuberculosis | H4:IC31 (Aeras-404) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT02109874 | Completed | Aeras | Product Development Partner | Phase 1 | 12/1/2008 | 12/1/2010 | 9/1/2012 | Adult | 40 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-6-3 | 26048780 | Dose escalation (ag only) | |||||||
10 | Tuberculosis | Mycobacterium tuberculosis | H4:IC31 (Aeras-404) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT02075203 | Completed | Aeras | Product Development Partner | Phase 2 | 2/1/2014 | 8/28/2017 | 10/6/2017 | Child | 990 | South Africa | Results not yet reported | Prevention of Mtb infection study, South African adolescents; the tracker had previously linked to an unrelated study as its publication of results so this incorrect publication has been removed | ||||||||||
11 | Tuberculosis | Mycobacterium tuberculosis | H56:IC31 (Aeras-456) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6, Rv2660c | Novel other: specify | IC31 | NCT01967134 | Completed | Aeras | Product Development Partner | Phase 1 | 11/1/2011 | 12/1/2012 | 6/1/2013 | Adult | 25 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-6-19 | 26095509 | Dose escalation (ag only) | |||||||
12 | Tuberculosis | Mycobacterium tuberculosis | H56:IC31 (Aeras-456) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6, Rv2660c | Novel other: specify | IC31 | NCT02375698 | Completed | Aeras | Product Development Partner | Phase 1 | 11/21/2014 | 6/24/2016 | 10/24/2016 | Adult | 22 | South Africa | Results not yet reported | |||||||||||
13 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Other: live, attenuated, cross-protecting organism | Other: specify | BCG | None | None | NCT00396370 | Completed | NIAID | Government | Phase 1 | 12/1/2008 | 7/1/2012 | 7/1/2012 | Adult | 69 | United States of America | Results not yet reported | ID v. oral v. combained routes of BCG administration | ||||||||||
14 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT00653627 | Completed | University of Oxford | Academic | Phase 1 | 8/1/2007 | 4/1/2010 | 4/1/2010 | Adult | 40 | UK | Results not yet reported | Quantifying BCG from injection site in BCG-naive adults; BCG immunogenicity | ||||||||||
15 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | ACTRN12608000227392 | Completed | Hospital The Mercy Hospital for Women | Academic | Phase 3 | 4/26/2008 | 4/1/2009 | 4/1/2009 | Child | 256 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-11-3 | 22071384 | Immunogenicity comparisons of 3 different BCG strains administered to infants | |||||||
16 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | EUCTR2011-005653-31-NL | Completed | LUMC, Department Infection Disease | Academic | Phase 4 | 6/28/2012 | 12/31/2014 | 12/31/2014 | Adult | 25 | Netherlands | Results not yet reported | BSG immunogenicity in TST-, QFN- adults | ||||||||||
17 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | CTRI/2014/03/004450 | Open, recruiting | JIPMER | Academic | Phase 3 | 2/11/2014 | 2/11/2017 | 2/11/2017 | Child | 2426 | India | Results not yet reported | Assessment of BCG death prevention in low birth weight babies | ||||||||||
18 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02413502 | Completed | Aeras | Product Development Partner | Phase 1 | 5/1/2015 | 9/1/2015 | 10/1/2015 | Adult | 10 | United States of America | Results not yet reported | |||||||||||
19 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02606526 | Open, recruiting | Makerere University | Academic | Phase 3 | 7/1/2016 | 6/1/2020 | 12/1/2020 | Child | 2200 | Uganda | Results not yet reported | Study Protocol published - PMID 28359325 | ||||||||||
20 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02692963 | Completed | Radboud University | Academic | Phase 2 | 4/1/2016 | 10/1/2016 | 2/1/2017 | Adult | 20 | Netherlands | Results not yet reported | |||||||||||
21 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02259608 | Completed | Radboud University | Academic | Phase 1 | 11/1/2013 | 3/1/2014 | 4/1/2014 | Adult | 15 | Netherlands | Results reported in registry | 1/25/2016 | ||||||||||
22 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02088892 | Completed | University of Oxford | Academic | Phase 3 | 3/1/2014 | 1/1/2015 | 1/1/2015 | Adult | 52 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-10-8 | 26450421 | Additional Publication - PMID 26450421 | |||||||
23 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02062580 | Completed | University of Cape Town | Academic | Phase 2 | 6/1/2010 | 4/1/2012 | 4/1/2012 | Child | 149 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-8-8 | 25108027 | 10/25/2016 | Additional Publications - PMID 26259542 & PMID 28405623 | ||||||
24 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02114255 | Completed | Radboud University | Academic | Phase 3 | 5/1/2014 | 9/1/2014 | 9/1/2014 | Adult | 40 | Netherlands | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-6-12 | 26071565 | ||||||||
25 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT02380508 | Completed | University of Oxford | Academic | Phase 4 | 2/1/2015 | 11/1/2016 | 11/1/2016 | Adult | 36 | UK | Results not yet reported | TB038 | ||||||||||
26 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT03175380 | Open, recruiting | Aeras | Product Development Partner | Phase 1 | 9/15/2017 | 4/1/2018 | 6/1/2018 | Adult | 15 | US | Results not yet reported | A-051 | ||||||||||
27 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | RBR-2gv984 | Completed | Fundação Oswaldo Cruz | Government | Phase 4 | 1/1/2010 | 1/1/2011 | 1/1/2011 | Adult | 75 | Brazil | Results not yet reported | Study results were mentioned as published at this link by the Brazil Registry: https://doi.org/10.1016/j.vaccine.2013.04.079 ; Results discussed in this publication as well: http://dx.doi.org/10.1590/0037-8682-0081-2017 | ||||||||||
28 | Tuberculosis | Mycobacterium tuberculosis | BCG & ESAT6-CFP10 | Registered | Live, attenuated target organism | Other: specify | BCG, ESAT6-CFP10 | None | None | NCT02389322 | Completed | AnHui Zhifei Longcom Biologic Pharmacy | Industry | Phase 2 | 3/1/2015 | 7/1/2015 | 9/1/2015 | Adult | 1044 | China | Results not yet reported | |||||||||||
29 | Tuberculosis | Mycobacterium tuberculosis | BCG (Tice) | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT01868464 | Completed | NIAID | Government | Phase 1 | 6/9/2014 | 12/18/2017 | 12/18/2017 | Adult | 92 | United States of America | Results not yet reported | Dose escalation study of safety, shedding for possible future use in human challenge studies | ||||||||||
30 | Tuberculosis | Mycobacterium tuberculosis | BCG + isoniazid | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT01119521 | Completed | NIAID | Government | Phase 1 | 10/1/2010 | 7/1/2013 | 7/1/2013 | Adult | 82 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-6-30 | 24814553 | 07-0083; Additional Publications - PMID 24135768, PMID 27845635, PMID 27412415 and PMID 29145483 | |||||||
31 | Tuberculosis | Mycobacterium tuberculosis | BCG, H4:IC31 (Aeras-404 ) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, Tb10.4 | Novel other: specify | IC31 | NCT02420444 | Completed | Aeras | Product Development Partner | Phase 1 | 1/1/2011 | 5/1/2012 | 11/1/2013 | Adult | 70 | Switzerland | Results not yet reported | |||||||||||
32 | Tuberculosis | Mycobacterium tuberculosis | ChAdOx1.85A / MVA85A | Active candidate / in development | Other: Simian adenovirus expressing antigen 85A | Protein: specify | Ag85A | None | None | NCT01829490 | Completed | University of Oxford | Academic | Phase 1 | 7/1/2013 | 4/1/2016 | 4/1/2016 | Adult | 42 | UK | Results not yet reported | |||||||||||
33 | Tuberculosis | Mycobacterium tuberculosis | D93 + AP10-602 and ID93 + GLA-SE | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Rv3619, Rv1813, Rv3620, and Rv2608 | Novel other: specify | GLA-SE, AP10-602 | NCT02508376 | Completed | NIAID | Government | Phase 1 | 10/22/2015 | 8/31/2017 | 8/31/2017 | Adult | 70 | United States of America | Results not yet reported | |||||||||||
34 | Tuberculosis | Mycobacterium tuberculosis | DAR-901 | Active candidate / in development | Other: inactivated non-tuberculosis mycobacterium | Other: specify | whole NTM | None | None | NCT02712424 | Open, not recruiting | Dartmouth Hitchcock Medical center | Academic | Phase 2 | 3/1/2016 | 11/1/2019 | 11/1/2019 | Child | 650 | United Republic of Tanzania | Results not yet reported | not yet complete | ||||||||||
35 | Tuberculosis | Mycobacterium tuberculosis | DAR-901 | Active candidate / in development | Other: inactivated non-tuberculous mycobacterium | Other: specify | whole NTM | None | None | NCT02063555 | Completed | Dartmouth Hitchcock Medical Center | Academic | Phase 1 | 2/1/2014 | 3/1/2016 | 6/1/2016 | Adult | 59 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-5-12 | 28498853 | Dose ranging safety and immunogenicity study; Additional Publication - PMID 29685114 | |||||||
36 | Tuberculosis | Mycobacterium tuberculosis | ESAT6-CFP10 | Registered | Live, attenuated target organism | Other: specify | BCG, ESAT6-CFP10 | None | None | NCT02795260 | Completed | AnHui Zhifei Longcom Biologic Pharmacy | Industry | Phase 3 | 5/1/2016 | 10/1/2016 | 10/1/2016 | Adult | 1802 | China | Results not yet reported | |||||||||||
37 | Tuberculosis | Mycobacterium tuberculosis | FP85A, MVA85A | Active candidate / in development (MVA85A only) | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00653770 | Completed | University of Oxford | Academic | Phase 1 | 9/1/2007 | 1/1/2010 | 1/1/2010 | Adult | 31 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-11-10 | 23143773 | FP85A = attenuated fowlpox vector; no longer in development | |||||||
38 | Tuberculosis | Mycobacterium tuberculosis | GamTBvac | Active candidate/in development | Recombinant subunit (non VLP) | Protein: specify | Ag85A, ESAT6-CFP10 | None | None | NCT03255278 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology | Government | Phase 1 | 1/15/2017 | 12/13/2017 | 12/13/2017 | Adult | 60 | Russia | Results not yet reported | GamTBvac Ph1 | ||||||||||
39 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT00600782 | Completed | GlaxoSmithKline | Industry | Phase 2 | 2/1/2008 | 12/1/2008 | 12/1/2008 | Adult | 45 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-8-15 | 23306546 | This product renamed M72, later adjuvanted | |||||||
40 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | Novel other: specify | AS01B | NCT00621322 | Completed | GlaxoSmithKline | Industry | Phase 2 | 4/1/2008 | 4/1/2009 | 4/1/2009 | Adult | 181 | Philippines | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-10-20 | 24142232 | 2/3/2018 | https://clinicaltrials.gov/ct2/show/results/NCT00621322 | Multi-armed study of M72 including adjuvanted and non-adjuvanted formulations | |||||
41 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | Novel other: specify | AS01 | NCT00707967 | Completed | GlaxoSmithKline | Industry | Phase 2 | 6/1/2008 | 5/1/2009 | 5/1/2009 | Adult | 37 | Switzerland | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-5-26 | 24864125 | 1/6/2017 | https://clinicaltrials.gov/ct2/show/results/NCT00707967 | Safety, immunogenicity of M72 + AS01 in HIV+ adults; Additional Publication - PMID 24911353 | |||||
42 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT00950612 | Completed | GlaxoSmithKline | Industry | Phase 2 | 12/1/2009 | 9/1/2010 | 9/1/2010 | Child | 60 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-6-10 | 26072017 | 11/9/2016 | https://clinicaltrials.gov/ct2/show/results/NCT00950612 | Safety, immunogenicity of non-adjuvanted M72 in HIV- adolescents | |||||
43 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT01098474 | Completed | GlaxoSmithKline | Industry | Phase 2 | 7/1/2010 | 4/1/2011 | 3/1/2012 | Child | 302 | Gambia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-8-9 | 25305000 | Concomitant administration study (with routine infant vaccines); safety & immunogenicity | |||||||
44 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT01262976 | Completed | GlaxoSmithKline | Industry | Phase 2 | 1/1/2011 | 7/1/2012 | 6/1/2015 | Adult | 240 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-1-1 | 26817879 | Safety, immunogenicity in HIV+ adults in TB endemic region | |||||||
45 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT01424501 | Completed | GlaxoSmithKline | Industry | Phase 2 | 11/1/2011 | 4/1/2014 | 4/1/2014 | Adult | 142 | Estonia | China | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2016-7-21 | 27553419 | 1/24/2017 | https://clinicaltrials.gov/ct2/show/results/NCT01424501 | Safety, immunogenicity in adults with active TB disease; study terminated due to safety signal found at interim safety review; related publication: http://journals.sagepub.com/doi/full/10.1177/2051013615593891 | |||||
46 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | NCT01669096 | Completed | GlaxoSmithKline | Industry | Phase 2 | 8/21/2012 | 12/6/2012 | 5/24/2013 | Adult | 20 | Belgium | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2018-3-26 | 29632533 | 8/24/2016 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002541-37/results | Evaluation of kinetics of mRNA expression following vaccination, healthy adults | |||||
47 | Tuberculosis | Mycobacterium tuberculosis | GSK TB vaccine 692342 (later M72) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | None | None | EUCTR2012-001820-36-EE | Completed | GlaxoSmithKline | Industry | Phase 2 | 10/15/2012 | 4/10/2014 | 4/10/2014 | Adult | 240 | Estonia | China | Results reported in registry | 2015-30-19 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001820-36/results | Safety, immunogenicity when administered to adults with active TB disease | ||||||||
48 | Tuberculosis | Mycobacterium tuberculosis | BCG, H4:IC31 (Aeras-404), H56:IC31 (Aeras-456) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, TB10.4/Ag85B, ESAT-6, Rv2660c | Novel other: specify | IC31 | NCT02378207 | Completed | Aeras | Product Development Partner | Phase 2 | 5/1/2015 | 10/31/2016 | 12/9/2016 | Child | 84 | South Africa | Results not yet reported | 4 arm study (with H56, BCG revaccination, placebo) | ||||||||||
49 | Tuberculosis | Mycobacterium tuberculosis | H56:IC31 (Aeras-456) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6, Rv2660c | Novel other: specify | IC31 | NCT01865487 | Completed | Aeras | Product Development Partner | Phase 2 | 8/1/2013 | 8/1/2015 | 11/1/2015 | Adult | 98 | South Africa | Results not yet reported | Phase 1b - 2a | ||||||||||
50 | Tuberculosis | Mycobacterium tuberculosis | H56:IC31 with etoricoxib | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | IC31 | NCT02503839 | Open, recruiting | Oslo University Hospital | Academic | Phase 1 | 11/1/2015 | 12/1/2018 | 12/1/2019 | Adult | 40 | Norway | Results not yet reported | |||||||||||
51 | Tuberculosis | Mycobacterium tuberculosis | ID93+GLA-SE | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Rv3619, Rv1813, Rv3620, and Rv2608 | Novel other: specify | GLA-SE | NCT02465216 | Completed | Infectious Disease Research Institute | Academic | Phase 2 | 6/1/2015 | 1/1/2017 | 1/1/2017 | Adult | 60 | South Africa | Results not yet reported | |||||||||||
52 | Tuberculosis | Mycobacterium tuberculosis | ID93+GLA-SE | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Rv3619, Rv1813, Rv3620, and Rv2608 | Novel other: specify | GLA-SE | NCT01599897 | Completed | Infectious Disease Research Institute | Product Development Partner | Phase 1 | 8/1/2012 | 5/1/2014 | 5/1/2014 | Adult | 60 | United States of America | Results not yet reported | Ag, adjuvant dose escalation safety, immunogenicity in adults | ||||||||||
53 | Tuberculosis | Mycobacterium tuberculosis | ID93+GLA-SE | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Rv3619, Rv1813, Rv3620, and Rv2608 | Novel other: specify | GLA-SE | NCT01927159 | Completed | Infectious Disease Research Institute | Product Development Partner | Phase 1 | 9/1/2013 | 7/1/2015 | 7/1/2015 | Adult | 66 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2018-4-1 | 29595510 | Safety, immunogenicity in BCG-vaccinated adults (prevention of pulmonary TB disease indication) | |||||||
54 | Tuberculosis | Mycobacterium tuberculosis | M72+AS01E | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Mtb 32A and 39A | Novel other: specify | AS01 | NCT01755598 | Open, not recruiting | GlaxoSmithKline | Industry | Phase 2 | 8/1/2014 | 11/1/2018 | 11/1/2018 | Adult | 3506 | Kenya | South Africa | Zambia | Results not yet reported | PACTR201311000639144 | ||||||||||
55 | Tuberculosis | Mycobacterium tuberculosis | MTBVAC | Active candidate / in development | Live, attenuated target organism | Other: specify | Whole, attenuated Mtb | None | None | NCT02933281 | Not yet recruiting | Aeras | Product Development Partner | Phase 2 | 7/1/2018 | 12/1/2018 | 3/1/2019 | Adult | 144 | South Africa | Results not yet reported | Phase 1b - 2a; only attenuated Mtb-derived vaccine currently in clinical trials | ||||||||||
56 | Tuberculosis | Mycobacterium tuberculosis | MTBVAC | Active candidate / in development | Live, attenuated target organism | Other: specify | Whole, attenuated Mtb | None | None | NCT02729571 | Open, not recruiting | Biofabri, S.L. | Industry | Phase 2 | 9/1/2015 | 9/1/2016 | 9/1/2017 | Child | Adult | 54 | South Africa | Results not yet reported | Dose escalation, safety and immunogenicity, newborns and adults | ||||||||||
57 | Tuberculosis | Mycobacterium tuberculosis | MTBVAC, BCG | Active candidate / in development | Live, attenuated target organism | Other: specify | Whole, attenuated Mtb | None | None | NCT02013245 | Completed | Biofabri, S.L. | Industry | Phase 1 | 1/1/2013 | 6/1/2014 | 11/1/2014 | Adult | 36 | Switzerland | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-12-1 | 26598141 | 3/24/2017 | https://clinicaltrials.gov/ct2/show/results/NCT02013245 | MTBVAC-01 | |||||
58 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Other: aerosolized and IM attenuated virus-vectored vaccine | Protein: specify | Ag85A | None | None | NCT02532036 | Open, recruiting | University of Oxford | Academic | Phase 1 | 9/1/2015 | 6/1/2018 | 6/1/2018 | Adult | 15 | UK | Results not yet reported | |||||||||||
59 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00480558 | Completed | University of Oxford | Academic | Phase 1 | 7/1/2007 | 1/1/2011 | 1/1/2011 | Adult | 48 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-1-26 | 22281831 | ||||||||
60 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00548444 | Completed | University of Oxford | Academic | Phase 1 | 10/1/2007 | 1/1/2010 | 1/1/2010 | Adult | 12 | UK | Results not yet reported | A publication on another study mentions the results: PMID 23733037 | ||||||||||
61 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00679159 | Completed | University of Oxford | Academic | Phase 2 | 2/1/2008 | 12/1/2009 | 12/1/2009 | Child | 168 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-6-15 | 21606542 | Dose finding in infants and children; Subset of data used in publication PMID 25523923 | |||||||
62 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00731471 | Completed | University of Oxford | Academic | Phase 1 | 8/1/2008 | 1/1/2011 | 1/1/2011 | Adult | 24 | Senegal | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-6-28 | 23840618 | Safety, immunogenicity of MVA85A in HIV+ adults | |||||||
63 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT00953927 | Completed | Aeras | Product Development Partner | Phase 2 | 7/1/2009 | 10/1/2012 | 10/1/2012 | Child | 2797 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-3-23 | 23391465 | 10/23/2013 | https://clinicaltrials.gov/ct2/show/results/NCT00953927 | Phase 2b safety, efficacy trial of MVA85A (Aeras-485 vaccine) in BCG-vaccinated infants; Additional Publications: PMID 24912498 and PMID 26554383 | |||||
64 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01181856 | Completed | University of Oxford | Academic | Phase 1 | 1/1/2010 | 1/1/2011 | 1/1/2011 | Adult | 24 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2012-12-21 | 23266342 | Safety, immunogencity of MVA85A administered IM and ID to BCG-vaccinated adults. Other regirstry ID: ISRCTN46804531 | |||||||
65 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01194180 | Completed | University of Oxford | Academic | Phase 1 | 5/1/2010 | 1/1/2012 | 1/1/2012 | Adult | 48 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-11-23 | 24273174 | MVA85A activity assessed in BCG-naive adults utilizing a BCG challenge model; samples from this trial were used in PMID 25381367 | |||||||
66 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01497769 | Completed | University of Oxford | Academic | Phase 1 | 9/1/2011 | 10/1/2012 | 4/1/2013 | Adult | 24 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-8-20 | 25151225 | Safety, immunogencity of ID and aerosol (inhaled) routes of administration | |||||||
67 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01954563 | Completed | University of Oxford | Academic | Phase 1 | 10/1/2013 | 1/1/2016 | 1/1/2016 | Adult | 37 | UK | Abstract / Poster / Conference proceedings | 2016-5-13 | Safety, immunogenicity of aerosol MVA85A followed by ID MVA85A boost | |||||||||
68 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT02178748 | Completed | University of Oxford | Academic | Phase 2 | 6/1/2014 | 1/1/2015 | 1/1/2015 | Child | 36 | Uganda | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-5-4 | 28472067 | Assessment of effect of Schistosoma mansoni infection on response to MVA85A vaccination in BCG-vaccinated African adolescents | |||||||
69 | Tuberculosis | Mycobacterium tuberculosis | MVA85A | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01151189 | Completed | Aeras | Product Development Partner | Phase 2 | 7/1/2011 | 5/1/2014 | 9/1/2014 | Adult | 650 | Senegal, South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-2-26 | 25726088 | 6/28/2015 | https://clinicaltrials.gov/ct2/show/results/NCT01151189 | C-030-485 | |||||
70 | Tuberculosis | Mycobacterium tuberculosis | MVA85A + BCG | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | None | None | NCT01650389 | Completed | University of Cape Town | Academic | Phase 2 | 10/1/2012 | 5/1/2015 | 5/1/2015 | Child | 248 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2018-2-1 | 29028973 | Safety, imunogenicity of MVA85A prime, BCG boost in HIV+ infants | |||||||
71 | Tuberculosis | Mycobacterium tuberculosis | MVA85A-IMX313 | Active candidate / in development | Recombinant viral vector | Protein: specify | Ag85A | Novel other: specify | IMX313 | NCT01879163 | Completed | University of Oxford | Academic | Phase 1 | 7/1/2013 | 12/1/2014 | 12/1/2014 | Adult | 30 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-2-5 | 26854906 | IMX313 no longer in clinical development? (check with Helen McShane) | |||||||
72 | Tuberculosis | Mycobacterium tuberculosis | RUTI | Active candidate / in development | Inactivated partial (split) target organism | Other: specify | fragmented, detoxified whole organism in liposomes | None | None | NCT01136161 | Completed | Archivel Farma | Industry | Phase 2 | 6/1/2010 | 5/1/2011 | 5/1/2011 | Adult | 95 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-2-26 | 24586912 | Being developed as immunotherapeutic adjunct to drug treatment of Mtb | |||||||
73 | Tuberculosis | Mycobacterium tuberculosis | RUTI | Active candidate / in development | Inactivated partial (split) target organism | Other: specify | fragmented, detoxified whole organism in liposomes | None | None | NCT00546273 | Completed | Archivel Farma | Industry | Phase 1 | 4/1/2007 | 6/1/2008 | 6/1/2008 | Adult | 24 | Spain | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2009-10-22 | 19853680 | 10/16/2018 | https://clinicaltrials.gov/ct2/show/results/NCT00546273 | ||||||
74 | Tuberculosis | Mycobacterium tuberculosis | RUTI | Active candidate / in development | Inactivated partial (split) target organism | Other: specify | fragmented, detoxified whole organism in liposomes | None | None | NCT02711735 | Not yet recruiting | University Medical Center Groningen | Academic | Phase 2 | 6/1/2016 | 12/1/2017 | 6/1/2018 | Adult | 27 | Unspecified | Results not yet reported | |||||||||||
75 | Tuberculosis | Mycobacterium tuberculosis | TB/FLU-04L | Active candidate / in development | Recombinant viral vector | Protein: specify | ESAT-6, Ag85A | None | None | NCT02501421 | Completed | Research Institute for Biological Safety Problems | Academic | Phase 1 | 10/1/2013 | 4/1/2014 | 2/1/2015 | Adult | 36 | Kazakhstan | Results not yet reported | registered also as NCT03017378 | complete, not published | |||||||||
76 | Tuberculosis | Mycobacterium tuberculosis | V-5 immunitor | Active candidate / in development | Other: specify | Other: specify | Information not available | None | None | NCT01222338 | Completed | Lisichansk Regional Tuberculosis Dispensary | Government | Phase 2 | 1/1/2010 | 12/1/2010 | 1/1/2011 | Adult | 123 | Ukraine | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2010-12-24 | 21182457 | Immunotherapeutic adjunct to standard mycobacterial drug treatment; description of V5 content does not appear to be available in published literature; Additional Publication - PMID 27868466 and PMID 21244690 | |||||||
77 | Tuberculosis | Mycobacterium tuberculosis | Vaccae | Active candidate / in development | Other: inactivated non-tuberculous mycobacterium | Other: specify | whole NTM | None | None | NCT01979900 | Unknown | AnHui Zhifei Longcom Biologic Pharmacy | Industry | Phase 3 | 10/1/2013 | 4/1/2018 | 5/1/2018 | Child | Adult | 10000 | China | Results not yet reported | Phase 3 prevention of TB disease study (6 dose regimen); vaccine licensed as immunotherapeutic adjunctive therapy in China; the "unknown" status has not been updated since August 2015; there may be a second Vaccae study, but it is not on the registry (check with Sponsor) | ||||||||||
78 | Tuberculosis | Mycobacterium tuberculosis | VPM 1002 (rBCG) | Active candidate / in development | Other: recombinant BCG | Other: specify | whole rBCG | None | None | NCT02391415 | Completed | Vakzine Projekt Management GmbH | Academic | Phase 2 | 6/1/2015 | 11/1/2017 | 11/1/2017 | Child | 416 | South Africa | Results not yet reported | Phase 2b BCG replacement study in South African infants | ||||||||||
79 | Tuberculosis | Mycobacterium tuberculosis | VPM 1002 (rBCG) | Active candidate / in development | Other: recombinant BCG | Other: specify | whole rBCG | None | None | NCT00749034 | Completed | Vakzine Projekt Management GmbH | Industry | Phase 1 | 9/1/2008 | 12/1/2009 | 12/1/2009 | Adult | 80 | Germany | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-1-3 | 23290835 | Dose escalation study; Trial results also mentioned in PMID 28974949 | |||||||
80 | Tuberculosis | Mycobacterium tuberculosis | VPM 1002 (rBCG) | Active candidate / in development | Other: recombinant BCG | Other: specify | whole rBCG | None | None | NCT01113281 | Completed | Vakzine Projekt Management GmbH | Industry | Phase 1 | 4/1/2010 | 12/1/2010 | 3/1/2011 | Adult | 24 | South Africa | Results not yet reported | **Trial results are reported in several other papers but no citation to study results is provided (see PMCID: PMC5299117); dose escalation study; Trial results also mentioned in PMID 28974949 | ||||||||||
81 | Tuberculosis | Mycobacterium tuberculosis | VPM 1002 (rBCG) | Active candidate / in development | Other: recombinant BCG | Other: specify | whole rBCG | None | None | NCT01479972 | Completed | Vakzine Projekt Management GmbH | Product Development Partner | Phase 2 | 11/1/2011 | 11/1/2012 | 11/1/2012 | Child | 48 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-12-14 | PMC5299117 | VPM1002-ZA-2.12TB|DOH-27-0911-3677 | |||||||
82 | Tuberculosis | Mycobacterium tuberculosis | VPM 1002 (rBCG) | Active candidate / in development | Other: recombinant BCG | Other: specify | whole rBCG | None | None | NCT03152903 | Open, recruiting | Serum Institute | Industry | Phase 3 | 12/15/2017 | 8/20/2019 | 11/20/2019 | Adult | 2000 | India | Results not yet reported | VPM1002-IN-3.01TBR; other trial ID CTRI/2017/03/008266 | ||||||||||
83 | Tuberculosis | Mycobacterium tuberculosis | BCG | Registered | Live, attenuated target organism | Other: specify | BCG | None | None | NCT03363178 | Open, recruiting | Green Cross Corporation | Industry | Phase 1 | 12/14/2017 | 3/31/2018 | 3/31/2018 | Adult | 20 | Republic of Korea | Results not yet reported | Other Study ID Number: GC3107_P1 | ||||||||||
84 | Tuberculosis | Mycobacterium tuberculosis | H56:IC31 (Aeras-456) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | IC31 | NCT03512249 | Not yet recruiting | Aeras | Product Development Partner | Phase 2 | 9/30/2018 | 9/30/2020 | 12/30/2020 | Adult | 900 | South Africa | Tanzania | Results not yet reported | Other Study ID Number: A-055 | ||||||||||
85 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT01017536 | Completed | Aeras | Product Development Partner | Phase 2 | 12/1/2009 | 3/1/2012 | 5/1/2012 | Adult | 26 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-2-17 | 25698492 | 10/8/2014 | https://clinicaltrials.gov/ct2/show/results/NCT01017536 | Dose escalation planned; study discontinued after low dose cohort enrolled | |||||
86 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT01198366 | Completed | Aeras | Product Development Partner | Phase 2 | 9/1/2010 | 1/1/2014 | 4/1/2014 | Child | 487 | Kenya | Mozambique | South Africa | Results reported in peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-4-28 | 25936724 | 6/10/2015 | https://clinicaltrials.gov/ct2/show/results/NCT01198366 | Aeras-402 safety, immunogenicity in BCG-vaccinated, HIV- infants | |||||
87 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT01378312 | Completed | Aeras | Product Development Partner | Phase 1 | 2/1/2011 | 10/1/2011 | 3/1/2012 | Adult | 12 | India | Results not yet reported | Safety, immunogenicity in adults; this trial had previusly been linked to a publication that mistakenly lists this trial so the publication has been removed | ||||||||||
88 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT01683773 | Completed | University of Oxford | Academic | Phase 1 | 9/1/2012 | 8/1/2014 | 8/1/2014 | Adult | 40 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-11-3 | 26529238 | Safety, immunogenicity of Aeras-402 administered sequentially with MVA85A | |||||||
89 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT02430506 | Completed | Aeras | Product Development Partner | Phase 1 | 9/1/2008 | 6/1/2009 | 7/1/2010 | Adult | 20 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-3-26 | 27026148 | Safety, immunogenicity in HIV-, BCG-vaccinated, QFT+_ and QFT- adults | |||||||
90 | Tuberculosis | Mycobacterium tuberculosis | Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT02414828 | Completed | Aeras | Product Development Partner | Phase 2 | 10/1/2008 | 7/1/2010 | 11/1/2010 | Adult | 72 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2017-1-6 | 28060545 | 3/4/2016 | https://clinicaltrials.gov/ct2/show/results/NCT02414828 | ||||||
91 | Tuberculosis | Mycobacterium tuberculosis | BCG, Aeras-402 (Ad35 + Ag85A, Ag85B, TB10.4) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Ag85A, Ag85B, TB10.4 | None | None | NCT02375256 | Completed | Aeras | Product Development Partner | Phase 1 | 10/1/2009 | 12/1/2010 | 12/1/2013 | Adult | 11 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-11-2 | PMC5141283 | ||||||||
92 | Tuberculosis | Mycobacterium tuberculosis | AERAS-422 | Inactive / no longer in development | Live, attenuated target organism | Other: specify | Whole, attenuated Mtb | None | None | NCT01340820 | Completed | Aeras | Product Development Partner | Phase 1 | 12/1/2010 | 2/1/2012 | 5/1/2012 | Adult | 24 | US | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-4-19 | 27322481 | C-007-422 | |||||||
93 | Tuberculosis | Mycobacterium tuberculosis | "Mycobacterium w" (Mycobacterium indicus pranii) | Inactive / no longer in development | Other: specify | Other: specify | Heat killed whole M. indicus pranii | None | None | PACTR2008060000892906 | Completed | University of Cape Town | Academic | Phase 1 | 1/1/2009 | 2/28/2014 | 2/28/2014 | Adult | 1400 | South Africa | India | Mozambique | Nigeria | Results not yet reported | Pilot clinical study of Mw vaccine + prednisone as adjunctive therapy to antimycobacterial drugs in treating Mtb pericarditis; actual status of vaccine development unclear | ||||||||||
94 | Tuberculosis | Mycobacterium tuberculosis | Ag85B-ESAT-6 (later H1) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | CAF01 | NCT00922363 | Completed | Statens Serum Institut | Academic | Phase 1 | 10/1/2009 | 10/1/2011 | 10/1/2011 | Adult | 38 | Netherlands | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-10-30 | 25454872 | Later called H56; adjuvant dose escalation; results also mentioned in PMID 26978390 | |||||||
95 | Tuberculosis | Mycobacterium tuberculosis | Ag85B-ESAT-6 (later H1) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | IC31 | NCT00929396 | Completed | Statens Serum Institut | Academic | Phase 1 | 9/1/2007 | 6/1/2009 | 6/1/2009 | Adult | 20 | Netherlands | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-1-20 | 21256189 | Safety, immunogenicity in TST+ adults; in BCG-vaccinated adults: IC31 = KLK + ODN1a) | |||||||
96 | Tuberculosis | Mycobacterium tuberculosis | Ag85B-ESAT-6 (later H1) + IC31 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | IC31 | PACTR201403000646306 | Completed | Statens Serum Institut | Academic | Phase 2 | 8/27/2012 | 12/19/2013 | 12/19/2013 | Child | 240 | South Africa | Results not yet reported | Safety, immunogenicity; 2 doses | ||||||||||
97 | Tuberculosis | Mycobacterium tuberculosis | GX-70 | Inactive / no longer in development | DNA | Protein: specify | 4 MTB antigens, Flt3 ligand | None | None | NCT03159975 | Not yet open | Yonsei University | Academic | Phase 1 | 3/1/2018 | 8/1/2018 | 8/1/2018 | Adult | 18 | South Korea | Results not yet reported | 4-2016-1144 | ||||||||||
98 | Tuberculosis | Mycobacterium tuberculosis | H1: IC31 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | ESAT-6, Ag85B | Novel other: specify | IC31 | NCT01049282 | Completed | Statens Serum Institut | Academic | Phase 1 | 12/1/2008 | 4/1/2010 | 4/1/2010 | Adult | 39 | Ethiopia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2018-1-10 | 29321075 | PI ( Jemal Hussein), study director (Peter Bang) | |||||||
99 | Tuberculosis | Mycobacterium tuberculosis | H1: IC31 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | ESAT-6, Ag85B | Novel other: specify | IC31 | PACTR201105000289276 | Completed | Statens Serum Institut | Academic | Phase 2 | 1/10/2012 | 9/10/2012 | 9/10/2012 | Adult | 48 | South Africa | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-12-9 | 25490675 | Safety, immunogenicity in HIV+ adults without TB; Additional Publication - PMID 25924764 | |||||||
100 | Tuberculosis | Mycobacterium tuberculosis | H1:LTK63 | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | Ag85B, ESAT-6 | Novel other: specify | LTK63 | NCT00440544 | Withdrawn | St. George's, U. of London | Academic | Phase 1 | 1/1/2007 | 11/1/2007 | 2/1/2008 | Adult | 9 | UK | Results not yet reported | Peer-reviewed publication or journal | 2009-09-16 | PMC2737308 | trial was terminated | |||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||||
3 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01064141 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2010-01-01 | 2012-09-01 | 2012-11-01 | Child | 210 | Philippines | Results reported in both peer-reviewed journal and registry | EudraCT | 2015-07-31 | 2014-001694-14/results | Pooled immunogenicity results published: https://www.ncbi.nlm.nih.gov/pubmed/28598256 | |||||||||||
4 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00740155 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2008-08-01 | 2009-10-01 | 2010-01-01 | Adult | 154 | Mexico | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-10-31 | 25483647 | ||||||||||||
5 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00617344 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2008-04-01 | 2009-12-01 | 2010-02-01 | Adult | 260 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-10-17 | 24021313 | ||||||||||||
6 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00993447 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2009-10-01 | 2011-09-01 | 2012-03-01 | Child | 600 | Colombia | Mexico | Honduras | Puerto Rico | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-10-01 | 24067553 | clinicaltrials.gov | 2016-10-04 | NCT00993447 | |||||||||
7 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01373281 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 3 | 2011-06-01 | 2014-08-01 | 2017-11-01 | Child | 10278 | Indonesia | Malaysia | Thailand | Philippines | Viet Nam | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-10-11 | 25018116 | clinicaltrials.gov | 2015-09-01 | NCT01373281 | |||||||||
8 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01374516 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 3 | 2011-06-01 | 2014-11-01 | 2018-04-01 | Child | 20875 | Brazil | Colombia | Honduras | Mexico | Puerto Rico | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-01-08 | 25365753 | EudraCT | 2015-08-02 | 2014-001716-19/results | |||||||||
9 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01134263 | Completed | Sanofi Pasteur | Industry | Phase 3 | 2010-10-01 | 2012-11-01 | 2013-02-01 | Adult | 712 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-09-22 | 26279339 | 28968794 | |||||||||||
10 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00875524 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2009-03-01 | 2014-08-01 | 2014-12-01 | Child | Adult | 180 | Viet Nam | Results reported in both peer-reviewed journal and registry | EudraCT | 2015-07-29 | 2014-001709-41/results | Pooled immunogenicity results published: https://www.ncbi.nlm.nih.gov/pubmed/28598256 | |||||||||||
11 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00842530 | Completed | Sanofi Pasteur | Industry | Phase 2b | 2009-02-01 | 2013-09-01 | 2014-02-01 | Child | 4002 | Thailand | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2012-11-03 | 22975340 | EudraCT | 2015-07-29 | 2014-001710-25/results | |||||||||
12 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00788151 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2008-10-01 | 2010-08-01 | 2010-12-01 | Child | 300 | Peru | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2012-09-07 | 22863660 | EudraCT | 2015-08-02 | 2014-001711-40/results | |||||||||
13 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT00880893 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2009-04-01 | 2014-10-01 | 2015-06-01 | Child | Adult | 1198 | Singapore | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2012-08-16 | 22894958 | EudraCT | 2015-07-17 | 2014-001713-26/results | 23839107 | ||||||||
14 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01436396 | Completed | Sanofi Pasteur | Industry | Phase 3 | 2011-09-01 | 2013-09-01 | 2014-03-01 | Child | 792 | Colombia | Peru | Results reported in both peer-reviewed journal and registry | EudraCT | 2015-07-29 | 2014-001714-26/results | Pooled immunogenicity results published: https://www.ncbi.nlm.nih.gov/pubmed/28598256 | |||||||||||
15 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01187433 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2010-08-01 | 2012-10-01 | 2012-12-01 | Child | 150 | Brazil | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-11-04 | 24189367 | clinicaltrials.gov | 2016-09-25 | NCT01187433 | |||||||||
16 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01254422 | Completed | Sanofi Pasteur | Industry | Phase 3 | 2010-12-01 | 2012-09-01 | 2013-01-01 | Child | 250 | Malaysia | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-10-14 | 24135573 | EudraCT | 2015-07-29 | 2014-001717-11/results | |||||||||
17 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01411241 | Completed | Sanofi Pasteur | Industry | Phase 3 | 2011-07-01 | 2014-02-01 | 2014-04-01 | Child | 720 | Mexico | Results reported in both peer-reviewed journal and registry | EudraCT | 2015-07-29 | 2014-001736-11/results | Pooled immunogenicity results published: https://www.ncbi.nlm.nih.gov/pubmed/28598256 | |||||||||||
18 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01550289 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2012-03-01 | 2013-12-01 | 2014-02-01 | Adult | 189 | India | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-08-20 | 26291554 | clinicaltrials.gov | 2016-09-14 | NCT01550289 | |||||||||
19 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01488890 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2011-12-01 | 2013-09-01 | 2014-04-01 | Adult | 390 | United States of America | Results reported in peer-reviewed journal | Pooled immunogenicity results published: https://www.ncbi.nlm.nih.gov/pubmed/28598256 Pooled safety results published: https://www.ncbi.nlm.nih.gov/pubmed/27414655 | ||||||||||||||
20 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT01943825 | Completed | Sanofi Pasteur | Industry | Phase 2 | 2013-09-01 | 2016-03-01 | 2016-03-01 | Adult | 90 | United States of America | Results not yet reported | |||||||||||||||
21 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02628444 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 2 | 2016-05-01 | 2020-02-01 | 2020-07-01 | Child | Adult | 1050 | Colombia | Philippines | Results not yet reported | |||||||||||||||
22 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02824198 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 2 | 2016-07-01 | 2018-09-01 | 2018-12-01 | Child | Adult | 260 | Singapore | Results not yet reported | |||||||||||||||
23 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02623725 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 2 | 2016-04-01 | 2019-01-01 | 2019-08-01 | Child | Adult | 252 | Brazil | Colombia | Honduras | Mexico | Puerto Rico | Results not yet reported | |||||||||||||||
24 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02992418 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 3 | 2016-12-01 | 2019-03-01 | 2019-03-01 | Child | Adult | 688 | Philippines | Results not yet reported | |||||||||||||||
25 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02993757 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 3 | 2016-12-01 | 2018-10-01 | 2018-10-01 | Child | 528 | Malaysia | Results not yet reported | |||||||||||||||
26 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02979535 | Open, not recruiting | Sanofi Pasteur | Industry | Phase 3 | 2016-11-01 | 2018-10-01 | 2018-10-01 | Child | 480 | Mexico | Results not yet reported | |||||||||||||||
27 | Dengue | DENV 1-4 | CYD-TDV | Registered | Recombinant viral vector | Protein: specify | PrM + E | None | NCT02741128 | Not yet open | Sanofi Pasteur | Industry | Phase 2 | 2017-03-01 | 2019-05-01 | 2019-05-01 | Adult | 150 | Brazil | Results not yet reported | |||||||||||||||
28 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01110551 | Completed | NIAID | Government | Phase 1 | 2010-05-01 | 2012-04-01 | 2012-12-01 | Adult | 72 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-03-19 | 25791116 | Referred to as DENVax | |||||||||||
29 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01224639 | Completed | Inviragen | Industry | Phase 1 | 2010-10-01 | 2011-06-01 | 2011-11-01 | Adult | 96 | Colombia | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-07-23 | 25087476 | clinicaltrials.gov | 2017-01-09 | NCT01224639 | |||||||||
30 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01765426 | Completed | Takeda | Industry | Phase 1 | 2013-02-01 | 2014-06-01 | 2014-06-01 | Adult | 67 | United States of America | Results reported in registry | clinicaltrials.gov | 2016-11-04 | NCT01765426 | ||||||||||||
31 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01542632 | Completed | Takeda | Industry | Phase 1 | 2012-01-01 | 2014-01-01 | 2014-01-01 | Adult | 140 | United States of America | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-09-15 | 26384447 | clinicaltrials.gov | 2014-12-31 | NCT01542632 | |||||||||
32 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01728792 | Completed | Takeda | Industry | Phase 1 | 2013-01-01 | 2013-11-01 | 2013-11-01 | Adult | 80 | United States of America | Results reported in registry | clinicaltrials.gov | 2016-08-30 | NCT01728792 | ||||||||||||
33 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01511250 | Completed | Takeda | Industry | Phase 2 | 2011-11-01 | 2016-04-01 | 2016-04-01 | Child | Adult | 344 | Colombia | Puerto Rico | Singapore | Thailand | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-12-23 | 26704612 | clinicaltrials.gov | 2018-03-27 | NCT01511250 | |||||||||
34 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02302066 | Open, not recruiting | Takeda | Industry | Phase 2 | 2014-12-01 | 2019-07-01 | 2019-07-01 | Child | 1800 | Dominican Republic | Panama | Philippines | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-06-01 | 28365225 | 29122463 | |||||||||||
35 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02193087 | Completed | Takeda | Industry | Phase 2 | 2014-07-01 | 2015-05-01 | 2015-05-01 | Adult | 1002 | United States of America | Results reported in registry | clinicaltrials.gov | 2016-05-19 | NCT02193087 | ||||||||||||
36 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02747927 | Open, not recruiting | Takeda | Industry | Phase 3 | 2016-09-01 | 2018-06-01 | 2021-12-01 | Child | 20100 | Brazil | Colombia | Dominican Republic | Nicaragua | Panama | Philippines | Sri Lanka | Thailand | Viet Nam | Results not yet reported | |||||||||||||||
37 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02948829 | Open, not recruiting | Takeda | Industry | Phase 2 | 2017-03-01 | 2017-07-01 | 2020-08-01 | Child | 200 | Panama | Philippines | Results not yet reported | |||||||||||||||
38 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02425098 | Completed | Takeda | Industry | Phase 2 | 2015-06-01 | 2017-08-01 | 2017-08-01 | Adult | 400 | Singapore | Results not yet reported | |||||||||||||||
39 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT03341637 | Open, recruiting | Takeda | Industry | Phase 3 | 2017-11-29 | 2018-06-16 | 2018-11-28 | Child | 400 | Mexico | Results not yet reported | |||||||||||||||
40 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT03342898 | Open, recruiting | Takeda | Industry | Phase 3 | 2017-11-27 | 2018-03-07 | 2019-02-05 | Adult | 900 | United States of America | Results not yet reported | |||||||||||||||
41 | Dengue | DENV 1-4 | TDV | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT03423173 | Open, not recruiting | Takeda | Industry | Phase 3 | 2018-02-18 | 2018-07-13 | 2018-12-17 | Adult | 924 | United States of America | Results not yet reported | |||||||||||||||
42 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01072786 | Completed | NIAID | Government | Phase 1 | 2010-07-01 | 2012-06-01 | 2012-06-01 | Adult | 141 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-01-17 | 23329850 | ||||||||||||
43 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01436422 | Completed | NIAID | Government | Phase 1 | 2011-08-01 | 2014-03-01 | 2014-03-01 | Adult | 112 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-03-22 | 25801652 | Check bc enrollment is low for publication | |||||||||||
44 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01506570 | Completed | NIAID | Government | Phase 1 | 2011-12-01 | 2013-09-01 | 2013-09-01 | Adult | 58 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-03-22 | 25801652 | Check bc enrollment is low for publication | |||||||||||
45 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01782300 | Completed | NIAID | Government | Phase 1 | 2013-01-01 | 2015-03-01 | 2016-06-01 | Adult | 48 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-02-16 | 26908742 | ||||||||||||
46 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02021968 | Completed | NIAID | Government | Phase 1 | 2013-11-01 | 2015-03-01 | 2015-12-01 | Adult | 48 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-03-16 | 27089205 | ||||||||||||
47 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT01696422 | Open, not recruiting | Butantan | Industry | Phase 2 | 2013-10-01 | 2016-04-01 | 2018-12-01 | Adult | 300 | Brazil | Results not yet reported | |||||||||||||||
48 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02332733 | Open, recruiting | NIAID | Government | Phase 2 | 2014-11-01 | 2018-08-01 | 2018-08-01 | Child | Adult | 266 | Thailand | Results not yet reported | |||||||||||||||
49 | Dengue | DENV 1-4 | V180/TV003/TV005 | Inactive / no longer in development | Prime-boost: specify | Protein: specify | Whole virus or PrM + E | Aluminum salts (alum) | NCT02450838 | Completed | NIAID | Government | Phase 1 | 2015-04-01 | 2015-10-01 | 2015-10-01 | Adult | 20 | United States of America | Results not yet reported | Abstract book: https://www.astmh.org/ASTMH/media/Documents/ASTMH-2016-Annual-Meeting-Abstract-Book.pdf | ||||||||||||||
50 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02406729 | Open, recruiting | Butantan | Industry | Phase 3 | 2016-02-01 | 2018-05-01 | 2022-11-01 | Child | Adult | 16944 | Brazil | Results not yet reported | |||||||||||||||
51 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02879266 | Completed | NIAID | Government | Phase 1 | 2016-02-01 | 2017-09-01 | 2019-03-01 | Adult | 28 | United States of America | Results not yet reported | |||||||||||||||
52 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02873260 | Completed | NIAID | Government | Phase 1 | 2016-08-01 | 2017-11-01 | 2017-11-01 | Adult | 48 | United States of America | Results not yet reported | |||||||||||||||
53 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02678455 | Open, not recruiting | NIAID | Government | Phase 2 | 2016-03-01 | 2020-02-01 | 2020-02-01 | Child | Adult | 192 | Bangladesh | Results not yet reported | |||||||||||||||
54 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02317900 | Completed | NIAID | Government | Phase 1 | 2014-12-01 | 2016-11-01 | 2016-11-01 | Adult | 48 | United States of America | Results not yet reported | |||||||||||||||
55 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus | None | ctri17222 | Open, not recruiting | Panacea Biotec | Industry | Phase 2 | 2017-02-20 | 2017-11-20 | 2017-11-20 | Child | Adult | 200 | India | Results not yet reported | |||||||||||||||
56 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus | None | NCT03416036 | Open, not recruiting | NIAID | Government | Phase 1 | 2017-11-28 | 2018-10-31 | 2019-06-30 | Adult | 60 | United States of America | Results not yet reported | |||||||||||||||
57 | Dengue | DENV 1-4 | TV003/ TV005 | Active candidate / in development | Recombinant viral vector | Protein: specify | Whole virus | None | NCT03485144 | Open, recruiting | Medigen Vaccine Biologics Corp. | Industry | Phase 2 | 2017-12-12 | 2018-12-01 | 2019-12-01 | Adult | 56 | Taiwan | Results not yet reported | |||||||||||||||
58 | Dengue | DENV 1, 3, 4 | Recombinant live attenuated trivalent dengue vaccine | Research Tool | Recombinant viral vector | Protein: specify | Whole virus or PrM + E | None | NCT02433652 | Completed | NIAID | Government | Phase 1 | 2015-09-01 | 2016-11-01 | 2016-11-01 | Adult | 24 | United States of America | Results not yet reported | Consider research category | ||||||||||||||
59 | Dengue | DENV 1-4 | TDENV-PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | Whole virus | Novel other: specify | Alum or AS03 or AS01 | NCT01666652 | Open, not recruiting | USAMRMC | Government | Phase 1 | 2012-09-01 | 2016-11-01 | 2017-02-01 | Adult | 100 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-07-01 | 28719287 | |||||||||||
60 | Dengue | DENV 1-4 | TDENV-PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | Whole virus | Novel other: specify | Alum or AS03 or AS01 | NCT01702857 | Completed | USAMRMC | Government | Phase 1 | 2012-11-01 | 2016-12-01 | 2019-12-01 | Adult | 100 | Puerto Rico | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2018-03-05 | 29512481 | |||||||||||
61 | Dengue | DENV 1-4 | TDENV-PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | Whole virus | Novel other: specify | AS03 | NCT02421367 | Open, recruiting | USAMRMC | Government | Phase 2 | 2015-08-01 | 2017-06-01 | 2017-06-01 | Adult | 140 | United States of America | Results not yet reported | Abstract 1350: https://www.astmh.org/ASTMH/media/Documents/Abstracts-1001-1500-ASTMH-2016-Annual-Meeting-Abstract-Book.pdf | |||||||||||||
62 | Dengue | DENV 1 | DENV1-PIV | Inactive / no longer in development | Inactivated whole target organism | Protein: specify | Whole virus | None | NCT01502735 | Completed | USAMRMC | Government | Phase 1 | 2011-12-01 | 2013-09-01 | 2013-09-01 | Adult | 20 | United States of America | Results not yet reported | |||||||||||||||
63 | Dengue | DENV 1-4 | PIV and LAV Prime-boost | Research Tool | Prime-boost: specify | Protein: specify | Whole virus | Aluminum salts (alum) | NCT02239614 | Completed | USAMRMC | Government | Phase 1 | 2014-11-01 | 2016-12-01 | 2019-12-01 | Adult | 80 | United States of America | Results not yet reported | |||||||||||||||
64 | Dengue | DENV 1-4 | PIV and LAV F17 Prime-boost | Active candidate / in development | Prime-boost: specify | Protein: specify | Whole virus | Aluminum salts (alum) | NCT03141138 | Open, recruiting | USAMRMC | Government | Phase 1 | 2017-11-02 | 2020-01-01 | 2022-01-01 | Adult | 40 | United States of America | Results not yet reported | |||||||||||||||
65 | Dengue | DENV 1-4 | PIV and LAV Prime-boost | Inactive / no longer in development | Prime-boost: specify | Protein: specify | Whole virus | Novel other: specify | AS03B | NCT03110952 | Withdrawn | USAMRMC | Government | Phase 1 | 2016-01-01 | 2017-04-01 | 2018-04-01 | Adult | 0 | United States of America | Results not yet reported | ||||||||||||||
66 | Dengue | DENV 1-4 | V180 | Active candidate / in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | PrM + E | Novel other: specify | ISCOMATRIX or Alhydrogel | NCT01477580 | Completed | Merck | Industry | Phase 1 | 2012-07-01 | 2014-01-01 | 2014-12-01 | Adult | 98 | United States of America | Results not yet reported | ||||||||||||||
67 | Dengue | DENV 1 | V180 (DEN1-80E) | Inactive / no longer in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Protein: specify | PrM + E | Aluminum salts (alum) | NCT00936429 | Completed | Hawaii Biotech | Industry | Phase 1 | 2009-07-01 | 2010-07-01 | 2011-01-01 | Adult | 16 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-10-14 | 26458804 | ||||||||||||
68 | Dengue | DENV 1-4 | TVDV | Active candidate / in development | DNA | Protein: specify | PrM + E | Novel other: specify | Vaxfectin | NCT01502358 | Completed | USAMRMC | Government | Phase 1 | 2011-12-01 | 2013-12-01 | 2013-12-01 | Adult | 40 | United States of America | Results not yet reported | ||||||||||||||
69 | Dengue | DENV 1 | rDEN1Δ30 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00473135 | Completed | NIAID | Government | Phase 1 | 2007-05-01 | 2010-01-01 | 2010-01-01 | Adult | 60 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2011-08-02 | 21829748 | 23735680 | |||||||||||
70 | Dengue | DENV 1 | rDEN1Δ30 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT01084291 | Completed | NIAID | Government | Phase 1 | 2010-04-01 | 2010-05-01 | 2010-06-01 | Adult | 18 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-06-02 | 23735680 | ||||||||||||
71 | Dengue | DENV 2 | rDEN2/4Δ30 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Whole virus | None | NCT00920517 | Completed | NIAID | Government | Phase 1 | 2009-01-01 | 2010-01-01 | 2010-01-01 | Adult | 25 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-06-02 | 23735680 | ||||||||||||
72 | Dengue | DENV 2 | rDEN2/4Δ30(ME) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Whole virus | None | NCT01073306 | Completed | NIAID | Government | Phase 1 | 2010-02-01 | 2010-06-01 | 2010-06-01 | Adult | 18 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-06-02 | 23735680 | ||||||||||||
73 | Dengue | DENV 2 | rDEN2Δ30-7169 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT01931176 | Completed | NIAID | Government | Phase 1 | 2013-06-01 | 2014-12-01 | 2015-05-01 | Adult | 14 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-09-28 | 26424605 | ||||||||||||
74 | Dengue | DENV 3 | rDEN3Δ30/31‐7164 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00831012 | Completed | NIAID | Government | Phase 1 | 2009-09-01 | 2011-06-01 | 2011-06-01 | Adult | 56 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-06-02 | 23735680 | ||||||||||||
75 | Dengue | DENV 3 | rDEN3-3'D4Δ30 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00712803 | Completed | NIAID | Government | Phase 1 | 2008-12-01 | 2009-09-01 | 2009-09-01 | Adult | 29 | United States of America | Results not yet reported | |||||||||||||||
76 | Dengue | DENV 4 | rDEN4Δ30 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00919178 | Completed | NIAID | Government | Phase 1 | 2009-07-01 | 2010-05-01 | 2010-05-01 | Adult | 70 | United States of America | Results not yet reported | |||||||||||||||
77 | Dengue | DENV 4 | rDEN4Δ30-4995 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00322946 | Completed | NIAID | Government | Phase 1 | 2007-01-01 | 2009-08-01 | 2009-08-01 | Adult | 84 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2009-11-01 | 19861619 | ||||||||||||
78 | Dengue | DENV 1, 2 | rDEN1Δ30, rDEN2/4Δ30(ME) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | Whole virus | None | NCT00458120 | Completed | NIAID | Government | Phase 1 | 2007-03-01 | 2008-08-01 | 2008-08-01 | Adult | 36 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2010-12-14 | 21208923 | ||||||||||||
79 | Dengue | DENV 3 | rDEN3Δ30 | Research Tool | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT02684383 | Completed | NIAID | Government | Phase 1 | Unspecified | 2016-07-01 | 2016-07-01 | Adult | 14 | United States of America | Results not yet reported | |||||||||||||||
80 | Dengue | DENV 1, 2 | rDEN1Δ30, rDEN2Δ30-7169 | Research Tool | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT02392325 | Completed | NIAID | Government | Phase 1 | 2015-05-01 | 2016-07-01 | 2017-02-01 | Adult | 12 | United States of America | Results not yet reported | |||||||||||||||
81 | Dengue | DENV 1-4 | T-DEN | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00468858 | Completed | USAMRMC | Government | Phase 2 | 2007-07-01 | 2010-04-01 | 2010-04-01 | Child | Adult | 636 | Puerto Rico | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2015-07-14 | 26175027 | clinicaltrials.gov | 2017-02-08 | NCT00468858 | |||||||||
82 | Dengue | DENV 1-4 | T-DEN | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | Whole virus | None | NCT00370682 | Completed | USAMRMC | Government | Phase 2 | 2007-04-01 | 2008-02-01 | 2008-02-01 | Adult | 120 | Thailand | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2014-05-27 | 24865677 | clinicaltrials.gov | 2017-03-08 | NCT00370682 | |||||||||
83 | |||||||||||||||||||||||||||||||||||
84 | |||||||||||||||||||||||||||||||||||
85 | |||||||||||||||||||||||||||||||||||
86 | |||||||||||||||||||||||||||||||||||
87 | |||||||||||||||||||||||||||||||||||
88 | |||||||||||||||||||||||||||||||||||
89 | |||||||||||||||||||||||||||||||||||
90 | |||||||||||||||||||||||||||||||||||
91 | |||||||||||||||||||||||||||||||||||
92 | |||||||||||||||||||||||||||||||||||
93 | |||||||||||||||||||||||||||||||||||
94 | |||||||||||||||||||||||||||||||||||
95 | |||||||||||||||||||||||||||||||||||
96 | |||||||||||||||||||||||||||||||||||
97 | |||||||||||||||||||||||||||||||||||
98 | |||||||||||||||||||||||||||||||||||
99 | |||||||||||||||||||||||||||||||||||
100 | |||||||||||||||||||||||||||||||||||
101 | |||||||||||||||||||||||||||||||||||
102 | |||||||||||||||||||||||||||||||||||
103 | |||||||||||||||||||||||||||||||||||
104 | |||||||||||||||||||||||||||||||||||
105 | |||||||||||||||||||||||||||||||||||
106 | |||||||||||||||||||||||||||||||||||
107 | |||||||||||||||||||||||||||||||||||
108 | |||||||||||||||||||||||||||||||||||
109 | |||||||||||||||||||||||||||||||||||
110 | |||||||||||||||||||||||||||||||||||
111 | |||||||||||||||||||||||||||||||||||
112 | |||||||||||||||||||||||||||||||||||
113 | |||||||||||||||||||||||||||||||||||
114 | |||||||||||||||||||||||||||||||||||
115 | |||||||||||||||||||||||||||||||||||
116 | |||||||||||||||||||||||||||||||||||
117 | |||||||||||||||||||||||||||||||||||
118 | |||||||||||||||||||||||||||||||||||
119 | |||||||||||||||||||||||||||||||||||
120 | |||||||||||||||||||||||||||||||||||
121 | |||||||||||||||||||||||||||||||||||
122 | |||||||||||||||||||||||||||||||||||
123 | |||||||||||||||||||||||||||||||||||
124 | |||||||||||||||||||||||||||||||||||
125 | |||||||||||||||||||||||||||||||||||
126 | |||||||||||||||||||||||||||||||||||
127 | |||||||||||||||||||||||||||||||||||
128 | |||||||||||||||||||||||||||||||||||
129 | |||||||||||||||||||||||||||||||||||
130 | |||||||||||||||||||||||||||||||||||
131 | |||||||||||||||||||||||||||||||||||
132 | |||||||||||||||||||||||||||||||||||
133 | |||||||||||||||||||||||||||||||||||
134 | |||||||||||||||||||||||||||||||||||
135 | |||||||||||||||||||||||||||||||||||
136 | |||||||||||||||||||||||||||||||||||
137 | |||||||||||||||||||||||||||||||||||
138 | |||||||||||||||||||||||||||||||||||
139 | |||||||||||||||||||||||||||||||||||
140 | |||||||||||||||||||||||||||||||||||
141 | |||||||||||||||||||||||||||||||||||
142 | |||||||||||||||||||||||||||||||||||
143 | |||||||||||||||||||||||||||||||||||
144 | |||||||||||||||||||||||||||||||||||
145 | |||||||||||||||||||||||||||||||||||
146 | |||||||||||||||||||||||||||||||||||
147 | |||||||||||||||||||||||||||||||||||
148 | |||||||||||||||||||||||||||||||||||
149 | |||||||||||||||||||||||||||||||||||
150 | |||||||||||||||||||||||||||||||||||
151 | |||||||||||||||||||||||||||||||||||
152 | |||||||||||||||||||||||||||||||||||
153 | |||||||||||||||||||||||||||||||||||
154 | |||||||||||||||||||||||||||||||||||
155 | |||||||||||||||||||||||||||||||||||
156 | |||||||||||||||||||||||||||||||||||
157 | |||||||||||||||||||||||||||||||||||
158 | |||||||||||||||||||||||||||||||||||
159 | |||||||||||||||||||||||||||||||||||
160 | |||||||||||||||||||||||||||||||||||
161 | |||||||||||||||||||||||||||||||||||
162 | |||||||||||||||||||||||||||||||||||
163 | |||||||||||||||||||||||||||||||||||
164 | |||||||||||||||||||||||||||||||||||
165 | |||||||||||||||||||||||||||||||||||
166 | |||||||||||||||||||||||||||||||||||
167 | |||||||||||||||||||||||||||||||||||
168 | |||||||||||||||||||||||||||||||||||
169 | |||||||||||||||||||||||||||||||||||
170 | |||||||||||||||||||||||||||||||||||
171 | |||||||||||||||||||||||||||||||||||
172 | |||||||||||||||||||||||||||||||||||
173 | |||||||||||||||||||||||||||||||||||
174 | |||||||||||||||||||||||||||||||||||
175 | |||||||||||||||||||||||||||||||||||
176 | |||||||||||||||||||||||||||||||||||
177 | |||||||||||||||||||||||||||||||||||
178 | |||||||||||||||||||||||||||||||||||
179 | |||||||||||||||||||||||||||||||||||
180 | |||||||||||||||||||||||||||||||||||
181 | |||||||||||||||||||||||||||||||||||
182 | |||||||||||||||||||||||||||||||||||
183 | |||||||||||||||||||||||||||||||||||
184 | |||||||||||||||||||||||||||||||||||
185 | |||||||||||||||||||||||||||||||||||
186 | |||||||||||||||||||||||||||||||||||
187 | |||||||||||||||||||||||||||||||||||
188 | |||||||||||||||||||||||||||||||||||
189 | |||||||||||||||||||||||||||||||||||
190 | |||||||||||||||||||||||||||||||||||
191 | |||||||||||||||||||||||||||||||||||
192 | |||||||||||||||||||||||||||||||||||
193 | |||||||||||||||||||||||||||||||||||
194 | |||||||||||||||||||||||||||||||||||
195 | |||||||||||||||||||||||||||||||||||
196 | |||||||||||||||||||||||||||||||||||
197 | |||||||||||||||||||||||||||||||||||
198 | |||||||||||||||||||||||||||||||||||
199 | |||||||||||||||||||||||||||||||||||
200 | |||||||||||||||||||||||||||||||||||
201 | |||||||||||||||||||||||||||||||||||
202 | |||||||||||||||||||||||||||||||||||
203 | |||||||||||||||||||||||||||||||||||
204 | |||||||||||||||||||||||||||||||||||
205 | |||||||||||||||||||||||||||||||||||
206 | |||||||||||||||||||||||||||||||||||
207 | |||||||||||||||||||||||||||||||||||
208 | |||||||||||||||||||||||||||||||||||
209 | |||||||||||||||||||||||||||||||||||
210 | |||||||||||||||||||||||||||||||||||
211 | |||||||||||||||||||||||||||||||||||
212 | |||||||||||||||||||||||||||||||||||
213 | |||||||||||||||||||||||||||||||||||
214 | |||||||||||||||||||||||||||||||||||
215 | |||||||||||||||||||||||||||||||||||
216 | |||||||||||||||||||||||||||||||||||
217 | |||||||||||||||||||||||||||||||||||
218 | |||||||||||||||||||||||||||||||||||
219 | |||||||||||||||||||||||||||||||||||
220 | |||||||||||||||||||||||||||||||||||
221 | |||||||||||||||||||||||||||||||||||
222 | |||||||||||||||||||||||||||||||||||
223 | |||||||||||||||||||||||||||||||||||
224 | |||||||||||||||||||||||||||||||||||
225 | |||||||||||||||||||||||||||||||||||
226 | |||||||||||||||||||||||||||||||||||
227 | |||||||||||||||||||||||||||||||||||
228 | |||||||||||||||||||||||||||||||||||
229 | |||||||||||||||||||||||||||||||||||
230 | |||||||||||||||||||||||||||||||||||
231 | |||||||||||||||||||||||||||||||||||
232 | |||||||||||||||||||||||||||||||||||
233 | |||||||||||||||||||||||||||||||||||
234 | |||||||||||||||||||||||||||||||||||
235 | |||||||||||||||||||||||||||||||||||
236 | |||||||||||||||||||||||||||||||||||
237 | |||||||||||||||||||||||||||||||||||
238 | |||||||||||||||||||||||||||||||||||
239 | |||||||||||||||||||||||||||||||||||
240 | |||||||||||||||||||||||||||||||||||
241 | |||||||||||||||||||||||||||||||||||
242 | |||||||||||||||||||||||||||||||||||
243 | |||||||||||||||||||||||||||||||||||
244 | |||||||||||||||||||||||||||||||||||
245 | |||||||||||||||||||||||||||||||||||
246 | |||||||||||||||||||||||||||||||||||
247 | |||||||||||||||||||||||||||||||||||
248 | |||||||||||||||||||||||||||||||||||
249 | |||||||||||||||||||||||||||||||||||
250 | |||||||||||||||||||||||||||||||||||
251 | |||||||||||||||||||||||||||||||||||
252 | |||||||||||||||||||||||||||||||||||
253 | |||||||||||||||||||||||||||||||||||
254 | |||||||||||||||||||||||||||||||||||
255 | |||||||||||||||||||||||||||||||||||
256 | |||||||||||||||||||||||||||||||||||
257 | |||||||||||||||||||||||||||||||||||
258 | |||||||||||||||||||||||||||||||||||
259 | |||||||||||||||||||||||||||||||||||
260 | |||||||||||||||||||||||||||||||||||
261 | |||||||||||||||||||||||||||||||||||
262 | |||||||||||||||||||||||||||||||||||
263 | |||||||||||||||||||||||||||||||||||
264 | |||||||||||||||||||||||||||||||||||
265 | |||||||||||||||||||||||||||||||||||
266 | |||||||||||||||||||||||||||||||||||
267 | |||||||||||||||||||||||||||||||||||
268 | |||||||||||||||||||||||||||||||||||
269 | |||||||||||||||||||||||||||||||||||
270 | |||||||||||||||||||||||||||||||||||
271 | |||||||||||||||||||||||||||||||||||
272 | |||||||||||||||||||||||||||||||||||
273 | |||||||||||||||||||||||||||||||||||
274 | |||||||||||||||||||||||||||||||||||
275 | |||||||||||||||||||||||||||||||||||
276 | |||||||||||||||||||||||||||||||||||
277 | |||||||||||||||||||||||||||||||||||
278 | |||||||||||||||||||||||||||||||||||
279 | |||||||||||||||||||||||||||||||||||
280 | |||||||||||||||||||||||||||||||||||
281 | |||||||||||||||||||||||||||||||||||
282 | |||||||||||||||||||||||||||||||||||
283 | |||||||||||||||||||||||||||||||||||
284 | |||||||||||||||||||||||||||||||||||
285 | |||||||||||||||||||||||||||||||||||
286 | |||||||||||||||||||||||||||||||||||
287 | |||||||||||||||||||||||||||||||||||
288 | |||||||||||||||||||||||||||||||||||
289 | |||||||||||||||||||||||||||||||||||
290 | |||||||||||||||||||||||||||||||||||
291 | |||||||||||||||||||||||||||||||||||
292 | |||||||||||||||||||||||||||||||||||
293 | |||||||||||||||||||||||||||||||||||
294 | |||||||||||||||||||||||||||||||||||
295 | |||||||||||||||||||||||||||||||||||
296 | |||||||||||||||||||||||||||||||||||
297 | |||||||||||||||||||||||||||||||||||
298 | |||||||||||||||||||||||||||||||||||
299 | |||||||||||||||||||||||||||||||||||
300 | |||||||||||||||||||||||||||||||||||
301 | |||||||||||||||||||||||||||||||||||
302 | |||||||||||||||||||||||||||||||||||
303 | |||||||||||||||||||||||||||||||||||
304 | |||||||||||||||||||||||||||||||||||
305 | |||||||||||||||||||||||||||||||||||
306 | |||||||||||||||||||||||||||||||||||
307 | |||||||||||||||||||||||||||||||||||
308 | |||||||||||||||||||||||||||||||||||
309 | |||||||||||||||||||||||||||||||||||
310 | |||||||||||||||||||||||||||||||||||
311 | |||||||||||||||||||||||||||||||||||
312 | |||||||||||||||||||||||||||||||||||
313 | |||||||||||||||||||||||||||||||||||
314 | |||||||||||||||||||||||||||||||||||
315 | |||||||||||||||||||||||||||||||||||
316 | |||||||||||||||||||||||||||||||||||
317 | |||||||||||||||||||||||||||||||||||
318 | |||||||||||||||||||||||||||||||||||
319 | |||||||||||||||||||||||||||||||||||
320 | |||||||||||||||||||||||||||||||||||
321 | |||||||||||||||||||||||||||||||||||
322 | |||||||||||||||||||||||||||||||||||
323 | |||||||||||||||||||||||||||||||||||
324 | |||||||||||||||||||||||||||||||||||
325 | |||||||||||||||||||||||||||||||||||
326 | |||||||||||||||||||||||||||||||||||
327 | |||||||||||||||||||||||||||||||||||
328 | |||||||||||||||||||||||||||||||||||
329 | |||||||||||||||||||||||||||||||||||
330 | |||||||||||||||||||||||||||||||||||
331 | |||||||||||||||||||||||||||||||||||
332 | |||||||||||||||||||||||||||||||||||
333 | |||||||||||||||||||||||||||||||||||
334 | |||||||||||||||||||||||||||||||||||
335 | |||||||||||||||||||||||||||||||||||
336 | |||||||||||||||||||||||||||||||||||
337 | |||||||||||||||||||||||||||||||||||
338 | |||||||||||||||||||||||||||||||||||
339 | |||||||||||||||||||||||||||||||||||
340 | |||||||||||||||||||||||||||||||||||
341 | |||||||||||||||||||||||||||||||||||
342 | |||||||||||||||||||||||||||||||||||
343 | |||||||||||||||||||||||||||||||||||
344 | |||||||||||||||||||||||||||||||||||
345 | |||||||||||||||||||||||||||||||||||
346 | |||||||||||||||||||||||||||||||||||
347 | |||||||||||||||||||||||||||||||||||
348 | |||||||||||||||||||||||||||||||||||
349 | |||||||||||||||||||||||||||||||||||
350 | |||||||||||||||||||||||||||||||||||
351 | |||||||||||||||||||||||||||||||||||
352 | |||||||||||||||||||||||||||||||||||
353 | |||||||||||||||||||||||||||||||||||
354 | |||||||||||||||||||||||||||||||||||
355 | |||||||||||||||||||||||||||||||||||
356 | |||||||||||||||||||||||||||||||||||
357 | |||||||||||||||||||||||||||||||||||
358 | |||||||||||||||||||||||||||||||||||
359 | |||||||||||||||||||||||||||||||||||
360 | |||||||||||||||||||||||||||||||||||
361 | |||||||||||||||||||||||||||||||||||
362 | |||||||||||||||||||||||||||||||||||
363 | |||||||||||||||||||||||||||||||||||
364 | |||||||||||||||||||||||||||||||||||
365 | |||||||||||||||||||||||||||||||||||
366 | |||||||||||||||||||||||||||||||||||
367 | |||||||||||||||||||||||||||||||||||
368 | |||||||||||||||||||||||||||||||||||
369 | |||||||||||||||||||||||||||||||||||
370 | |||||||||||||||||||||||||||||||||||
371 | |||||||||||||||||||||||||||||||||||
372 | |||||||||||||||||||||||||||||||||||
373 | |||||||||||||||||||||||||||||||||||
374 | |||||||||||||||||||||||||||||||||||
375 | |||||||||||||||||||||||||||||||||||
376 | |||||||||||||||||||||||||||||||||||
377 | |||||||||||||||||||||||||||||||||||
378 | |||||||||||||||||||||||||||||||||||
379 | |||||||||||||||||||||||||||||||||||
380 | |||||||||||||||||||||||||||||||||||
381 | |||||||||||||||||||||||||||||||||||
382 | |||||||||||||||||||||||||||||||||||
383 | |||||||||||||||||||||||||||||||||||
384 | |||||||||||||||||||||||||||||||||||
385 | |||||||||||||||||||||||||||||||||||
386 | |||||||||||||||||||||||||||||||||||
387 | |||||||||||||||||||||||||||||||||||
388 | |||||||||||||||||||||||||||||||||||
389 | |||||||||||||||||||||||||||||||||||
390 | |||||||||||||||||||||||||||||||||||
391 | |||||||||||||||||||||||||||||||||||
392 | |||||||||||||||||||||||||||||||||||
393 | |||||||||||||||||||||||||||||||||||
394 | |||||||||||||||||||||||||||||||||||
395 | |||||||||||||||||||||||||||||||||||
396 | |||||||||||||||||||||||||||||||||||
397 | |||||||||||||||||||||||||||||||||||
398 | |||||||||||||||||||||||||||||||||||
399 | |||||||||||||||||||||||||||||||||||
400 | |||||||||||||||||||||||||||||||||||
401 | |||||||||||||||||||||||||||||||||||
402 | |||||||||||||||||||||||||||||||||||
403 | |||||||||||||||||||||||||||||||||||
404 | |||||||||||||||||||||||||||||||||||
405 | |||||||||||||||||||||||||||||||||||
406 | |||||||||||||||||||||||||||||||||||
407 | |||||||||||||||||||||||||||||||||||
408 | |||||||||||||||||||||||||||||||||||
409 | |||||||||||||||||||||||||||||||||||
410 | |||||||||||||||||||||||||||||||||||
411 | |||||||||||||||||||||||||||||||||||
412 | |||||||||||||||||||||||||||||||||||
413 | |||||||||||||||||||||||||||||||||||
414 | |||||||||||||||||||||||||||||||||||
415 | |||||||||||||||||||||||||||||||||||
416 | |||||||||||||||||||||||||||||||||||
417 | |||||||||||||||||||||||||||||||||||
418 | |||||||||||||||||||||||||||||||||||
419 | |||||||||||||||||||||||||||||||||||
420 | |||||||||||||||||||||||||||||||||||
421 | |||||||||||||||||||||||||||||||||||
422 | |||||||||||||||||||||||||||||||||||
423 | |||||||||||||||||||||||||||||||||||
424 | |||||||||||||||||||||||||||||||||||
425 | |||||||||||||||||||||||||||||||||||
426 | |||||||||||||||||||||||||||||||||||
427 | |||||||||||||||||||||||||||||||||||
428 | |||||||||||||||||||||||||||||||||||
429 | |||||||||||||||||||||||||||||||||||
430 | |||||||||||||||||||||||||||||||||||
431 | |||||||||||||||||||||||||||||||||||
432 | |||||||||||||||||||||||||||||||||||
433 | |||||||||||||||||||||||||||||||||||
434 | |||||||||||||||||||||||||||||||||||
435 | |||||||||||||||||||||||||||||||||||
436 | |||||||||||||||||||||||||||||||||||
437 | |||||||||||||||||||||||||||||||||||
438 | |||||||||||||||||||||||||||||||||||
439 | |||||||||||||||||||||||||||||||||||
440 | |||||||||||||||||||||||||||||||||||
441 | |||||||||||||||||||||||||||||||||||
442 | |||||||||||||||||||||||||||||||||||
443 | |||||||||||||||||||||||||||||||||||
444 | |||||||||||||||||||||||||||||||||||
445 | |||||||||||||||||||||||||||||||||||
446 | |||||||||||||||||||||||||||||||||||
447 | |||||||||||||||||||||||||||||||||||
448 | |||||||||||||||||||||||||||||||||||
449 | |||||||||||||||||||||||||||||||||||
450 | |||||||||||||||||||||||||||||||||||
451 | |||||||||||||||||||||||||||||||||||
452 | |||||||||||||||||||||||||||||||||||
453 | |||||||||||||||||||||||||||||||||||
454 | |||||||||||||||||||||||||||||||||||
455 | |||||||||||||||||||||||||||||||||||
456 | |||||||||||||||||||||||||||||||||||
457 | |||||||||||||||||||||||||||||||||||
458 | |||||||||||||||||||||||||||||||||||
459 | |||||||||||||||||||||||||||||||||||
460 | |||||||||||||||||||||||||||||||||||
461 | |||||||||||||||||||||||||||||||||||
462 | |||||||||||||||||||||||||||||||||||
463 | |||||||||||||||||||||||||||||||||||
464 | |||||||||||||||||||||||||||||||||||
465 | |||||||||||||||||||||||||||||||||||
466 | |||||||||||||||||||||||||||||||||||
467 | |||||||||||||||||||||||||||||||||||
468 | |||||||||||||||||||||||||||||||||||
469 | |||||||||||||||||||||||||||||||||||
470 | |||||||||||||||||||||||||||||||||||
471 | |||||||||||||||||||||||||||||||||||
472 | |||||||||||||||||||||||||||||||||||
473 | |||||||||||||||||||||||||||||||||||
474 | |||||||||||||||||||||||||||||||||||
475 | |||||||||||||||||||||||||||||||||||
476 | |||||||||||||||||||||||||||||||||||
477 | |||||||||||||||||||||||||||||||||||
478 | |||||||||||||||||||||||||||||||||||
479 | |||||||||||||||||||||||||||||||||||
480 | |||||||||||||||||||||||||||||||||||
481 | |||||||||||||||||||||||||||||||||||
482 | |||||||||||||||||||||||||||||||||||
483 | |||||||||||||||||||||||||||||||||||
484 | |||||||||||||||||||||||||||||||||||
485 | |||||||||||||||||||||||||||||||||||
486 | |||||||||||||||||||||||||||||||||||
487 | |||||||||||||||||||||||||||||||||||
488 | |||||||||||||||||||||||||||||||||||
489 | |||||||||||||||||||||||||||||||||||
490 | |||||||||||||||||||||||||||||||||||
491 | |||||||||||||||||||||||||||||||||||
492 | |||||||||||||||||||||||||||||||||||
493 | |||||||||||||||||||||||||||||||||||
494 | |||||||||||||||||||||||||||||||||||
495 | |||||||||||||||||||||||||||||||||||
496 | |||||||||||||||||||||||||||||||||||
497 | |||||||||||||||||||||||||||||||||||
498 | |||||||||||||||||||||||||||||||||||
499 | |||||||||||||||||||||||||||||||||||
500 | |||||||||||||||||||||||||||||||||||
501 | |||||||||||||||||||||||||||||||||||
502 | |||||||||||||||||||||||||||||||||||
503 | |||||||||||||||||||||||||||||||||||
504 | |||||||||||||||||||||||||||||||||||
505 | |||||||||||||||||||||||||||||||||||
506 | |||||||||||||||||||||||||||||||||||
507 | |||||||||||||||||||||||||||||||||||
508 | |||||||||||||||||||||||||||||||||||
509 | |||||||||||||||||||||||||||||||||||
510 | |||||||||||||||||||||||||||||||||||
511 | |||||||||||||||||||||||||||||||||||
512 | |||||||||||||||||||||||||||||||||||
513 | |||||||||||||||||||||||||||||||||||
514 | |||||||||||||||||||||||||||||||||||
515 | |||||||||||||||||||||||||||||||||||
516 | |||||||||||||||||||||||||||||||||||
517 | |||||||||||||||||||||||||||||||||||
518 | |||||||||||||||||||||||||||||||||||
519 | |||||||||||||||||||||||||||||||||||
520 | |||||||||||||||||||||||||||||||||||
521 | |||||||||||||||||||||||||||||||||||
522 | |||||||||||||||||||||||||||||||||||
523 | |||||||||||||||||||||||||||||||||||
524 | |||||||||||||||||||||||||||||||||||
525 | |||||||||||||||||||||||||||||||||||
526 | |||||||||||||||||||||||||||||||||||
527 | |||||||||||||||||||||||||||||||||||
528 | |||||||||||||||||||||||||||||||||||
529 | |||||||||||||||||||||||||||||||||||
530 | |||||||||||||||||||||||||||||||||||
531 | |||||||||||||||||||||||||||||||||||
532 | |||||||||||||||||||||||||||||||||||
533 | |||||||||||||||||||||||||||||||||||
534 | |||||||||||||||||||||||||||||||||||
535 | |||||||||||||||||||||||||||||||||||
536 | |||||||||||||||||||||||||||||||||||
537 | |||||||||||||||||||||||||||||||||||
538 | |||||||||||||||||||||||||||||||||||
539 | |||||||||||||||||||||||||||||||||||
540 | |||||||||||||||||||||||||||||||||||
541 | |||||||||||||||||||||||||||||||||||
542 | |||||||||||||||||||||||||||||||||||
543 | |||||||||||||||||||||||||||||||||||
544 | |||||||||||||||||||||||||||||||||||
545 | |||||||||||||||||||||||||||||||||||
546 | |||||||||||||||||||||||||||||||||||
547 | |||||||||||||||||||||||||||||||||||
548 | |||||||||||||||||||||||||||||||||||
549 | |||||||||||||||||||||||||||||||||||
550 | |||||||||||||||||||||||||||||||||||
551 | |||||||||||||||||||||||||||||||||||
552 | |||||||||||||||||||||||||||||||||||
553 | |||||||||||||||||||||||||||||||||||
554 | |||||||||||||||||||||||||||||||||||
555 | |||||||||||||||||||||||||||||||||||
556 | |||||||||||||||||||||||||||||||||||
557 | |||||||||||||||||||||||||||||||||||
558 | |||||||||||||||||||||||||||||||||||
559 | |||||||||||||||||||||||||||||||||||
560 | |||||||||||||||||||||||||||||||||||
561 | |||||||||||||||||||||||||||||||||||
562 | |||||||||||||||||||||||||||||||||||
563 | |||||||||||||||||||||||||||||||||||
564 | |||||||||||||||||||||||||||||||||||
565 | |||||||||||||||||||||||||||||||||||
566 | |||||||||||||||||||||||||||||||||||
567 | |||||||||||||||||||||||||||||||||||
568 | |||||||||||||||||||||||||||||||||||
569 | |||||||||||||||||||||||||||||||||||
570 | |||||||||||||||||||||||||||||||||||
571 | |||||||||||||||||||||||||||||||||||
572 | |||||||||||||||||||||||||||||||||||
573 | |||||||||||||||||||||||||||||||||||
574 | |||||||||||||||||||||||||||||||||||
575 | |||||||||||||||||||||||||||||||||||
576 | |||||||||||||||||||||||||||||||||||
577 | |||||||||||||||||||||||||||||||||||
578 | |||||||||||||||||||||||||||||||||||
579 | |||||||||||||||||||||||||||||||||||
580 | |||||||||||||||||||||||||||||||||||
581 | |||||||||||||||||||||||||||||||||||
582 | |||||||||||||||||||||||||||||||||||
583 | |||||||||||||||||||||||||||||||||||
584 | |||||||||||||||||||||||||||||||||||
585 | |||||||||||||||||||||||||||||||||||
586 | |||||||||||||||||||||||||||||||||||
587 | |||||||||||||||||||||||||||||||||||
588 | |||||||||||||||||||||||||||||||||||
589 | |||||||||||||||||||||||||||||||||||
590 | |||||||||||||||||||||||||||||||||||
591 | |||||||||||||||||||||||||||||||||||
592 | |||||||||||||||||||||||||||||||||||
593 | |||||||||||||||||||||||||||||||||||
594 | |||||||||||||||||||||||||||||||||||
595 | |||||||||||||||||||||||||||||||||||
596 | |||||||||||||||||||||||||||||||||||
597 | |||||||||||||||||||||||||||||||||||
598 | |||||||||||||||||||||||||||||||||||
599 | |||||||||||||||||||||||||||||||||||
600 | |||||||||||||||||||||||||||||||||||
601 | |||||||||||||||||||||||||||||||||||
602 | |||||||||||||||||||||||||||||||||||
603 | |||||||||||||||||||||||||||||||||||
604 | |||||||||||||||||||||||||||||||||||
605 | |||||||||||||||||||||||||||||||||||
606 | |||||||||||||||||||||||||||||||||||
607 | |||||||||||||||||||||||||||||||||||
608 | |||||||||||||||||||||||||||||||||||
609 | |||||||||||||||||||||||||||||||||||
610 | |||||||||||||||||||||||||||||||||||
611 | |||||||||||||||||||||||||||||||||||
612 | |||||||||||||||||||||||||||||||||||
613 | |||||||||||||||||||||||||||||||||||
614 | |||||||||||||||||||||||||||||||||||
615 | |||||||||||||||||||||||||||||||||||
616 | |||||||||||||||||||||||||||||||||||
617 | |||||||||||||||||||||||||||||||||||
618 | |||||||||||||||||||||||||||||||||||
619 | |||||||||||||||||||||||||||||||||||
620 | |||||||||||||||||||||||||||||||||||
621 | |||||||||||||||||||||||||||||||||||
622 | |||||||||||||||||||||||||||||||||||
623 | |||||||||||||||||||||||||||||||||||
624 | |||||||||||||||||||||||||||||||||||
625 | |||||||||||||||||||||||||||||||||||
626 | |||||||||||||||||||||||||||||||||||
627 | |||||||||||||||||||||||||||||||||||
628 | |||||||||||||||||||||||||||||||||||
629 | |||||||||||||||||||||||||||||||||||
630 | |||||||||||||||||||||||||||||||||||
631 | |||||||||||||||||||||||||||||||||||
632 | |||||||||||||||||||||||||||||||||||
633 | |||||||||||||||||||||||||||||||||||
634 | |||||||||||||||||||||||||||||||||||
635 | |||||||||||||||||||||||||||||||||||
636 | |||||||||||||||||||||||||||||||||||
637 | |||||||||||||||||||||||||||||||||||
638 | |||||||||||||||||||||||||||||||||||
639 | |||||||||||||||||||||||||||||||||||
640 | |||||||||||||||||||||||||||||||||||
641 | |||||||||||||||||||||||||||||||||||
642 | |||||||||||||||||||||||||||||||||||
643 | |||||||||||||||||||||||||||||||||||
644 | |||||||||||||||||||||||||||||||||||
645 | |||||||||||||||||||||||||||||||||||
646 | |||||||||||||||||||||||||||||||||||
647 | |||||||||||||||||||||||||||||||||||
648 | |||||||||||||||||||||||||||||||||||
649 | |||||||||||||||||||||||||||||||||||
650 | |||||||||||||||||||||||||||||||||||
651 | |||||||||||||||||||||||||||||||||||
652 | |||||||||||||||||||||||||||||||||||
653 | |||||||||||||||||||||||||||||||||||
654 | |||||||||||||||||||||||||||||||||||
655 | |||||||||||||||||||||||||||||||||||
656 | |||||||||||||||||||||||||||||||||||
657 | |||||||||||||||||||||||||||||||||||
658 | |||||||||||||||||||||||||||||||||||
659 | |||||||||||||||||||||||||||||||||||
660 | |||||||||||||||||||||||||||||||||||
661 | |||||||||||||||||||||||||||||||||||
662 | |||||||||||||||||||||||||||||||||||
663 | |||||||||||||||||||||||||||||||||||
664 | |||||||||||||||||||||||||||||||||||
665 | |||||||||||||||||||||||||||||||||||
666 | |||||||||||||||||||||||||||||||||||
667 | |||||||||||||||||||||||||||||||||||
668 | |||||||||||||||||||||||||||||||||||
669 | |||||||||||||||||||||||||||||||||||
670 | |||||||||||||||||||||||||||||||||||
671 | |||||||||||||||||||||||||||||||||||
672 | |||||||||||||||||||||||||||||||||||
673 | |||||||||||||||||||||||||||||||||||
674 | |||||||||||||||||||||||||||||||||||
675 | |||||||||||||||||||||||||||||||||||
676 | |||||||||||||||||||||||||||||||||||
677 | |||||||||||||||||||||||||||||||||||
678 | |||||||||||||||||||||||||||||||||||
679 | |||||||||||||||||||||||||||||||||||
680 | |||||||||||||||||||||||||||||||||||
681 | |||||||||||||||||||||||||||||||||||
682 | |||||||||||||||||||||||||||||||||||
683 | |||||||||||||||||||||||||||||||||||
684 | |||||||||||||||||||||||||||||||||||
685 | |||||||||||||||||||||||||||||||||||
686 | |||||||||||||||||||||||||||||||||||
687 | |||||||||||||||||||||||||||||||||||
688 | |||||||||||||||||||||||||||||||||||
689 | |||||||||||||||||||||||||||||||||||
690 | |||||||||||||||||||||||||||||||||||
691 | |||||||||||||||||||||||||||||||||||
692 | |||||||||||||||||||||||||||||||||||
693 | |||||||||||||||||||||||||||||||||||
694 | |||||||||||||||||||||||||||||||||||
695 | |||||||||||||||||||||||||||||||||||
696 | |||||||||||||||||||||||||||||||||||
697 | |||||||||||||||||||||||||||||||||||
698 | |||||||||||||||||||||||||||||||||||
699 | |||||||||||||||||||||||||||||||||||
700 | |||||||||||||||||||||||||||||||||||
701 | |||||||||||||||||||||||||||||||||||
702 | |||||||||||||||||||||||||||||||||||
703 | |||||||||||||||||||||||||||||||||||
704 | |||||||||||||||||||||||||||||||||||
705 | |||||||||||||||||||||||||||||||||||
706 | |||||||||||||||||||||||||||||||||||
707 | |||||||||||||||||||||||||||||||||||
708 | |||||||||||||||||||||||||||||||||||
709 | |||||||||||||||||||||||||||||||||||
710 | |||||||||||||||||||||||||||||||||||
711 | |||||||||||||||||||||||||||||||||||
712 | |||||||||||||||||||||||||||||||||||
713 | |||||||||||||||||||||||||||||||||||
714 | |||||||||||||||||||||||||||||||||||
715 | |||||||||||||||||||||||||||||||||||
716 | |||||||||||||||||||||||||||||||||||
717 | |||||||||||||||||||||||||||||||||||
718 | |||||||||||||||||||||||||||||||||||
719 | |||||||||||||||||||||||||||||||||||
720 | |||||||||||||||||||||||||||||||||||
721 | |||||||||||||||||||||||||||||||||||
722 | |||||||||||||||||||||||||||||||||||
723 | |||||||||||||||||||||||||||||||||||
724 | |||||||||||||||||||||||||||||||||||
725 | |||||||||||||||||||||||||||||||||||
726 | |||||||||||||||||||||||||||||||||||
727 | |||||||||||||||||||||||||||||||||||
728 | |||||||||||||||||||||||||||||||||||
729 | |||||||||||||||||||||||||||||||||||
730 | |||||||||||||||||||||||||||||||||||
731 | |||||||||||||||||||||||||||||||||||
732 | |||||||||||||||||||||||||||||||||||
733 | |||||||||||||||||||||||||||||||||||
734 | |||||||||||||||||||||||||||||||||||
735 | |||||||||||||||||||||||||||||||||||
736 | |||||||||||||||||||||||||||||||||||
737 | |||||||||||||||||||||||||||||||||||
738 | |||||||||||||||||||||||||||||||||||
739 | |||||||||||||||||||||||||||||||||||
740 | |||||||||||||||||||||||||||||||||||
741 | |||||||||||||||||||||||||||||||||||
742 | |||||||||||||||||||||||||||||||||||
743 | |||||||||||||||||||||||||||||||||||
744 | |||||||||||||||||||||||||||||||||||
745 | |||||||||||||||||||||||||||||||||||
746 | |||||||||||||||||||||||||||||||||||
747 | |||||||||||||||||||||||||||||||||||
748 | |||||||||||||||||||||||||||||||||||
749 | |||||||||||||||||||||||||||||||||||
750 | |||||||||||||||||||||||||||||||||||
751 | |||||||||||||||||||||||||||||||||||
752 | |||||||||||||||||||||||||||||||||||
753 | |||||||||||||||||||||||||||||||||||
754 | |||||||||||||||||||||||||||||||||||
755 | |||||||||||||||||||||||||||||||||||
756 | |||||||||||||||||||||||||||||||||||
757 | |||||||||||||||||||||||||||||||||||
758 | |||||||||||||||||||||||||||||||||||
759 | |||||||||||||||||||||||||||||||||||
760 | |||||||||||||||||||||||||||||||||||
761 | |||||||||||||||||||||||||||||||||||
762 | |||||||||||||||||||||||||||||||||||
763 | |||||||||||||||||||||||||||||||||||
764 | |||||||||||||||||||||||||||||||||||
765 | |||||||||||||||||||||||||||||||||||
766 | |||||||||||||||||||||||||||||||||||
767 | |||||||||||||||||||||||||||||||||||
768 | |||||||||||||||||||||||||||||||||||
769 | |||||||||||||||||||||||||||||||||||
770 | |||||||||||||||||||||||||||||||||||
771 | |||||||||||||||||||||||||||||||||||
772 | |||||||||||||||||||||||||||||||||||
773 | |||||||||||||||||||||||||||||||||||
774 | |||||||||||||||||||||||||||||||||||
775 | |||||||||||||||||||||||||||||||||||
776 | |||||||||||||||||||||||||||||||||||
777 | |||||||||||||||||||||||||||||||||||
778 | |||||||||||||||||||||||||||||||||||
779 | |||||||||||||||||||||||||||||||||||
780 | |||||||||||||||||||||||||||||||||||
781 | |||||||||||||||||||||||||||||||||||
782 | |||||||||||||||||||||||||||||||||||
783 | |||||||||||||||||||||||||||||||||||
784 | |||||||||||||||||||||||||||||||||||
785 | |||||||||||||||||||||||||||||||||||
786 | |||||||||||||||||||||||||||||||||||
787 | |||||||||||||||||||||||||||||||||||
788 | |||||||||||||||||||||||||||||||||||
789 | |||||||||||||||||||||||||||||||||||
790 | |||||||||||||||||||||||||||||||||||
791 | |||||||||||||||||||||||||||||||||||
792 | |||||||||||||||||||||||||||||||||||
793 | |||||||||||||||||||||||||||||||||||
794 | |||||||||||||||||||||||||||||||||||
795 | |||||||||||||||||||||||||||||||||||
796 | |||||||||||||||||||||||||||||||||||
797 | |||||||||||||||||||||||||||||||||||
798 | |||||||||||||||||||||||||||||||||||
799 | |||||||||||||||||||||||||||||||||||
800 | |||||||||||||||||||||||||||||||||||
801 | |||||||||||||||||||||||||||||||||||
802 | |||||||||||||||||||||||||||||||||||
803 | |||||||||||||||||||||||||||||||||||
804 | |||||||||||||||||||||||||||||||||||
805 | |||||||||||||||||||||||||||||||||||
806 | |||||||||||||||||||||||||||||||||||
807 | |||||||||||||||||||||||||||||||||||
808 | |||||||||||||||||||||||||||||||||||
809 | |||||||||||||||||||||||||||||||||||
810 | |||||||||||||||||||||||||||||||||||
811 | |||||||||||||||||||||||||||||||||||
812 | |||||||||||||||||||||||||||||||||||
813 | |||||||||||||||||||||||||||||||||||
814 | |||||||||||||||||||||||||||||||||||
815 | |||||||||||||||||||||||||||||||||||
816 | |||||||||||||||||||||||||||||||||||
817 | |||||||||||||||||||||||||||||||||||
818 | |||||||||||||||||||||||||||||||||||
819 | |||||||||||||||||||||||||||||||||||
820 | |||||||||||||||||||||||||||||||||||
821 | |||||||||||||||||||||||||||||||||||
822 | |||||||||||||||||||||||||||||||||||
823 | |||||||||||||||||||||||||||||||||||
824 | |||||||||||||||||||||||||||||||||||
825 | |||||||||||||||||||||||||||||||||||
826 | |||||||||||||||||||||||||||||||||||
827 | |||||||||||||||||||||||||||||||||||
828 | |||||||||||||||||||||||||||||||||||
829 | |||||||||||||||||||||||||||||||||||
830 | |||||||||||||||||||||||||||||||||||
831 | |||||||||||||||||||||||||||||||||||
832 | |||||||||||||||||||||||||||||||||||
833 | |||||||||||||||||||||||||||||||||||
834 | |||||||||||||||||||||||||||||||||||
835 | |||||||||||||||||||||||||||||||||||
836 | |||||||||||||||||||||||||||||||||||
837 | |||||||||||||||||||||||||||||||||||
838 | |||||||||||||||||||||||||||||||||||
839 | |||||||||||||||||||||||||||||||||||
840 | |||||||||||||||||||||||||||||||||||
841 | |||||||||||||||||||||||||||||||||||
842 | |||||||||||||||||||||||||||||||||||
843 | |||||||||||||||||||||||||||||||||||
844 | |||||||||||||||||||||||||||||||||||
845 | |||||||||||||||||||||||||||||||||||
846 | |||||||||||||||||||||||||||||||||||
847 | |||||||||||||||||||||||||||||||||||
848 | |||||||||||||||||||||||||||||||||||
849 | |||||||||||||||||||||||||||||||||||
850 | |||||||||||||||||||||||||||||||||||
851 | |||||||||||||||||||||||||||||||||||
852 | |||||||||||||||||||||||||||||||||||
853 | |||||||||||||||||||||||||||||||||||
854 | |||||||||||||||||||||||||||||||||||
855 | |||||||||||||||||||||||||||||||||||
856 | |||||||||||||||||||||||||||||||||||
857 | |||||||||||||||||||||||||||||||||||
858 | |||||||||||||||||||||||||||||||||||
859 | |||||||||||||||||||||||||||||||||||
860 | |||||||||||||||||||||||||||||||||||
861 | |||||||||||||||||||||||||||||||||||
862 | |||||||||||||||||||||||||||||||||||
863 | |||||||||||||||||||||||||||||||||||
864 | |||||||||||||||||||||||||||||||||||
865 | |||||||||||||||||||||||||||||||||||
866 | |||||||||||||||||||||||||||||||||||
867 | |||||||||||||||||||||||||||||||||||
868 | |||||||||||||||||||||||||||||||||||
869 | |||||||||||||||||||||||||||||||||||
870 | |||||||||||||||||||||||||||||||||||
871 | |||||||||||||||||||||||||||||||||||
872 | |||||||||||||||||||||||||||||||||||
873 | |||||||||||||||||||||||||||||||||||
874 | |||||||||||||||||||||||||||||||||||
875 | |||||||||||||||||||||||||||||||||||
876 | |||||||||||||||||||||||||||||||||||
877 | |||||||||||||||||||||||||||||||||||
878 | |||||||||||||||||||||||||||||||||||
879 | |||||||||||||||||||||||||||||||||||
880 | |||||||||||||||||||||||||||||||||||
881 | |||||||||||||||||||||||||||||||||||
882 | |||||||||||||||||||||||||||||||||||
883 | |||||||||||||||||||||||||||||||||||
884 | |||||||||||||||||||||||||||||||||||
885 | |||||||||||||||||||||||||||||||||||
886 | |||||||||||||||||||||||||||||||||||
887 | |||||||||||||||||||||||||||||||||||
888 | |||||||||||||||||||||||||||||||||||
889 | |||||||||||||||||||||||||||||||||||
890 | |||||||||||||||||||||||||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||||
3 | RSV | RSV | MVA-BN-RSV (MVA-mBN294B) | Active candidate / in development | Recombinant viral vector | Protein: specify | 2 surface proteins and internal conserved protein | None | NCT02864628 | Not yet open | Bavarian Nordic | Industry | Phase 1 | 2018-09-01 | 2019-08-01 | 2019-08-01 | Adult | Senior | 96 | USA | Results not yet reported | Trial population: 55+ years | ||||||||||||||
4 | RSV | RSV | MVA-BN RSV (MVA-mBN294B) | Active candidate / in development | Recombinant viral vector | Protein: specify | 2 surface proteins and internal conserved protein | None | NCT02873286 | Open, not recruiting | Bavarian Nordic | Industry | Phase 2 | 2016-09-01 | 2018-08-01 | 2018-08-01 | Adult | Senior | 400 | USA | Results not yet reported | Trial population: 55+ years | ||||||||||||||
5 | RSV | RSV | MVA-BN RSV (MVA-mBN294B) | Active candidate / in development | Recombinant viral vector | Protein: specify | 2 surface proteins and internal conserved protein | None | NCT02419391 | Completed | Bavarian Nordic | Industry | Phase 1 | 2015-08-01 | 2015-12-01 | 2016-05-01 | Adult | 63 | USA | Results not yet reported | Trial population: 18-65 years | ||||||||||||||
6 | RSV | RSV | DPX-RSV(A) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | Small Hydrophobic protein ectodomain | Novel other: specify | DepoVaxTM or alum | NCT02472548 | Open, not recruiting | Dalhousie University | Academic | Phase 1 | 2015-05-01 | 2018-07-01 | 2019-07-01 | Adult | 40 | Canada | Results not yet reported | Trial population: 50-64 years | |||||||||||||
7 | RSV | RSV | GSK3003891A (RSV F) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT03191383 | Withdrawn | GlaxoSmithKline | Industry | Phase 2 | 2017-07-11 | 2019-04-20 | 2020-12-25 | Adult | 0 | USA | Finland | Spain | Results not yet reported | Trial population: pregnant females 18-40 years; EUCTR2016-002733-30-ES | ||||||||||||||
8 | RSV | RSV | GSK3003891A (RSV F) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT02956837 | Completed | GlaxoSmithKline | Industry | Phase 2 | 2016-11-10 | 2017-08-30 | 2018-02-05 | Adult | 406 | Belgium | Estonia | France |Germany | Results not yet reported | Trial population: females, 18-45 years; EUCTR2016-001135-12-DE | ||||||||||||||
9 | RSV | RSV | GSK3003891A (RSV F) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT02753413 | Completed | GlaxoSmithKline | Industry | Phase 2 | 2016-04-01 | 2016-06-28 | 2016-06-28 | Adult | 102 | Belgium | Results reported in both peer-reviewed journal and registry | Peer-reviewed | 2018-02-01 | clinicaltrials.gov | 2017-06-13 | Trial population: females, 18-45 years; EUCTR2015-005742-58-BE | ||||||||||
10 | RSV | RSV | GSK3003891A (RSV F) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT02360475 | Completed | GlaxoSmithKline | Industry | Phase 2 | 2015-03-20 | 2015-07-02 | 2016-06-21 | Adult | 507 | USA | Australia | Czech Republic | Germany | Results reported in both peer-reviewed journal and registry | Peer-reviewed | 2018-02-01 | clinicaltrials.gov | 2016-11-29 | Trial population: females, 18-45 years; EUCTR2014-002688-14-CZ | ||||||||||
11 | RSV | RSV | GSK3003891A (RSV F) | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT01905215 | Completed | GlaxoSmithKline | Industry | Phase 1 | 2013-07-22 | 2014-04-09 | 2015-03-16 | Adult | 128 | Canada | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-09-29 | Trial population: males, 18-44 years | ||||||||||||
12 | RSV | RSV | RSV F subunit vaccine | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Licensed other: specify | MF59 or aluminum salts (alum) | NCT02298179 | Completed | GlaxoSmithKline | Industry | Phase 1 | 2014-12-19 | 2017-03-27 | 2017-03-27 | Adult | 288 | Belgium | Results not yet reported | Trial populatin: 18-45 years | |||||||||||||
13 | RSV | RSV | GSK3389245A (ChAd155-RSV) | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV Fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1) | None | NCT02927873 | Open, recruiting | GlaxoSmithKline | Industry | Phase 2 | 2017-01-11 | 2018-11-15 | 2020-10-07 | Child | 96 | USA | Spain | Italy | Results not yet reported | Trial population: 12-23 months; EUCTR2016-000117-76-ES | ||||||||||||||
14 | RSV | RSV | GSK3389245A (ChAd155-RSV) | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV Fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1) | None | NCT02491463 | Open, not recruiting | GlaxoSmithKline | Industry | Phase 1 | 2015-07-01 | 2016-04-01 | 2017-02-01 | Adult | 73 | UK | Results not yet reported | Trial population: 18-45 years | ||||||||||||||
15 | RSV | RSV | Ad26.RSV.preF | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT03339713 | Open, not recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2017-12-07 | 2018-03-29 | 2018-07-13 | Adult | Senior | 180 | US | Results not yet reported | Trial population: ≥60 years; co-delivered with flu vaccine | ||||||||||||||
16 | RSV | RSV | Ad26.RSV.preF | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT03334695 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2017-10-16 | 2018-05-22 | 2018-10-30 | Adult | 44 | UK | Results not yet reported | Trial population: 18-50 years, virus challenge study | ||||||||||||||
17 | RSV | RSV | Ad26.RSV.preF | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT03303625 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2017-11-29 | 2019-03-25 | 2019-08-30 | Child | Adult | 48 | Finland | UK | Results not yet reported | Trial populations: 18-50 years; seropositive 12-24 months; EUCTR2017-001345-27-FI | ||||||||||||||
18 | RSV | RSV | Ad26.RSV.preF | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT02926430 | Open, not recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 1 | 2016-11-08 | 2018-03-14 | 2018-12-03 | Adult | Senior | 72 | USA | Results not yet reported | Trial population: 60+ years | ||||||||||||||
19 | RSV | RSV | Ad35.RSV.FA2/Ad26.RSV.FA2 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT02440035 | Completed | Crucell Holland BV | Industry | Phase 1 | 2015-04-01 | 2016-06-09 | 2016-06-09 | Adult | 54 | USA | Results not yet reported | Trial popluation: 18-50 years | ||||||||||||||
20 | RSV | RSV | Ad35.RSV.FA2/Ad26.RSV.FA2 | Inactive / no longer in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT02561871 | Completed | Crucell Holland BV | Industry | Phase 1 | 2015-09-01 | 2016-09-01 | 2016-09-01 | Adult | 34 | USA | Results not yet reported | Trial population: 18-50 years | ||||||||||||||
21 | RSV | RSV | MEDI-534 (PIV3/RSV F) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | PIV3 and RSV fusion (F) | None | NCT00345670 | Completed | MedImmune LLC | Industry | Phase 1 | 2006-06-01 | 2007-05-01 | Child | 120 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2009-07-01 | Trial population: 1-9 years | |||||||||||||
22 | RSV | RSV | MEDI-534 (PIV3/RSV F) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | PIV3 and RSV fusion (F) | None | NCT00686075 | Completed | MedImmune LLC | Industry | Phase 2 | 2008-06-01 | 2012-08-01 | 2012-08-01 | Child | 1338 | USA | Australia | Brazil | Canada | Finland | Germany | Israel | South Africa | Spain | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2013-06-10 | clinicaltrials.gov | 2014-09-22 | Trial population: 2-23 months | ||||||||||
23 | RSV | RSV | MEDI-534 (PIV3/RSV F) | Inactive / no longer in development | Recombinant viral vector | Protein: specify | PIV3 and RSV fusion (F) | None | NCT00493285 | Completed | MedImmune LLC | Industry | Phase 1 | 2007-07-01 | 2009-11-01 | 2010-04-01 | Child | 49 | USA | Results reported in registry | clinicaltrials.gov | 2012-03-12 | Trial population: 6-23 months | ||||||||||||
24 | RSV | RSV | MEDI-559 (RSV live-attenuated) | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | All viral proteins | None | NCT00767416 | Completed | MedImmune LLC | Industry | Phase 2 | 2008-10-01 | 2011-12-01 | 2011-12-01 | Child | 116 | USA | Puerto Rico | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-10-29 | Trial population: 1-23 months | ||||||||||||
25 | RSV | RSV | MEDI7510 (RSV sF + Adj) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Novel other: specify | GLA-SE | NCT02508194 | Withdrawn | MedImmune LLC | Industry | Phase 2b | 2015-09-25 | 2016-09-09 | 2016-11-07 | Adult | Senior | 2044 | USA | Canada | Estonia |Chile | Latvia | Lithuania | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2017-12-12 | clinicaltrials.gov | 2018-12-20 | Trial population: 60-99 years | |||||||||
26 | RSV | RSV | MEDI7510 (RSV sF + Adj) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Novel other: specify | GLA-SE | NCT02289820 | Completed | MedImmune LLC | Industry | Phase 1 | 2015-01-05 | 2016-02-24 | 2016-02-24 | Adult | Senior | 363 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-09-05 | Trial population: 60-99 years | |||||||||||
27 | RSV | RSV | MEDI7510 (RSV sF + Adj) | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Novel other: specify | GLA-SE | NCT02115815 | Completed | MedImmune LLC | Industry | Phase 1 | 2014-04-01 | 2015-06-01 | 2015-06-01 | Adult | Senior | 246 | USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2016-05-27 | clinicaltrials.gov | 2016-07-15 | Trial population: 60-99 years | |||||||||
28 | RSV | RSV | MEDI8897 (Anti-RSV mAb) | Active candidate / in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: specify | None | NCT02878330 | Open, not recruiting | MedImmune LLC | Industry | Phase 2b | 2016-11-03 | 2018-12-03 | 2018-12-03 | Child | 1500 | USA | Bulgaria | Canada | Czech Republic | France | Hungary | Italy | Poland | South Africa | Spain | UK | Results not yet reported | Trial population: <1 year, born preterm between 29-34 wks GA | |||||||||||||||
29 | RSV | RSV | MEDI8897 (Anti-RSV mAb) | Active candidate / in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: specify | None | NCT02290340 | Completed | MedImmune LLC | Industry | Phase 1 | 2015-01-01 | 2016-09-01 | 2016-09-01 | Child | 151 | USA | Chile | South Africa | Results not yet reported | Trial population: <12 months, born preterm between 32-34 wks GA | |||||||||||||||
30 | RSV | RSV | MEDI8897 (Anti-RSV mAb) | Active candidate / in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: specify | None | NCT02114268 | Completed | MedImmune LLC | Industry | Phase 1 | 2014-04-01 | 2015-06-01 | 2015-06-01 | Adult | 342 | USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2017-02-23 | clinicaltrials.gov | 2016-07-26 | Trial population: 18-49 years | |||||||||||
31 | RSV | RSV | SynGEM | Active candidate / in development | Recombinant bacterial vector | Protein: specify | RSV fusion (F) | None | NCT02958540 | Open, not recruiting | Mucosis BV | Industry | Phase 1 | 2016-10-01 | 2017-07-01 | 2017-12-01 | Adult | 48 | UK | Results not yet reported | Trial population: 18-49 years | ||||||||||||||
32 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT02624947 | Open, recruiting | Novavax | Industry | Phase 3 | 2015-12-01 | 2020-05-01 | 2020-06-01 | Adult | 8618 | USA | Argentina | Australia | Chile | New Zealand | South Africa | Spain | United Kingdom | Bangladesh |Mexico | Philippines | Results not yet reported | Trial population: pregnant females 18-40 years | ||||||||||||||
33 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT02247726 | Completed | Novavax | Industry | Phase 2 | 2014-09-01 | 2016-07-01 | 2016-07-01 | Adult | 50 | USA | Interim results reported | Abstract / Poster / Conference proceedings | 2015-10-07 | Trial population: pregnant females 18-40 years | ||||||||||||
34 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT01960686 | Completed | Novavax | Industry | Phase 2 | 2013-10-01 | 2014-04-01 | 2014-04-01 | Adult | 720 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | Peer-reviewed publication or journal | 2017-06-27 | Trial population: females, 18-35 years | |||||||||||
35 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT01704365 | Completed | Novavax | Industry | Phase 2 | 2012-10-01 | 2013-04-01 | 2013-05-01 | Adult | 330 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-02-01 | Trial poplulation: females, 18-35 years | ||||||||||||
36 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT01290419 | Completed | Novavax | Industry | Phase 1 | 2010-12-01 | 2011-12-01 | 2011-12-01 | Adult | 150 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2013-01-07 | Trial population: 18-49 years | ||||||||||||
37 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Novel other: specify | Matrix-M1 | NCT03026348 | Open, not recruiting | Novavax | Industry | Phase 2 | 2017-01-01 | 2017-04-01 | 2018-07-01 | Adult | Senior | 300 | Australia | Results not yet reported | Trial population: 60-80 years | |||||||||||||
38 | RSV | RSV | RSV F Nanoparticle | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT02608502 | Completed | Novavax | Industry | Phase 3 | 2015-11-01 | 2016-12-01 | 2016-12-01 | Adult | Senior | 11850 | USA | Results not yet reported | Trial populatin: 60+ years | ||||||||||||||
39 | RSV | RSV | RSV F Nanoparticle | Inactive / no longer in development | Recombinant subunit VLP (non-fusion) | Protein: specify | RSV fusion (F) | None | NCT02593071 | Completed | Novavax | Industry | Phase 2 | 2015-10-01 | 2016-11-01 | 2016-11-01 | Adult | Senior | 1330 | USA | Results not yet reported | Trial population: 60+ years | ||||||||||||||
40 | RSV | RSV | RSV F Nanoparticle | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT02266628 | Completed | Novavax | Industry | Phase 2 | 2014-10-01 | 2016-03-01 | 2016-03-01 | Adult | Senior | 1599 | USA | Interim results reported | Abstract / Poster / Conference proceedings | Trial population: 60+ years | |||||||||||||
41 | RSV | RSV | RSV F Nanoparticle | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | None | NCT01709019 | Completed | Novavax | Industry | Phase 1 | 2012-10-01 | 2013-07-01 | 2014-03-01 | Adult | Senior | 220 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-04-12 | Trial population: 60+ years | ||||||||||||
42 | RSV | RSV | RSV F Nanoparticle | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT02296463 | Completed | Novavax | Industry | Phase 1 | 2014-11-01 | 2015-09-01 | 2016-04-01 | Child | 32 | Canada | Results not yet reported | Trial population: 24-72 months | ||||||||||||||
43 | RSV | RSV | SeVRSV | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | None | NCT03473002 | Open, recruiting | NIAID | Government | Phase 1 | 2018-05-10 | 2019-05-31 | 2019-05-31 | Adult | 25 | USA | Results not yet reported | clinicaltrials.gov | Trial population: 18-45 years | |||||||||||||
44 | RSV | RSV | RSV F DS-Cav1 | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | RSV fusion (F) | Aluminum salts (alum) | NCT03049488 | Open, recruiting | NIAID | Government | Phase 1 | 2017-02-22 | 2019-01-03 | 2020-01-03 | Adult | 100 | USA | Results not yet reported | Trial population: 18-50 years | ||||||||||||||
45 | RSV | RSV | RSV D46/NS2/N/ΔM2-2-HindIII | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT03099291 | Open, recruiting | NIAID | Government | Phase 1 | 2017-04-01 | 2019-04-01 | 2019-04-01 | Child | 33 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
46 | RSV | RSV | RSV D46/NS2/N/ΔM2-2-HindIII | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT03102034 | Open, recruiting | NIAID | Government | Phase 1 | 2017-03-30 | 2018-04-01 | 2018-04-01 | Child | 33 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
47 | RSV | RSV | RSV LID cp ΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02948127 | Open, not recruiting | NIAID | Government | Phase 1 | 2016-09-01 | 2017-04-30 | 2018-04-30 | Child | 8 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
48 | RSV | RSV | RSV LID cp ΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02890381 | Completed | NIAID | Government | Phase 1 | 2016-09-01 | 2017-04-24 | 2017-04-24 | Child | 17 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
49 | RSV | RSV | RSV LID ΔM2-2 1030s | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02794870 | Completed | NIAID | Government | Phase 1 | 2016-06-01 | 2017-07-07 | 2017-07-07 | Child | 33 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
50 | RSV | RSV | RSV D46 cpΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02601612 | Open, recruiting | NIAID | Government | Phase 1 | 2015-10-01 | 2017-05-01 | Child | 45 | USA | Results not yet reported | Trial population: 6-60 months | |||||||||||||||
51 | RSV | RSV | RSV LID ΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02952339 | Completed | NIAID | Government | Phase 1 | 2016-08-01 | 2017-07-01 | 2017-07-01 | Child | 33 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
52 | RSV | RSV | RSV LID ΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02237209 | Completed | NIAID | Government | Phase 1 | 2014-09-01 | 2015-04-01 | 2015-04-01 | Child | 29 | USA | Results reported in a peer-reviewed journal | Peer-reviewed | 2018-04-11 | Trial population: 6-24 months | ||||||||||||
53 | RSV | RSV | RSV LID ΔM2-2 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT02040831 | Completed | NIAID | Government | Phase 1 | 2014-09-01 | 2015-04-01 | 2015-04-01 | Child | 3 | USA | Results reported in a peer-reviewed journal | Peer-reviewed | 2018-04-11 | Trial population: 6-24 months | ||||||||||||
54 | RSV | RSV | RSV MEDI ΔM2-2 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT01459198 | Completed | NIAID | Government | Phase 1 | 2011-08-01 | 2015-06-01 | 2015-08-01 | Adult | Child | 60 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-11-04 | Trial population: 6 months-49 years | ||||||||||||
55 | RSV | RSV | RSV 6120/∆NS2/1030s | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-3 | None | NCT03387137 | Open, recruiting | NIAID | Government | Phase 1 | 2017-10-13 | 2019-12-26 | 2021-04-30 | Child | 45 | USA | Results not yet reported | clinicaltrials.gov | Trial population: RSV-seropositive 12-59 months; RSV-seronegative 6-24 months | |||||||||||||
56 | RSV | RSV | RSV ΔNS2/Δ1313/I1314L ; RSV 276 | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-4 | None | NCT03422237 | Open, recruiting | NIAID | Government | Phase 1 | 2017-10-04 | 2019-05-01 | 2019-12-01 | Child | 88 | USA | Results not yet reported | clinicaltrials.gov | Trial population: RSV-seronegative 6-24 months | |||||||||||||
57 | RSV | RSV | RSV ΔNS2 Δ1313 I1314L | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except M2-2 | None | NCT03227029 | Open, recruiting | NIAID | Government | Phase 1 | 2017-08-04 | 2019-05-01 | 2019-05-01 | Child | 80 | USA | Results not yet reported | Trial population: 6-24 months | ||||||||||||||
58 | RSV | RSV | RSV ΔNS2 Δ1313 I1314L | Active candidate / in development | Live, attenuated target organism | Protein: specify | All viral proteins except NS2 | None | NCT01893554 | Open, recruiting | NIAID | Government | Phase 1 | 2013-06-01 | 2020-05-01 | Child | 75 | USA | Results not yet reported | Trial population: 6-59 months | |||||||||||||||
59 | RSV | RSV | RSV cps2 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | All viral proteins | None | NCT01852266 | Completed | NIAID | Government | Phase 1 | 2013-10-01 | 2015-07-01 | Child | 50 | USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed | 2018-04-11 | clinicaltrials.gov | Trial population: 6-24 months | ||||||||||||
60 | RSV | RSV | RSV cps2 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | All viral proteins | None | NCT01968083 | Completed | NIAID | Government | Phase 1 | 2013-09-01 | 2015-05-01 | 2015-05-01 | Child | 51 | USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed | 2018-04-11 | clinicaltrials.gov | Trial population: 6-24 months | |||||||||||
61 | RSV | RSV | rBCG-N-hRSV | Active candidate / in development | Recombinant bacterial vector | Protein: specify | RSV nucleoprotein | None | NCT03213405 | Open, recruiting | Pontificia Universidad Catolica de Chile | Academic | Phase 1 | 2017-06-27 | 2018-05-20 | 2018-05-20 | Adult | 24 | Chile | Results not yet reported | Trial population: 18-50 years | ||||||||||||||
62 | RSV | RSV | RSV001 (PanAd3-RSV MVA-RSV) | Inactive / no longer in development | Prime-boost: PanAd3-RSV/MVA-RSV | Protein: specify | RSV fusion (F), Nucleoprotein (N), transcription processivity factor (M2-1) | None | NCT01805921 | Completed | ReiThera Srl | Industry | Phase 1 | 2013-05-01 | 2015-08-01 | 2015-08-01 | Adult | Senior | 72 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-08-12 | Peer-reviewed publication or journal | 2015-10-28 | Trial population: 18-75 years | ||||||||||
63 | RSV | RSV | REGN2222 (Anti-RSV mAb) | Inactive / no longer in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: RSV F-specific neutralizing mAb | None | NCT02325791 | Completed | Regeneron Pharmaceuticals | Industry | Phase 3 | 2015-06-21 | 2017-07-05 | 2017-09-26 | Child | 1538 | USA | Bulgaria | Australia | Canada | Chile | Denmark | Finland | Germany | Hungary | Netherlands | New Zealand | Panama |Puerto Rico | South Africa | Spain |Sweden | Turkey | Ukraine | UK | Results not yet reported | Trial population: <6 months, born preterm ≤35 wks GA | |||||||||||||||
64 | RSV | RSV | REGN2222 (Anti-RSV mAb) | Inactive / no longer in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: RSV F-specific neutralizing mAb | None | NCT02828397 | Completed | Regeneron Pharmaceuticals | Industry | Phase 1 | 2016-04-01 | 2016-09-01 | 2016-09-01 | Adult | 28 | USA | Results not yet reported | Trial population: 18-60 years | |||||||||||||||
65 | RSV | RSV | REGN2222 (Anti-RSV mAb) | Inactive / no longer in development | Other: monoclonal antibody specific for RSV fusion (F) | Other: RSV F-specific neutralizing mAb | None | NCT02121080 | Completed | Regeneron Pharmaceuticals | Industry | Phase 1 | 2014-05-01 | 2015-02-01 | 2015-02-01 | Adult | 132 | USA | Interim results reported | Abstract / Poster / Conference proceedings | 2015-10-11 | Trial population: 18-60 years | |||||||||||||
66 | RSV | RSV | VXA-RSV-f oral | Active candidate / in development | Recombinant viral vector | Protein: specify | RSV fusion (F) | Novel other: specify | dsRNA (TLR3 agonist) | NCT02830932 | Open, recruiting | Vaxart | Industry | Phase 1 | 2016-06-22 | 2017-09-09 | 2017-12-01 | Adult | 66 | USA | Results not yet reported | Trial population: 18-49 years | |||||||||||||
2 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes |
4 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC | Registered | CTRI/2014/04/004548 | Open, recruiting | Bharat Biotech International Limited | Industry | Phase 3 | 17/4/2014 | Child | 900 | India | Results not yet reported | Registered in India | |||||||||||
5 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC | Registered | CTRI/2014/05/004592 | Completed | Bharat Biotech International Limited | Industry | Phase 3 | 13/5/2014 | Child | 1356 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 16/5/2017 | PMC5435614 | |||||||||
6 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC | Registered | NCT03367559 | Open, recruiting | Bharat Biotech International Limited | Industry | Phase 3 | 5/1/2018 | 10/1/2018 | 12/1/2018 | Child | 360 | Vietnam | Results not yet reported | ||||||||||
7 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC | Registered | NCT01305109 | Completed | Bharat Biotech International Limited | Industry | Other | Phase 3 | 1/3/2011 | 12/1/2012 | 1/4/2014 | Child | 6800 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 12/6/2014 | 24629994 | Collaborators: PATH. Additional Citation: Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliyil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg. HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK; India Rotavirus Vaccine Group.. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. 2014 Aug 11;32 Suppl 1:A110-6. doi: 10.1016/j.vaccine.2014.04.079. | ||||||
8 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC | Registered | NCT00439660 | Completed | Bharat Biotech International Limited | Industry | Phase 2 | 1/12/2006 | 1/11/2008 | 1/11/2008 | Child | 540 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/7/2006 | 16735085 | Collaborators: Bharat Biotech International Limited, Ministry of Science and Technology, India, Centers for Disease Control and Prevention, National Institutes of Health (NIH), Stanford University, Indian Council of Medical Research, PATH. | ||||||
9 | Rotavirus Gastroenteritis | Rotavirus | ROTAVAC-5C | Registered | CTRI/2015/02/005577 | Open, recruiting | Bharat Biotech International Limited | Industry | Phase 3 | 25/2/2016 | 1/2/2018 | 1/2/2018 | Child | 1975 | India | Vietnam | Results not yet reported | ||||||||||
10 | Rotavirus Gastroenteritis | Rotavirus | Attenuated Pentavalent Rotavirus Vaccine (Serotypes G1, G2, G3, G4, G9) | Active candidate / in development | NCT00981669 | Completed | Butantan Institute | Other | Phase 1 | 1/4/2009 | 1/4/2010 | 1/6/2010 | Adult | 80 | Brazil | Results reported in both peer-reviewed journal and registry | clinicaltrials.gov | 17/9/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00981669 | |||||||
11 | Rotavirus Gastroenteritis | Rotavirus | Attenuated Pentavalent Rotavirus Vaccine (Serotypes G1, G2, G3, G4, G9) | Active candidate / in development | NTC00981669 | Completed | Butantan Institute | Other | Phase 1 | 1/3/2009 | 1/6/2010 | 1/6/2010 | Adult | 80 | Brazil | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 4/2/2013 | clinicaltrials.gov | 4/3/2013 | https://clinicaltrials.gov/ct2/show/results/NCT00981669?term=00981669&rank=1 | |||||
12 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix / RotaTeq | Registered | NCT02542462 | Completed | Children's Hospital Medical Center, Cincinnati | Academic | Phase 4 | 6/24/2015 | 1/4/2017 | 1/7/2017 | Child | 100 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/9/2016 | https://doi.org/10.1542/peds.2016-1952 | clinicaltrials.gov | https://clinicaltrials.gov/ct2/show/NCT02542462 | |||||
13 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq (Alt. Dosing) | Registered | NCT01960725 | Completed | Dennis Clements | Other | Industry | Phase 4 | 1/2/2014 | 1/12/2015 | 1/5/2016 | Child | 66 | United States | Results reported in registry | https://clinicaltrials.gov/ | 8/11/2016 | https://clinicaltrials.gov/ct2/show/results/NCT01960725 | Collaborators: Merck Sharp & Dohme Corp. | ||||||
14 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Registered | NCT02145000 | Completed | Epicentre | Other | Phase 3 | 1/6/2014 | 1/12/2015 | 1/12/2017 | Child | 7770 | Niger | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 23/3/2017 | 28328346 | Sponsors: Epicentre; Medecins Sans Frontieres, Netherlands; Serum Institute of India Pvt. Ltd.; FORSANI (Forum Santé Niger); Ministry of Public Health Niger; Children's Hospital Medical Center, Cincinnati, Licensed in India | ||||||
15 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT02141204 | Open, not recruiting | GlaxoSmithKline | Industry | Phase 3 | 23/11/2017 | 27/5/2018 | 27/5/2018 | Child | 308 | Unspecified | Results not yet reported | ||||||||||
16 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | EUCTR2006-003239-61-FI | Completed | GlaxoSmithKline | Industry | Phase 3 | 21/7/2006 | 24/8/2007 | 24/8/2007 | Child | 1200 | Finland | Results reported in registry | https://www.clinicaltrialsregister.eu/ | 26/8/2016 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003239-61/results | |||||||
17 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | EUCTR2012-005200-18-Outside-EU/EEA | Open, not recruiting | GlaxoSmithKline | Industry | Phase 3 | 13/5/2015 | Child | 3333 | China | Results not yet reported | ||||||||||||
18 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Active candidate / in development | NCT03207750 | Open, recruiting | GlaxoSmithKline | Industry | Phase 3 | 9/14/2017 | 9/28/2018 | 3/8/2018 | Child | 1280 | USA | Results not yet reported | ||||||||||
19 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT02914184 | Open, not recruiting | GlaxoSmithKline | Industry | Phase 3 | 10/8/2016 | 13/7/2016 | 16/11/2018 | Child | 1600 | Costa Rica | Finland | Germany | Japan | South Korea | Taiwan | United States | Results not yet reported | Other registry ID: EUCTR2016-000598-19-FI | |||||||||
20 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT02907216 | Completed | GlaxoSmithKline | Industry | Phase 4 | 9/16/2016 | 5/26/2017 | 5/26/2017 | Child | 292 | Japan | Results not yet reported | Estimated completion. | |||||||||
21 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT01171963 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/8/2010 | 1/5/2012 | 1/5/2012 | Child | 3340 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/8/2013 | 23807360 | Additional Publication: https://www.ncbi.nlm.nih.gov/pubmed/23807360 | ||||||
22 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT01107587 | Completed | GlaxoSmithKline | Industry | Phase 1 | 1/4/2010 | 1/6/2010 | 1/6/2010 | Child | 50 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/8/2013 | 23807360 | Collaborators: Centre for Vaccine Development, Mali; University of Maryland | ||||||
23 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT01086436 | Completed | GlaxoSmithKline | Industry | Phase 1 | 1/3/2010 | 1/4/2010 | 1/4/2010 | Child | 50 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/8/2013 | 23807360 | |||||||
24 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT01162590 | Completed | GlaxoSmithKline | Industry | Phase 1 | 1/3/2010 | 31/3/2010 | 31/3/2010 | Adult | 52 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/8/2013 | 23807360 | |||||||
25 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT00432380 | Completed | GlaxoSmithKline | Industry | Phase 2 | 1/3/2007 | 1/9/2007 | 1/9/2007 | Child | 375 | Philippines | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 3/3/2011 | 21256876 | |||||||
26 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT00345956 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/9/2006 | 1/3/2007 | 1/3/2007 | Child | 375 | Vietnam | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 3/3/2011 | 21256876 | |||||||
27 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT01198769 | Completed | GlaxoSmithKline | Industry | Phase 4 | 1/11/2010 | 1/4/2011 | 1/4/2011 | Child | 15 | Taiwan | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/9/2013 | 24079716 | https://clinicaltrials.gov | 22/3/2012 | https://clinicaltrials.gov/ct2/show/results/NCT01198769 | ||||
28 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00969228 | Completed | GlaxoSmithKline | Industry | Phase 4 | 1/8/2009 | 1/7/2010 | 1/7/2010 | Child | 684 | South Korea | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/6/2012 | 22699440 | https://clinicaltrials.gov | 16/6/2011 | https://clinicaltrials.gov/ct2/show/results/NCT00969228 | ||||
29 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00779779 | Completed | GlaxoSmithKline | Industry | Phase 4 | 1/11/2008 | 1/8/2009 | 1/8/2009 | Child | 522 | Sri Lanka | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/8/2014 | 25424932 | https://clinicaltrials.gov/ | 29/6/2010 | https://clinicaltrials.gov/ct2/show/results/NCT00779779 | ||||
30 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00334607 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/6/2007 | 1/2/2007 | 1/6/2007 | Child | 484 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/11/2008 | 18977955 | |||||||
31 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00480324 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/6/2007 | 1/3/2009 | 1/11/2009 | Child | 765 | Japan | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 26/8/2011 | 21640780 | https://clinicaltrials.gov/ | 30/3/2010 | https://clinicaltrials.gov/ct2/show/results/NCT00480324 | ||||
32 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00396630 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/1/2007 | 1/1/2008 | 1/2/2008 | Child | 200 | Dominican Republic | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 28/11/2011 | 22008819 | |||||||
33 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT00197210 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/12/2003 | 1/7/2007 | 1/7/2007 | Child | 10708 | Singapore | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 9/10/2009 | 19679216 | |||||||
34 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix / Liquid Rotarix | Registered | NCT00420316 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/2/2007 | 1/8/2007 | 1/8/2007 | Child | 2601 | Finland | Results reported in registry | https://clinicaltrials.gov | 5/1/2017 | https://clinicaltrials.gov/ct2/show/results/NCT00420316 | |||||||
35 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix / Liquid Rotarix | Registered | NCT00363545 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/9/2006 | 1/4/2007 | 1/4/2007 | Child | 1270 | Panama | Results reported in registry | https://clinicaltrials.gov | 5/1/2017 | https://clinicaltrials.gov/ct2/show/results/NCT00363545 | |||||||
36 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix / Liquid Rotarix | Registered | NCT00382772 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/11/2006 | 1/4/2007 | 1/8/2007 | Child | 1200 | Finland | Results reported in peer-reviewed journal | Peer-reviewed | 1/3/2011 | 21238572 | |||||||
37 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00420745 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/1/2007 | 1/3/2008 | 1/3/2008 | Child | 1009 | France | Poland | Portugal | Spain | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/5/2012 | 22228231 | |||||||
38 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00329745 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/1/2007 | 1/7/2008 | 1/7/2008 | Child | 8687 | Singapore | Results reported in registry | https://clinicaltrials.gov | 2/7/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00329745 | |||||||
39 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00241644 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/10/2005 | 1/6/2008 | 1/6/2008 | Child | 2089 | Malawi | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 13/9/2012 | 22974466 | clinicaltrials.gov | https://clinicaltrials.gov/ct2/show/results/NCT00241644 | |||||
40 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00263666 | Completed | GlaxoSmithKline | Industry | Phase 2 | 1/3/2005 | 1/2/2008 | 1/2/2008 | Child | 100 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 5/1/2006 | 16394298 | https://clinicaltrials.gov | 13/2/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00263666 | ||||
41 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00139347 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/12/2003 | 1/3/2007 | 1/3/2007 | Child | 6360 | Argentina | Brazil | Colombia | Dominican Republic | Honduras | Panama | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/6/2011 | 21378594 | |||||||
42 | Rotavirus Gastroenteritis | Rotavirus | Rotavin-M1 | Registered | NCT01502969 | Completed | GlaxoSmithKline | Industry | Phase 3 | 1/5/2010 | 1/9/2011 | 1/10/2011 | Child | 799 | Vietnam | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 20/11/2009 | 19931712 | Licensed Exlusively in Vietnam | ||||||
43 | Rotavirus Gastroenteritis | Rotavirus | Hexavalent BRV Vaccine | Active candidate / in development | ChiCTR-PIR-16008824 | Open, recruiting | Hebei Center for Disease Control and Prevention | Government | Phase 1 | 12/7/2017 | Child, Adult | 200 | China | Results not yet reported | ||||||||||||
44 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT01825109 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | Other | Phase 3 | 1/7/2010 | 1/4/2011 | 1/12/2011 | Child, Adult | 300 | Bangladesh | Results not yet reported | Sponsors: International Centre for Diarrhoeal Disease Research, Bangladesh European Centre for Disease Prevention and Control, SE-171, Stockholm The Swedish Institute for Infectious Disease Control, SE-171 82 SOLNA Centers for Disease Control and Prevention National Institutes of Health (NIH) | |||||||||
45 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00737503 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | Other | Phase 4 | 1/9/2008 | 1/3/2011 | 1/3/2011 | Child | 4550 | Bangladesh | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 18/4/2017 | 28419095 | clinicaltrials.gov | 16/8/2008 | https://clinicaltrials.gov/ct2/show/NCT00737503 | Sponsors: PATH. | |||
46 | Rotavirus Gastroenteritis | Rotavirus | RotaSheild | Inactive / no longer in development | Not registered | Completed | International Medica Foundation | Other | Phase 2 | Child | 998 | Ghana | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 23599316 | |||||||||||
47 | Rotavirus Gastroenteritis | Rotavirus | Trivalent Genetic Reassortment Vaccine | Active candidate / in development | NCT01738074 | Completed | Lanzhou Institute of Biological Products, China | Industry | Phase 3 | 1/8/2012 | 1/6/2014 | 1/12/2014 | Child | 10020 | China | Results not yet reported | Per Registry, the Provincial CDC is the sponsor for Lanzhou's Trivalent Genetic Reassortment Vaccine. | |||||||||
48 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT01026779 | Open, not recruiting | Lifespan | Industry | Phase 4 | 1/7/2009 | 1/6/2017 | 1/6/2017 | Child | 560 | USA | Results not yet reported | Anticipated | |||||||||
49 | Rotavirus Gastroenteritis | Rotavirus | Experimental Formulation of RotaTeq | Registered | NCT01600092 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 1/4/2013 | 1/3/2014 | 1/3/2014 | Child | 1020 | Canada, Czech Republic, Denmark, Finland, Israel, Mexico, Poland, Spain, Sweden, USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/4/2017 | 28141698 | https://clinicaltrials.gov/ | 9/3/2015 | https://clinicaltrials.gov/ct2/show/results/NCT01600092 | ||||
50 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT02062385 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 1/5/2014 | 1/6/2015 | 1/6/2015 | Child | 4040 | China | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 10/13/2017 | 28935470 | https://clinicaltrials.gov/ | 3/3/2016 | https://clinicaltrials.gov/ct2/show/results/NCT02062385 | ||||
51 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00953056 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 1 | 1/9/2010 | 1/3/2010 | 1/3/2010 | Child, Adult | 144 | China | Results reported in registry | https://clinicaltrials.gov/ | 4/8/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00953056 | |||||||
52 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00836498 | Withdrawn | Merck Sharp & Dohme Corp. | Industry | Phase 1 | 1/1/2009 | 1/1/2010 | 1/1/2010 | Adult | 66 | N/A | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 8/5/2014 | 25424929 | https://clinicaltrials.gov/ | 12/1/2011 | https://clinicaltrials.gov/ct2/show/results/NCT00836498 | Terminated (Strategic business decision not to pursue indication due to lack of demonstrable medical need) | |||
53 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00718237 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 1/8/2008 | 1/8/2009 | 1/8/2009 | Child | 762 | Japan | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/8/2013 | 23732903 | https://clinicaltrials.gov/ | 23/6/2010 | https://clinicaltrials.gov/ct2/show/results/NCT00718237 | ||||
54 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00496054 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 1/5/2008 | 1/10/2008 | 1/10/2008 | Child | 110 | India | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/1/2013 | 23442588 | https://clinicaltrials.gov | 12/11/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00496054 | ||||
55 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00362648 | Completed | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 1/3/2007 | 1/3/2009 | 1/3/2009 | Child | 7504 | Ghana | Kenya | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 21/8/2010 | 20692030 | |||||||
56 | Rotavirus Gastroenteritis | Rotavirus | Heat Stable Rotavirus (HSRV) Vaccine | Active candidate / in development | NCT02728869 | Open, not recruiting | MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Industry | Phase 2 | 1/6/2016 | 1/3/2017 | 1/5/2017 | Child, Adult | 100 | Bangladesh | Results not yet reported | Sponsors: Parexel | |||||||||
57 | Rotavirus Gastroenteritis | Rotavirus | RV3-BB | Active candidate / in development | ACTRN12610000525088 | Completed | Murdoch Children's Reseach Institute | Academic | Phase 1 | 25/6/2010 | Child, Adult | 60 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 16/04/2013 | ||||||||||
58 | Rotavirus Gastroenteritis | Rotavirus | RV3-BB | Active candidate / in development | ACTRN12611001212943 | Completed | Murdoch Children's Reseach Institute | Academic | Phase 2 | 24/11/2011 | Child | 93 | New Zealand | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/12/2015 | 26318715 | |||||||||
59 | Rotavirus Gastroenteritis | Rotavirus | RV3-BB | Active candidate / in development | NCT03483116 | Open, not recruiting | Murdoch Children's Reseach Institute | Academic | Phase 2 | 4/1/2018 | 5/1/2019 | 8/1/2019 | Child | 688 | Malawi | Results not yet reported | ||||||||||
60 | Rotavirus Gastroenteritis | Rotavirus | RV3-BB | Active candidate / in development | ACTRN12612001282875 | Completed | Murdoch Children's Reseach Institute | Academic | Phase 2 | 12/12/2012 | Child | 1647 | Indonesia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/12/2015 | 26318715 | |||||||||
61 | Rotavirus Gastroenteritis | Rotavirus | Rotarix / RotaTeq | Registered | NCT01266850 | Completed | National Institute of Allergy and Infectious Diseases | Government | Phase 4 | 1/3/2011 | 1/10/2013 | 1/3/2014 | Child | 1384 | USA | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 1/2/2016 | 26823540 | clinicaltrials.gov | 9/10/2014 | https://clinicaltrials.gov/ct2/show/results/NCT01266850 | ||||
62 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00880698 | Completed | National Institute of Allergy and Infectious Diseases | Government | Phase 2 | 1/12/2004 | 1/1/2014 | 1/1/2014 | Child | 202 | Botswana | Tanzania | Zambia | Zimbabwe | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/5/2009 | 19332437 | Collaborators: American Society of Pediatrics. Additional Citations: Kiulia NM, Nyaundi JK, Peenze I, Nyachieo A, Musoke RN, Steele AD, Mwenda JM. Rotavirus infections among HIV-infected children in Nairobi, Kenya. J Trop Pediatr. 2009 Oct;55(5):318-23. doi: 10.1093/tropej/fmp016. Epub 2009 Mar 10. Parashar UD, Glass RI. Rotavirus vaccines--early success, remaining questions. N Engl J Med. 2009 Mar 12;360(11):1063-5. doi: 10.1056/NEJMp0810154. | ||||||
63 | Rotavirus Gastroenteritis | Rotavirus | Rotavin-M1 | Registered | NCT01377571 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | Government | Phase 2 | 1/10/2009 | 1/3/2010 | 1/4/2010 | Child | 200 | Vietnam | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 27/4/2012 | 22520120 | Licensed Exlusively in Vietnam | ||||||
64 | Rotavirus Gastroenteritis | Rotavirus | Rotavin-M1 | Registered | NCT01375907 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | Government | Phase 1 | 1/8/2009 | 1/10/2009 | 1/10/2009 | Adult | 29 | Vietnam | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 27/4/2012 | 22520120 | Additional Collaborators: Center for Research and Production of Vaccines and Biologicals, Licensed Exlusively in Vietnam | ||||||
65 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq / Rotarix | Registered | NCT02193061 | Completed | National Institute of Pediatrics, Mexico | Government | Phase 3 | 1/11/2013 | 1/10/2016 | 1/11/2016 | Child | 1498 | Mexico | Results not yet reported | Collaborators: Centro Nacional para la Salud del la Infancia y la Adolescencia, Merck Sharp & Dohme Corp. | |||||||||
66 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT01575197 | Completed | PATH | Product Development Partner | Phase 4 | 1/9/2012 | 1/2/2013 | 1/2/2013 | Child | 456 | Ghana | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 27/4/2016 | 23599316 | clinicaltrials.gov | 6/4/2012 | https://clinicaltrials.gov/ct2/show/NCT01575197 | Collaborators: Noguchi Memorial Institute for Medical Research, Navrongo Health Research Center, Centers for Disease Control and Prevention. Also referred to as GHANA-HRV-01, OPP1017334 ( Other Grant/Funding Number: Bill and Melinda Gates Foundation ). | |||
67 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT01616693 | Completed | PATH | Product Development Partner | Phase 4 | 1/7/2012 | 1/7/2013 | 1/7/2013 | Child | 620 | India | Results reported in both peer-reviewed journal and registry | clinicaltrials.gov | https://clinicaltrials.gov/ct2/show/study/NCT01616693 | Collaborators: Christian Medical College & Ministry of Science and Technology, India. Also referred to as CMC ZP 2012; PATH HS-658. | |||||||
68 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotarix | Registered | NCT01199874 | Completed | PATH | Product Development Partner | Phase 4 | 1/4/2011 | 1/9/2012 | 1/6/2013 | Child | 1140 | Pakistan | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2/6/2015 | 26035743 | clinicaltrials.gov | 9/9/2013 | |||||
69 | Rotavirus Gastroenteritis | Rotavirus | Monovalent P2-VP8 Subunit Rotavirus Vaccine | Inactive / no longer in development | NCT02109484 | Completed | PATH | Product Development Partner | Phase 2 | 1/3/2014 | 1/11/2015 | 1/11/2015 | Child | 204 | South Africa | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 17/8/2017 | 28483414 | Funder: Bill and Melinda Gates Foundation | ||||||
70 | Rotavirus Gastroenteritis | Rotavirus | Monovalent P2-VP8 Subunit Rotavirus Vaccine | Inactive / no longer in development | NCT01764256 | Completed | PATH | Product Development Partner | Phase 1 | 1/12/2012 | 1/6/2013 | 1/9/2013 | Adult | 48 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 26065919 | clinicaltrials.gov | 7/1/2013 | https://clinicaltrials.gov/ct2/show/results/NCT01764256 | |||||
71 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT02286895 | Completed | PATH | Product Development Partner | Phase 4 | 1/10/2014 | 1/3/2015 | 1/3/2015 | Child | 605 | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/12/2018 | 29659924 | |||||||
72 | Rotavirus Gastroenteritis | Rotavirus | Trivalent P2-VP8 subunit rotavirus vaccine | Active candidate / in development | NCT02646891 | Completed | PATH | Product Development Partner | Phase 2 | 1/2/2016 | 1/10/2017 | 1/10/2017 | Child | 660 | South Africa | Results reported in registry | Peer-reviewed publication or journal | 8/17/2017 | https://clinicaltrials.gov/ | 12/13/2017 | https://clinicaltrials.gov/ct2/show/results/NCT02109484 | |||||
73 | Rotavirus Gastroenteritis | Rotavirus | Rotavirus Vaccine Bio Farma | Active candidate / in development | NCT03462108 | Open, recruiting | PT Bio Farma | Industry | Phase 1 | 4/9/2018 | 12/1/2018 | 3/1/2018 | Child | 100 | Indonesia | Results not yet reported | ||||||||||
74 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT00995813 | Completed | Seattle Children's Hospital | Academic | Phase 4 | 1/12/2009 | 1/5/2012 | 1/7/2017 | Child | 15 | USA | Results reported in both peer-reviewed journal and registry | clinicaltrials.gov | https://clinicaltrials.gov/ct2/show/NCT00995813 | Collaborators: Thrasher Research Fund, National Center for Research Resources (NCRR) | |||||||
75 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotasiil | Active candidate / in development | CTRI/2015/11/006384 | Open, not recruiting | Serum Institute of India Pvt. Ltd. | Industry | Phase 1 | 26/11/2015 | 1/3/2016 | 1/3/2016 | Child | 20 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 3/14/2018 | 29439867 | Estimated Dates | ||||||
76 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotasiil | Active candidate / in development | NCT03474055 | Open, recruiting | Serum Institute of India Pvt. Ltd. | Industry | Phase 3 | 10/30/2017 | 6/20/2018 | 9/30/2019 | Child | 1500 | India | Results not yet reported | ||||||||||
77 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Registered | CTRI/2009/091/000821 | Completed | Serum Institute of India Pvt. Ltd. | Industry | Phase 2 | 21/10/2009 | 21/12/2010 | 21/12/2010 | Adult | 114 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 11/8/2014 | Registered in India | |||||||
78 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Active candidate / in development | NCT02584816 | Completed | Serum Institute of India Pvt. Ltd. | Industry | Phase 3 | 11/1/2015 | 4/1/2017 | 6/1/2017 | Child | 1500 | India | Results not yet reported | ||||||||||
79 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Registered | CTRI/2015/07/006034 | Completed | Serum Institute of India Pvt. Ltd. | Industry | Phase 3 | 7/20/2015 | 1/10/2016 | 1/10/2016 | Child | 1500 | India | Results not yet reported | Sponsors: PATH, Additional IDs: ROTA: 04 VAC-020 | Estimated Dates, Licensed in India | |||||||||
80 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Registered | NCT02133690 | Completed | Serum Institute of India Pvt. Ltd. | Industry | Phase 3 | 1/5/2014 | 1/3/2016 | 1/3/2017 | Child | 7500 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 11/27/2017 | 28967523 | clinicaltrials.gov | 6/5/2014 | Sponsors: PATH. Licensed in India | ||||
81 | Rotavirus Gastroenteritis | Rotavirus | Lyophilized Rotasiil | Registered | CTRI/2010/091/003064 | Completed | Serum Institute of India Pvt. Ltd. | Industry | Phase 2 | 10/1/2011 | 10/6/2011 | Child | 60 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 11/8/2014 | Registered in India | ||||||||
82 | Rotavirus Gastroenteritis | Rotavirus | BRV-TV | Active candidate / in development | CTRI/2012/07/002820 | Completed | Shantha Biotechnics Limited | Industry | Phase 2 | 23/7/2012 | Adult | 120 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/8/2014 | 25091664 | |||||||||
83 | Rotavirus Gastroenteritis | Rotavirus | BRV-TV | Active candidate / in development | CTRI/2014/08/004893 | Completed | Shantha Biotechnics Limited | Industry | Phase 3 | 20/8/2014 | Child | 1182 | India | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 16/6/2017 | ||||||||||
84 | Rotavirus Gastroenteritis | Rotavirus | BRV-TV | Active candidate / in development | NCT01061658 | Unknown | Shantha Biotechnics Limited | Industry | Phase 2 | 1/7/2010 | 1/11/2010 | 1/12/2010 | Child | 90 | India | Results not yet reported | ||||||||||
85 | Rotavirus Gastroenteritis | Rotavirus | BRV-TV | Active candidate / in development | NCT01091298 | Completed | Shantha Biotechnics Limited | Industry | Phase 1 | 1/4/2010 | 1/5/2010 | 1/5/2010 | Adult | 20 | India | Results not yet reported | ||||||||||
86 | Rotavirus Gastroenteritis | Rotavirus | BRV-TV | Active candidate / in development | NCT00757926 | Withdrawn | Shantha Biotechnics Limited | Other | Industry | Phase 2 | 1/9/2009 | N/A | N/A | N/A | Results not yet reported | Collaborators: PATH | |||||||||||
87 | Rotavirus Gastroenteritis | Rotavirus | Liquid Rotarix | Registered | NCT02941107 | Open, recruiting | Telethon Kids Institute | Other | Phase 4 | 1/12/2016 | 1/12/2020 | 1/12/2020 | Child | 1000 | Unspecified | Results not yet reported | Collaborators: Menzies School of Health Research | |||||||||
88 | Rotavirus Gastroenteritis | Rotavirus | RotaTeq | Registered | NCT00740935 | Completed | University Hostpital, Brest | Academic | Phase 4 | 1/5/2007 | 1/12/2010 | 1/6/2011 | Child | 7204 | France | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/5/2011 | 21443962 | Collaborators: MCM Vaccines B.V. | ||||||
89 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT02992197 | Open, recruiting | University of Vermont | Academic | Phase 4 | 6/1/2018 | 6/1/2018 | 6/1/2018 | Child | 220 | Bangladesh | Results not yet reported | Anticipated | |||||||||
90 | Rotavirus Gastroenteritis | Rotavirus | Rotarix | Registered | NCT01375647 | Completed | University of Vermont | Academic | Phase 3 | 1/5/2011 | 1/10/2014 | 1/11/2014 | Child | 700 | Bangladesh | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/4/2015 | 25711607 | Collaborators: Bill and Melinda Gates Foundation, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Washington University School of Medicine, Stanford University, Centers for Disease Control and Prevention | ||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | |||||
3 | Shigellosis | Shigella flexneri 2a | CVD 1208S | Inactive / no longer in development | Live, attenuated target organism | Other: specify | LPS | None | NCT01531530 | Completed | University of Maryland | Academic | Phase 1 | 2011-07-01 | 2012-09-01 | 2012-09-01 | Adult | 26 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
4 | Shigellosis | Shigella flexneri 2a | CVD 1208S | Inactive / no longer in development | Live, attenuated target organism | Other: specify | LPS | None | NCT00866476 | Withdrawn | University of Maryland | Academic | Phase 2 | 2010-01-01 | 2010-02-01 | 2010-02-01 | Adult | 20 | USA | Results not yet reported | ClinicalTrials.gov | Reactogenicity met study halting criteria | ||||||||||||||
5 | Shigellosis | Shigella flexneri 2a | CVD 1208S | Inactive / no longer in development | Live, attenuated target organism | Other: specify | LPS | None | NCT00866242 | Withdrawn | University of Maryland | Academic | Phase 2 | 2010-01-01 | 2010-02-01 | 2010-02-01 | Adult | 20 | USA | Results not yet reported | ClinicalTrials.gov | Reactogenicity met study halting criteria | ||||||||||||||
6 | Shigellosis | Shigella flexneri 2a | Sf2aWC | Active candidate / in development | Inactivated whole target organism | Other: specify | LPS. Ipas | Novel other: specify | dmLT | NCT01509846 | Completed | PATH | Other | Phase 1 | 2011-03-01 | 2012-12-01 | 2012-12-01 | Adult | 82 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4-Apr.-2016 | ClinicalTrials.gov | ||||||||||||
7 | Shigellosis | Shigella flexneri 2a | Sf2aWC | Active candidate / in development | Inactivated whole target organism | Other: specify | LPS, Ipas | Novel other: specify | dmLT | NCT03038243 | Withdrawn | PATH | Other | Phase 2 | 2017-08-01 | 2018-12-31 | 2019-12-31 | Adult | 0 | USA | Results not yet reported | ClinicalTrials.gov | Lack of funding | |||||||||||||
8 | Shigellosis | Shigella flexneri 2a | Flexyn2a | Active candidate / in development | Subunit conjugate | Carbohydrate: specify | LPS | Aluminum salts (alum) | NCT02388009 | Completed | LimmaTech Biologics AG | Industry | Phase 1 | 2015-02-01 | 2015-05-01 | 2015-09-01 | Adult | 30 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 5-Dez.-2016 | ClinicalTrials.gov | |||||||||||||
9 | Shigellosis | Shigella flexneri 2a | Flexyn2a | Active candidate / in development | Subunit conjugate | Carbohydrate: specify | LPS | Aluminum salts (alum) | NCT02646371 | Completed | LimmaTech Biologics AG | Industry | Phase 2 | 2015-12-01 | 2016-09-01 | 2017-07-01 | Adult | 67 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
10 | Shigellosis | Shigella flexneri 2a | Invaplex 50 | Inactive / no longer in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Other: specify | LPS, Ipas | None | NCT00082069 | Completed | US Army Medical Research and Material Commad | Government | Phase 1 | 2004-04-01 | 2006-11-01 | 2006-11-01 | Adult | 32 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 23-Aug.-2010 | ClinicalTrials.gov | |||||||||||||
11 | Shigellosis | Shigella flexneri 2a | Invaplex 50 | Inactive / no longer in development | Subunit (e.g., toxoid, carbohydrate) from target organism | Other: specify | LPS, Ipas | None | NCT00485134 | Completed | US Army Medical Research and Material Commad | Government | Other: Phase 1/2 | 2007-05-01 | 2009-07-01 | 2010-09-01 | Adult | 113 | USA | Results reported in registry | ClinicalTrials.gov | 2017-09-11 | https://clinicaltrials.gov/ct2/show/results/NCT00485134 | |||||||||||||
12 | Shigellosis | Shigella flexneri 2a | InvaplexAR | Active candidate / in development | Recombinant subunit (non VLP) | Other: specify | LPS, IpaB, IpaC | None | NCT02445963 | Open, not recruiting | US Army Medical Research and Material Commad | Government | Phase 1 | 2015-10-01 | 2018-03-01 | 2019-03-01 | Adult | 40 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
13 | Shigellosis | Shigella flexneri 2a | SF2a-TT15 | Active candidate / in development | Subunit conjugate | Carbohydrate: specify | Synthetic O-specific polysaccharide fragment | None | NCT02797236 | Completed | Institut Pasteur | Industry | Phase 1 | 2016-09-01 | 2017-06-01 | 2017-12-01 | Adult | 64 | ISR | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
14 | Shigellosis | Shigella sonnei; Shigella flexneri 2a | S. Sonnei O-SP-rEPA and S. flexneri 2a O-SP-rEPA | Active candidate / in development | Subunit conjugate | Carbohydrate: specify | LPS | None | NCT00368316 | Completed | NICHD | Government | Phase 3 | 2003-01-01 | 2008-01-01 | 2009-02-01 | Child | 2799 | ISR | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 2-März-2010 | ClinicalTrials.gov | 2012-06-19 | https://clinicaltrials.gov/ct2/show/results/NCT00368316 | |||||||||||
15 | Shigellosis | Shigella sonnei | O-SPC/rBRU | Inactive / no longer in development | Subunit conjugate | Conjugate: specify antigen & carrier | Synthetic O-specific polysaccharide fragment | None | NCT01369927 | Completed | NICHD | Government | Phase 1 | 2011-05-15 | 2013-04-24 | 2013-04-24 | Adult | 60 | ISR | Results reported in peer-reviewed journal | ClinicalTrials.gov | |||||||||||||||
16 | Shigellosis | Shigella sonnei | O-SPC/rBRU | Inactive / no longer in development | Subunit conjugate | Carbohydrate: specify | Synthetic O-specific polysaccharide fragment | None | NCT01399424 | Withdrawn | NICHD | Government | Phase 1 | 2011-07-16 | 2012-04-25 | 2012-04-25 | Adult | 0 | N/A | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 12-Mai-2009 | ClinicalTrials.gov | |||||||||||||
17 | Shigellosis | Shigella sonnei | 1790GAHB | Active candidate / in development | Other: naturally secreted outer membrane vesicle | Other: specify | LPS; lipoproteins | Aluminum salts (alum) | NCT02017899 | Completed | GlaxoSmithKline | Industry | Phase 1 | 2014-02-01 | 2015-03-01 | 2015-03-01 | Adult | 50 | FRA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 22-Aug.-2017 | ClinicalTrials.gov | Submission Cycle 1: Results submitted 6 Sept 2017 | ||||||||||||
18 | Shigellosis | Shigella sonnei | 1790GAHB | Active candidate / in development | Other: naturally secreted outer membrane vesicle | Other: specify | LPS; lipoproteins | Aluminum salts (alum) | NCT02034500 | Completed | GlaxoSmithKline | Industry | Phase 1 | 2014-03-01 | 2015-04-01 | 2015-04-01 | Adult | 52 | GRB | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 22-Aug.-2017 | ClinicalTrials.gov | Submission Cycle 1: Results submitted 6 Sept 2017 | ||||||||||||
19 | Shigellosis | Shigella sonnei | 1790GAHB | Active candidate / in development | Other: naturally secreted outer membrane vesicle | Other: specify | LPS; lipoproteins | Aluminum salts (alum) | NCT02676895 | Completed | GlaxoSmithKline | Industry | Phase 2 | 2016-08-01 | 2017-03-10 | 2017-03-10 | Adult | 72 | KEN | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 22-Dez.-2017 | ClinicalTrials.gov | Submission Cycle 1: Results submitted 9 Mar 2018 | ||||||||||||
20 | Shigellosis | Shigella sonnei | 1790GAHB | Active candidate / in development | Other: naturally secreted outer membrane vesicle | Other: specify | LPS; lipoproteins | Aluminum salts (alum) | NCT03089879 | Completed | GlaxoSmithKline | Industry | Phase 1 | 2017-03-16 | 2017-08-31 | 2017-08-31 | Adult | 35 | FRA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
21 | Shigellosis | Shigella sonnei | WRSS1 | Active candidate / in development | Live, attenuated target organism | Other: specify | LPS, Ipas | None | NCT01080716 | Completed | US Army Medical Research and Material Commad | Government | Other: Phase 1/2 | 2010-05-01 | 2010-12-01 | 2010-12-01 | Adult | 40 | THA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 5-Juli-2016 | ClinicalTrials.gov | Sumbission Cylce 7: Results submitted 1 Feb 2018; Results returned after QCR 1 Mar 2018 | ||||||||||||
22 | Shigellosis | Shigella sonnei | WRSS1 | Active candidate / in development | Live, attenuated target organism | Other: specify | LPS, Ipas | None | NCT01813071 | Completed | PATH | Other | Phase 2 | 2013-08-01 | 2016-04-01 | 2016-04-01 | Child, Adult | 103 | BGD | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
23 | Shigellosis | Shigella sonnei | WRSS1 | Active candidate / in development | Live, attenuated target organism | Other: specify | LPS, Ipas | None | NCT02934178 | Withdraw | PATH | Other | Phase 1 | 2016-11-01 | 2018-01-10 | 2018-01-10 | Child | 16 | BGD | Results not yet reported | ClinicalTrials.gov | Withdrawn for lack of funding | ||||||||||||||
24 | Shigellosis | Shigella sonnei | WRSs2 and WRSs3 | Active candidate / in development | Live, attenuated target organism | Other: specify | LPS, Ipas | None | NCT01336699 | Completed | NIAID | Government | Phase 1 | 2013-01-01 | 2015-05-01 | 2015-05-01 | Adult | 90 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
25 | Shigellosis | Shigella sonnei | SsWC | Inactive / no longer in development | Inactivated whole target organism | Other: specify | LPS | Novel other: specify | mLT | Not registered | Completed | Johns Hopkins University | Academic | Phase 1 | Adult | 66 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 21-Juli-2005 | Study not found on database/registry. | |||||||||||||||
26 | Shigellosis | Shigella dysenteriae | SC599 | Inactive / no longer in development | Live, attenuated target organism | Other: specify | LPS | None | NCT00210288 | Completed | Institut Pasteur | Industry | Phase 2 | 2005-05-01 | 2006-09-01 | 2007-04-01 | Adult | 111 | FRA, GBR | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
27 | Shigellosis | Shigella dysenteriae | SC599 | Inactive / no longer in development | Live, attenuated target organism | Other: specify | LPS | None | Open, not recruiting | Institut Pasteur | Industry | Phase 2 | 2005-06-12 | Adult | 111 | FRA, GBR | Results not yet reported | |||||||||||||||||||
28 | Shigellosis | Shigella dysenteriae | GVXN SD133 | Active candidate / in development | Subunit conjugate | Carbohydrate: specify | LPS | Aluminum salts (alum) | NCT01069471 | Completed | GlycoVaxyn AG | Industry | Phase 1 | 2010-02-01 | 2010-10-01 | 2010-10-01 | Adult | 40 | CHE | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 6-Aug.-2015 | ClinicalTrials.gov | |||||||||||||
29 | ||||||||||||||||||||||||||||||||||||
30 | ||||||||||||||||||||||||||||||||||||
31 | ||||||||||||||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||||||||||||
33 | ||||||||||||||||||||||||||||||||||||
34 | ||||||||||||||||||||||||||||||||||||
35 | ||||||||||||||||||||||||||||||||||||
36 | ||||||||||||||||||||||||||||||||||||
37 | ||||||||||||||||||||||||||||||||||||
38 | ||||||||||||||||||||||||||||||||||||
39 | ||||||||||||||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||||||||||||
41 | ||||||||||||||||||||||||||||||||||||
42 | ||||||||||||||||||||||||||||||||||||
43 | ||||||||||||||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||||||||||||
45 | ||||||||||||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||||
3 | Zika | ZIKV | GLS-5700 | Active candidate / in development | DNA | Protein: specify | prME | None | NCT02809443 | Completed | GeneOne Life Science, Inc. / Inovio Pharmaceuticals | Industry | Phase 1 | 2016-07-01 | 2017-11-01 | 2017-12-01 | Adult | 40 | United States of America | Canada | Interim results reported | Peer-reviewed publication or journal | 2017-10-04 | 28976850 | ||||||||||||
4 | Zika | ZIKV | GLS-5700 | Active candidate / in development | DNA | Protein: specify | prME | None | NCT02887482 | Completed | GeneOne Life Science, Inc. / Inovio Pharmaceuticals | Industry | Phase 1 | 2016-08-01 | 2017-10-01 | 2018-06-01 | Adult | 160 | Puerto Rico | Results not yet reported | |||||||||||||||
5 | Mosquito-borne | ZIKV and others | AGS-v | Active candidate / in development | Peptide | Protein: specify | Mosquito salivary proteins | Novel other: specify | ISA-51 | NCT03055000 | Completed | NIH | Government | Phase 1 | 2017-02-15 | 2018-12-28 | 2018-12-28 | Adult | 49 | United States of America | Results not yet reported | ||||||||||||||
6 | Zika | ZIKV | MV-Zika | Active candidate / in development | Recombinant viral vector | Protein: specify | prME | None | NCT02996890 | Completed | Themis Bioscience | Industry | Phase 1 | 2017-04-04 | 2017-01-04 | 2018-04-17 | Adult | 48 | Austria | Results not yet reported | |||||||||||||||
7 | Zika | ZIKV | mRNA-1325 | Active candidate / in development | mRNA | Protein: specify | prME | None | NCT03014089 | Open, not recruiting | Moderna Therapeutics | Industry | Phase 2 | 2016-12-01 | 2019-02-01 | 2019-02-01 | Adult | 90 | United States of America | Results not yet reported | |||||||||||||||
8 | Zika | ZIKV | VRC-ZKADNA085-00-VP | Active candidate / in development | DNA | Protein: specify | prME | None | NCT02840487 | Open, not recruiting | NIAID | Government | Phase 1 | 2016-08-02 | 2019-12-28 | 2019-12-28 | Adult | 80 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-12-04 | 29217376 | ||||||||||||
9 | Zika | ZIKV | VRC-ZKADNA090-00-VP | Active candidate / in development | DNA | Protein: specify | prME | None | NCT02996461 | Open, not recruiting | NIAID | Government | Phase 1 | 2016-12-16 | 2019-12-28 | 2019-12-28 | Adult | 45 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-12-04 | 29217376 | ||||||||||||
10 | Zika | ZIKV | VRC-ZKADNA090-00-VP | Active candidate / in development | DNA | Protein: specify | prME | None | NCT03110770 | Open, recruiting | NIAID | Government | Phase 2 | 2017-03-29 | 2020-01-01 | 2020-01-01 | Child | Adult | 2338 | United States of America | Puerto Rico | Results not yet reported | |||||||||||||||
11 | Zika | ZIKV | ZIKV PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT02963909 | Completed | NIAID | Government | Phase 1 | 2016-11-01 | 2018-10-30 | 2018-10-30 | Adult | 75 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-12-04 | 29217375 | ||||||||||||
12 | Zika | ZIKV | ZIKV PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT02952833 | Completed | NIAID | Government | Phase 1 | 2016-10-14 | 2018-12-05 | 2018-12-05 | Adult | 91 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-12-04 | 29217375 | ||||||||||||
13 | Zika | ZIKV | ZIKV PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT02937233 | Completed | BIDMC | Academic | Phase 1 | 2016-12-08 | 2018-06-04 | 2018-06-04 | Adult | 36 | United States of America | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-12-04 | 29217375 | ||||||||||||
14 | Zika | ZIKV | ZIKV PIV | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT03008122 | Open, recruiting | NIAID | Government | Phase 1 | 2017-02-24 | 2019-07-18 | 2020-01-15 | Adult | 90 | Puerto Rico | Results not yet reported | |||||||||||||||
15 | Zika | ZIKV | PIZV or TAK-426 | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT03343626 | Open, recruiting | Takeda | Industry | Phase 1 | 2017-11-13 | 2020-11-19 | 2021-02-28 | Adult | 240 | United States of America | Puerto Rico | Results not yet reported | |||||||||||||||
16 | Zika | ZIKV | VLA1601 | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | NCT03425149 | Completed | Valneva Austria GmbH | Industry | Phase 1 | 2018-02-24 | 2018-06-26 | 2018-11-16 | Adult | 67 | United States of America | Results not yet reported | |||||||||||||||
17 | Zika | ZIKV | rZIKV/D4Δ30-713 | Active candidate / in development | Recombinant viral vector | Protein: specify | ZIKV prME in DENV backbone | None | NCT03611946 | Open, recruiting | NIAID | Government | Phase 1 | 2018-07-06 | 2018-12-31 | 2019-09-30 | Adult | 28 | United States of America | Results not yet reported | |||||||||||||||
18 | Zika | ZIKV | BBV121 | Active candidate / in development | Inactivated whole target organism | Protein: specify | whole virus | Aluminum salts (alum) | CTRI/2017/05/008539 | Completed | Bharat Biotech | Industry | Phase 1 | 2017-06-01 | Not listed | Not listed | Adult | 48 | India | Results not yet reported | |||||||||||||||
19 | |||||||||||||||||||||||||||||||||||
20 | |||||||||||||||||||||||||||||||||||
21 | |||||||||||||||||||||||||||||||||||
22 | |||||||||||||||||||||||||||||||||||
23 | |||||||||||||||||||||||||||||||||||
24 | |||||||||||||||||||||||||||||||||||
25 | |||||||||||||||||||||||||||||||||||
26 | |||||||||||||||||||||||||||||||||||
27 | |||||||||||||||||||||||||||||||||||
28 | |||||||||||||||||||||||||||||||||||
29 | |||||||||||||||||||||||||||||||||||
30 | |||||||||||||||||||||||||||||||||||
31 | |||||||||||||||||||||||||||||||||||
32 | |||||||||||||||||||||||||||||||||||
33 | |||||||||||||||||||||||||||||||||||
34 | |||||||||||||||||||||||||||||||||||
35 | |||||||||||||||||||||||||||||||||||
36 | |||||||||||||||||||||||||||||||||||
37 | |||||||||||||||||||||||||||||||||||
38 | |||||||||||||||||||||||||||||||||||
39 | |||||||||||||||||||||||||||||||||||
40 | |||||||||||||||||||||||||||||||||||
41 | |||||||||||||||||||||||||||||||||||
42 | |||||||||||||||||||||||||||||||||||
43 | |||||||||||||||||||||||||||||||||||
44 | |||||||||||||||||||||||||||||||||||
45 | |||||||||||||||||||||||||||||||||||
46 | |||||||||||||||||||||||||||||||||||
47 | |||||||||||||||||||||||||||||||||||
48 | |||||||||||||||||||||||||||||||||||
49 | |||||||||||||||||||||||||||||||||||
50 | |||||||||||||||||||||||||||||||||||
51 | |||||||||||||||||||||||||||||||||||
52 | |||||||||||||||||||||||||||||||||||
53 | |||||||||||||||||||||||||||||||||||
54 | |||||||||||||||||||||||||||||||||||
55 | |||||||||||||||||||||||||||||||||||
56 | |||||||||||||||||||||||||||||||||||
57 | |||||||||||||||||||||||||||||||||||
58 | |||||||||||||||||||||||||||||||||||
59 | |||||||||||||||||||||||||||||||||||
60 | |||||||||||||||||||||||||||||||||||
61 | |||||||||||||||||||||||||||||||||||
62 | |||||||||||||||||||||||||||||||||||
63 | |||||||||||||||||||||||||||||||||||
64 | |||||||||||||||||||||||||||||||||||
65 | |||||||||||||||||||||||||||||||||||
66 | |||||||||||||||||||||||||||||||||||
67 | |||||||||||||||||||||||||||||||||||
68 | |||||||||||||||||||||||||||||||||||
69 | |||||||||||||||||||||||||||||||||||
70 | |||||||||||||||||||||||||||||||||||
71 | |||||||||||||||||||||||||||||||||||
72 | |||||||||||||||||||||||||||||||||||
73 | |||||||||||||||||||||||||||||||||||
74 | |||||||||||||||||||||||||||||||||||
75 | |||||||||||||||||||||||||||||||||||
76 | |||||||||||||||||||||||||||||||||||
77 | |||||||||||||||||||||||||||||||||||
78 | |||||||||||||||||||||||||||||||||||
79 | |||||||||||||||||||||||||||||||||||
80 | |||||||||||||||||||||||||||||||||||
81 | |||||||||||||||||||||||||||||||||||
82 | |||||||||||||||||||||||||||||||||||
83 | |||||||||||||||||||||||||||||||||||
84 | |||||||||||||||||||||||||||||||||||
85 | |||||||||||||||||||||||||||||||||||
86 | |||||||||||||||||||||||||||||||||||
87 | |||||||||||||||||||||||||||||||||||
88 | |||||||||||||||||||||||||||||||||||
89 | |||||||||||||||||||||||||||||||||||
90 | |||||||||||||||||||||||||||||||||||
91 | |||||||||||||||||||||||||||||||||||
92 | |||||||||||||||||||||||||||||||||||
93 | |||||||||||||||||||||||||||||||||||
94 | |||||||||||||||||||||||||||||||||||
95 | |||||||||||||||||||||||||||||||||||
96 | |||||||||||||||||||||||||||||||||||
97 | |||||||||||||||||||||||||||||||||||
98 | |||||||||||||||||||||||||||||||||||
99 | |||||||||||||||||||||||||||||||||||
100 | |||||||||||||||||||||||||||||||||||
101 | |||||||||||||||||||||||||||||||||||
102 | |||||||||||||||||||||||||||||||||||
103 | |||||||||||||||||||||||||||||||||||
104 | |||||||||||||||||||||||||||||||||||
105 | |||||||||||||||||||||||||||||||||||
106 | |||||||||||||||||||||||||||||||||||
107 | |||||||||||||||||||||||||||||||||||
108 | |||||||||||||||||||||||||||||||||||
109 | |||||||||||||||||||||||||||||||||||
110 | |||||||||||||||||||||||||||||||||||
111 | |||||||||||||||||||||||||||||||||||
112 | |||||||||||||||||||||||||||||||||||
113 | |||||||||||||||||||||||||||||||||||
114 | |||||||||||||||||||||||||||||||||||
115 | |||||||||||||||||||||||||||||||||||
116 | |||||||||||||||||||||||||||||||||||
117 | |||||||||||||||||||||||||||||||||||
118 | |||||||||||||||||||||||||||||||||||
119 | |||||||||||||||||||||||||||||||||||
120 | |||||||||||||||||||||||||||||||||||
121 | |||||||||||||||||||||||||||||||||||
122 | |||||||||||||||||||||||||||||||||||
123 | |||||||||||||||||||||||||||||||||||
124 | |||||||||||||||||||||||||||||||||||
125 | |||||||||||||||||||||||||||||||||||
126 | |||||||||||||||||||||||||||||||||||
127 | |||||||||||||||||||||||||||||||||||
128 | |||||||||||||||||||||||||||||||||||
129 | |||||||||||||||||||||||||||||||||||
130 | |||||||||||||||||||||||||||||||||||
131 | |||||||||||||||||||||||||||||||||||
132 | |||||||||||||||||||||||||||||||||||
133 | |||||||||||||||||||||||||||||||||||
134 | |||||||||||||||||||||||||||||||||||
135 | |||||||||||||||||||||||||||||||||||
136 | |||||||||||||||||||||||||||||||||||
137 | |||||||||||||||||||||||||||||||||||
138 | |||||||||||||||||||||||||||||||||||
139 | |||||||||||||||||||||||||||||||||||
140 | |||||||||||||||||||||||||||||||||||
141 | |||||||||||||||||||||||||||||||||||
142 | |||||||||||||||||||||||||||||||||||
143 | |||||||||||||||||||||||||||||||||||
144 | |||||||||||||||||||||||||||||||||||
145 | |||||||||||||||||||||||||||||||||||
146 | |||||||||||||||||||||||||||||||||||
147 | |||||||||||||||||||||||||||||||||||
148 | |||||||||||||||||||||||||||||||||||
149 | |||||||||||||||||||||||||||||||||||
150 | |||||||||||||||||||||||||||||||||||
151 | |||||||||||||||||||||||||||||||||||
152 | |||||||||||||||||||||||||||||||||||
153 | |||||||||||||||||||||||||||||||||||
154 | |||||||||||||||||||||||||||||||||||
155 | |||||||||||||||||||||||||||||||||||
156 | |||||||||||||||||||||||||||||||||||
157 | |||||||||||||||||||||||||||||||||||
158 | |||||||||||||||||||||||||||||||||||
159 | |||||||||||||||||||||||||||||||||||
160 | |||||||||||||||||||||||||||||||||||
161 | |||||||||||||||||||||||||||||||||||
162 | |||||||||||||||||||||||||||||||||||
163 | |||||||||||||||||||||||||||||||||||
164 | |||||||||||||||||||||||||||||||||||
165 | |||||||||||||||||||||||||||||||||||
166 | |||||||||||||||||||||||||||||||||||
167 | |||||||||||||||||||||||||||||||||||
168 | |||||||||||||||||||||||||||||||||||
169 | |||||||||||||||||||||||||||||||||||
170 | |||||||||||||||||||||||||||||||||||
171 | |||||||||||||||||||||||||||||||||||
172 | |||||||||||||||||||||||||||||||||||
173 | |||||||||||||||||||||||||||||||||||
174 | |||||||||||||||||||||||||||||||||||
175 | |||||||||||||||||||||||||||||||||||
176 | |||||||||||||||||||||||||||||||||||
177 | |||||||||||||||||||||||||||||||||||
178 | |||||||||||||||||||||||||||||||||||
179 | |||||||||||||||||||||||||||||||||||
180 | |||||||||||||||||||||||||||||||||||
181 | |||||||||||||||||||||||||||||||||||
182 | |||||||||||||||||||||||||||||||||||
183 | |||||||||||||||||||||||||||||||||||
184 | |||||||||||||||||||||||||||||||||||
185 | |||||||||||||||||||||||||||||||||||
186 | |||||||||||||||||||||||||||||||||||
187 | |||||||||||||||||||||||||||||||||||
188 | |||||||||||||||||||||||||||||||||||
189 | |||||||||||||||||||||||||||||||||||
190 | |||||||||||||||||||||||||||||||||||
191 | |||||||||||||||||||||||||||||||||||
192 | |||||||||||||||||||||||||||||||||||
193 | |||||||||||||||||||||||||||||||||||
194 | |||||||||||||||||||||||||||||||||||
195 | |||||||||||||||||||||||||||||||||||
196 | |||||||||||||||||||||||||||||||||||
197 | |||||||||||||||||||||||||||||||||||
198 | |||||||||||||||||||||||||||||||||||
199 | |||||||||||||||||||||||||||||||||||
200 | |||||||||||||||||||||||||||||||||||
201 | |||||||||||||||||||||||||||||||||||
202 | |||||||||||||||||||||||||||||||||||
203 | |||||||||||||||||||||||||||||||||||
204 | |||||||||||||||||||||||||||||||||||
205 | |||||||||||||||||||||||||||||||||||
206 | |||||||||||||||||||||||||||||||||||
207 | |||||||||||||||||||||||||||||||||||
208 | |||||||||||||||||||||||||||||||||||
209 | |||||||||||||||||||||||||||||||||||
210 | |||||||||||||||||||||||||||||||||||
211 | |||||||||||||||||||||||||||||||||||
212 | |||||||||||||||||||||||||||||||||||
213 | |||||||||||||||||||||||||||||||||||
214 | |||||||||||||||||||||||||||||||||||
215 | |||||||||||||||||||||||||||||||||||
216 | |||||||||||||||||||||||||||||||||||
217 | |||||||||||||||||||||||||||||||||||
218 | |||||||||||||||||||||||||||||||||||
219 | |||||||||||||||||||||||||||||||||||
220 | |||||||||||||||||||||||||||||||||||
221 | |||||||||||||||||||||||||||||||||||
222 | |||||||||||||||||||||||||||||||||||
223 | |||||||||||||||||||||||||||||||||||
224 | |||||||||||||||||||||||||||||||||||
225 | |||||||||||||||||||||||||||||||||||
226 | |||||||||||||||||||||||||||||||||||
227 | |||||||||||||||||||||||||||||||||||
228 | |||||||||||||||||||||||||||||||||||
229 | |||||||||||||||||||||||||||||||||||
230 | |||||||||||||||||||||||||||||||||||
231 | |||||||||||||||||||||||||||||||||||
232 | |||||||||||||||||||||||||||||||||||
233 | |||||||||||||||||||||||||||||||||||
234 | |||||||||||||||||||||||||||||||||||
235 | |||||||||||||||||||||||||||||||||||
236 | |||||||||||||||||||||||||||||||||||
237 | |||||||||||||||||||||||||||||||||||
238 | |||||||||||||||||||||||||||||||||||
239 | |||||||||||||||||||||||||||||||||||
240 | |||||||||||||||||||||||||||||||||||
241 | |||||||||||||||||||||||||||||||||||
242 | |||||||||||||||||||||||||||||||||||
243 | |||||||||||||||||||||||||||||||||||
244 | |||||||||||||||||||||||||||||||||||
245 | |||||||||||||||||||||||||||||||||||
246 | |||||||||||||||||||||||||||||||||||
247 | |||||||||||||||||||||||||||||||||||
248 | |||||||||||||||||||||||||||||||||||
249 | |||||||||||||||||||||||||||||||||||
250 | |||||||||||||||||||||||||||||||||||
251 | |||||||||||||||||||||||||||||||||||
252 | |||||||||||||||||||||||||||||||||||
253 | |||||||||||||||||||||||||||||||||||
254 | |||||||||||||||||||||||||||||||||||
255 | |||||||||||||||||||||||||||||||||||
256 | |||||||||||||||||||||||||||||||||||
257 | |||||||||||||||||||||||||||||||||||
258 | |||||||||||||||||||||||||||||||||||
259 | |||||||||||||||||||||||||||||||||||
260 | |||||||||||||||||||||||||||||||||||
261 | |||||||||||||||||||||||||||||||||||
262 | |||||||||||||||||||||||||||||||||||
263 | |||||||||||||||||||||||||||||||||||
264 | |||||||||||||||||||||||||||||||||||
265 | |||||||||||||||||||||||||||||||||||
266 | |||||||||||||||||||||||||||||||||||
267 | |||||||||||||||||||||||||||||||||||
268 | |||||||||||||||||||||||||||||||||||
269 | |||||||||||||||||||||||||||||||||||
270 | |||||||||||||||||||||||||||||||||||
271 | |||||||||||||||||||||||||||||||||||
272 | |||||||||||||||||||||||||||||||||||
273 | |||||||||||||||||||||||||||||||||||
274 | |||||||||||||||||||||||||||||||||||
275 | |||||||||||||||||||||||||||||||||||
276 | |||||||||||||||||||||||||||||||||||
277 | |||||||||||||||||||||||||||||||||||
278 | |||||||||||||||||||||||||||||||||||
279 | |||||||||||||||||||||||||||||||||||
280 | |||||||||||||||||||||||||||||||||||
281 | |||||||||||||||||||||||||||||||||||
282 | |||||||||||||||||||||||||||||||||||
283 | |||||||||||||||||||||||||||||||||||
284 | |||||||||||||||||||||||||||||||||||
285 | |||||||||||||||||||||||||||||||||||
286 | |||||||||||||||||||||||||||||||||||
287 | |||||||||||||||||||||||||||||||||||
288 | |||||||||||||||||||||||||||||||||||
289 | |||||||||||||||||||||||||||||||||||
290 | |||||||||||||||||||||||||||||||||||
291 | |||||||||||||||||||||||||||||||||||
292 | |||||||||||||||||||||||||||||||||||
293 | |||||||||||||||||||||||||||||||||||
294 | |||||||||||||||||||||||||||||||||||
295 | |||||||||||||||||||||||||||||||||||
296 | |||||||||||||||||||||||||||||||||||
297 | |||||||||||||||||||||||||||||||||||
298 | |||||||||||||||||||||||||||||||||||
299 | |||||||||||||||||||||||||||||||||||
300 | |||||||||||||||||||||||||||||||||||
301 | |||||||||||||||||||||||||||||||||||
302 | |||||||||||||||||||||||||||||||||||
303 | |||||||||||||||||||||||||||||||||||
304 | |||||||||||||||||||||||||||||||||||
305 | |||||||||||||||||||||||||||||||||||
306 | |||||||||||||||||||||||||||||||||||
307 | |||||||||||||||||||||||||||||||||||
308 | |||||||||||||||||||||||||||||||||||
309 | |||||||||||||||||||||||||||||||||||
310 | |||||||||||||||||||||||||||||||||||
311 | |||||||||||||||||||||||||||||||||||
312 | |||||||||||||||||||||||||||||||||||
313 | |||||||||||||||||||||||||||||||||||
314 | |||||||||||||||||||||||||||||||||||
315 | |||||||||||||||||||||||||||||||||||
316 | |||||||||||||||||||||||||||||||||||
317 | |||||||||||||||||||||||||||||||||||
318 | |||||||||||||||||||||||||||||||||||
319 | |||||||||||||||||||||||||||||||||||
320 | |||||||||||||||||||||||||||||||||||
321 | |||||||||||||||||||||||||||||||||||
322 | |||||||||||||||||||||||||||||||||||
323 | |||||||||||||||||||||||||||||||||||
324 | |||||||||||||||||||||||||||||||||||
325 | |||||||||||||||||||||||||||||||||||
326 | |||||||||||||||||||||||||||||||||||
327 | |||||||||||||||||||||||||||||||||||
328 | |||||||||||||||||||||||||||||||||||
329 | |||||||||||||||||||||||||||||||||||
330 | |||||||||||||||||||||||||||||||||||
331 | |||||||||||||||||||||||||||||||||||
332 | |||||||||||||||||||||||||||||||||||
333 | |||||||||||||||||||||||||||||||||||
334 | |||||||||||||||||||||||||||||||||||
335 | |||||||||||||||||||||||||||||||||||
336 | |||||||||||||||||||||||||||||||||||
337 | |||||||||||||||||||||||||||||||||||
338 | |||||||||||||||||||||||||||||||||||
339 | |||||||||||||||||||||||||||||||||||
340 | |||||||||||||||||||||||||||||||||||
341 | |||||||||||||||||||||||||||||||||||
342 | |||||||||||||||||||||||||||||||||||
343 | |||||||||||||||||||||||||||||||||||
344 | |||||||||||||||||||||||||||||||||||
345 | |||||||||||||||||||||||||||||||||||
346 | |||||||||||||||||||||||||||||||||||
347 | |||||||||||||||||||||||||||||||||||
348 | |||||||||||||||||||||||||||||||||||
349 | |||||||||||||||||||||||||||||||||||
350 | |||||||||||||||||||||||||||||||||||
351 | |||||||||||||||||||||||||||||||||||
352 | |||||||||||||||||||||||||||||||||||
353 | |||||||||||||||||||||||||||||||||||
354 | |||||||||||||||||||||||||||||||||||
355 | |||||||||||||||||||||||||||||||||||
356 | |||||||||||||||||||||||||||||||||||
357 | |||||||||||||||||||||||||||||||||||
358 | |||||||||||||||||||||||||||||||||||
359 | |||||||||||||||||||||||||||||||||||
360 | |||||||||||||||||||||||||||||||||||
361 | |||||||||||||||||||||||||||||||||||
362 | |||||||||||||||||||||||||||||||||||
363 | |||||||||||||||||||||||||||||||||||
364 | |||||||||||||||||||||||||||||||||||
365 | |||||||||||||||||||||||||||||||||||
366 | |||||||||||||||||||||||||||||||||||
367 | |||||||||||||||||||||||||||||||||||
368 | |||||||||||||||||||||||||||||||||||
369 | |||||||||||||||||||||||||||||||||||
370 | |||||||||||||||||||||||||||||||||||
371 | |||||||||||||||||||||||||||||||||||
372 | |||||||||||||||||||||||||||||||||||
373 | |||||||||||||||||||||||||||||||||||
374 | |||||||||||||||||||||||||||||||||||
375 | |||||||||||||||||||||||||||||||||||
376 | |||||||||||||||||||||||||||||||||||
377 | |||||||||||||||||||||||||||||||||||
378 | |||||||||||||||||||||||||||||||||||
379 | |||||||||||||||||||||||||||||||||||
380 | |||||||||||||||||||||||||||||||||||
381 | |||||||||||||||||||||||||||||||||||
382 | |||||||||||||||||||||||||||||||||||
383 | |||||||||||||||||||||||||||||||||||
384 | |||||||||||||||||||||||||||||||||||
385 | |||||||||||||||||||||||||||||||||||
386 | |||||||||||||||||||||||||||||||||||
387 | |||||||||||||||||||||||||||||||||||
388 | |||||||||||||||||||||||||||||||||||
389 | |||||||||||||||||||||||||||||||||||
390 | |||||||||||||||||||||||||||||||||||
391 | |||||||||||||||||||||||||||||||||||
392 | |||||||||||||||||||||||||||||||||||
393 | |||||||||||||||||||||||||||||||||||
394 | |||||||||||||||||||||||||||||||||||
395 | |||||||||||||||||||||||||||||||||||
396 | |||||||||||||||||||||||||||||||||||
397 | |||||||||||||||||||||||||||||||||||
398 | |||||||||||||||||||||||||||||||||||
399 | |||||||||||||||||||||||||||||||||||
400 | |||||||||||||||||||||||||||||||||||
401 | |||||||||||||||||||||||||||||||||||
402 | |||||||||||||||||||||||||||||||||||
403 | |||||||||||||||||||||||||||||||||||
404 | |||||||||||||||||||||||||||||||||||
405 | |||||||||||||||||||||||||||||||||||
406 | |||||||||||||||||||||||||||||||||||
407 | |||||||||||||||||||||||||||||||||||
408 | |||||||||||||||||||||||||||||||||||
409 | |||||||||||||||||||||||||||||||||||
410 | |||||||||||||||||||||||||||||||||||
411 | |||||||||||||||||||||||||||||||||||
412 | |||||||||||||||||||||||||||||||||||
413 | |||||||||||||||||||||||||||||||||||
414 | |||||||||||||||||||||||||||||||||||
415 | |||||||||||||||||||||||||||||||||||
416 | |||||||||||||||||||||||||||||||||||
417 | |||||||||||||||||||||||||||||||||||
418 | |||||||||||||||||||||||||||||||||||
419 | |||||||||||||||||||||||||||||||||||
420 | |||||||||||||||||||||||||||||||||||
421 | |||||||||||||||||||||||||||||||||||
422 | |||||||||||||||||||||||||||||||||||
423 | |||||||||||||||||||||||||||||||||||
424 | |||||||||||||||||||||||||||||||||||
425 | |||||||||||||||||||||||||||||||||||
426 | |||||||||||||||||||||||||||||||||||
427 | |||||||||||||||||||||||||||||||||||
428 | |||||||||||||||||||||||||||||||||||
429 | |||||||||||||||||||||||||||||||||||
430 | |||||||||||||||||||||||||||||||||||
431 | |||||||||||||||||||||||||||||||||||
432 | |||||||||||||||||||||||||||||||||||
433 | |||||||||||||||||||||||||||||||||||
434 | |||||||||||||||||||||||||||||||||||
435 | |||||||||||||||||||||||||||||||||||
436 | |||||||||||||||||||||||||||||||||||
437 | |||||||||||||||||||||||||||||||||||
438 | |||||||||||||||||||||||||||||||||||
439 | |||||||||||||||||||||||||||||||||||
440 | |||||||||||||||||||||||||||||||||||
441 | |||||||||||||||||||||||||||||||||||
442 | |||||||||||||||||||||||||||||||||||
443 | |||||||||||||||||||||||||||||||||||
444 | |||||||||||||||||||||||||||||||||||
445 | |||||||||||||||||||||||||||||||||||
446 | |||||||||||||||||||||||||||||||||||
447 | |||||||||||||||||||||||||||||||||||
448 | |||||||||||||||||||||||||||||||||||
449 | |||||||||||||||||||||||||||||||||||
450 | |||||||||||||||||||||||||||||||||||
451 | |||||||||||||||||||||||||||||||||||
452 | |||||||||||||||||||||||||||||||||||
453 | |||||||||||||||||||||||||||||||||||
454 | |||||||||||||||||||||||||||||||||||
455 | |||||||||||||||||||||||||||||||||||
456 | |||||||||||||||||||||||||||||||||||
457 | |||||||||||||||||||||||||||||||||||
458 | |||||||||||||||||||||||||||||||||||
459 | |||||||||||||||||||||||||||||||||||
460 | |||||||||||||||||||||||||||||||||||
461 | |||||||||||||||||||||||||||||||||||
462 | |||||||||||||||||||||||||||||||||||
463 | |||||||||||||||||||||||||||||||||||
464 | |||||||||||||||||||||||||||||||||||
465 | |||||||||||||||||||||||||||||||||||
466 | |||||||||||||||||||||||||||||||||||
467 | |||||||||||||||||||||||||||||||||||
468 | |||||||||||||||||||||||||||||||||||
469 | |||||||||||||||||||||||||||||||||||
470 | |||||||||||||||||||||||||||||||||||
471 | |||||||||||||||||||||||||||||||||||
472 | |||||||||||||||||||||||||||||||||||
473 | |||||||||||||||||||||||||||||||||||
474 | |||||||||||||||||||||||||||||||||||
475 | |||||||||||||||||||||||||||||||||||
476 | |||||||||||||||||||||||||||||||||||
477 | |||||||||||||||||||||||||||||||||||
478 | |||||||||||||||||||||||||||||||||||
479 | |||||||||||||||||||||||||||||||||||
480 | |||||||||||||||||||||||||||||||||||
481 | |||||||||||||||||||||||||||||||||||
482 | |||||||||||||||||||||||||||||||||||
483 | |||||||||||||||||||||||||||||||||||
484 | |||||||||||||||||||||||||||||||||||
485 | |||||||||||||||||||||||||||||||||||
486 | |||||||||||||||||||||||||||||||||||
487 | |||||||||||||||||||||||||||||||||||
488 | |||||||||||||||||||||||||||||||||||
489 | |||||||||||||||||||||||||||||||||||
490 | |||||||||||||||||||||||||||||||||||
491 | |||||||||||||||||||||||||||||||||||
492 | |||||||||||||||||||||||||||||||||||
493 | |||||||||||||||||||||||||||||||||||
494 | |||||||||||||||||||||||||||||||||||
495 | |||||||||||||||||||||||||||||||||||
496 | |||||||||||||||||||||||||||||||||||
497 | |||||||||||||||||||||||||||||||||||
498 | |||||||||||||||||||||||||||||||||||
499 | |||||||||||||||||||||||||||||||||||
500 | |||||||||||||||||||||||||||||||||||
501 | |||||||||||||||||||||||||||||||||||
502 | |||||||||||||||||||||||||||||||||||
503 | |||||||||||||||||||||||||||||||||||
504 | |||||||||||||||||||||||||||||||||||
505 | |||||||||||||||||||||||||||||||||||
506 | |||||||||||||||||||||||||||||||||||
507 | |||||||||||||||||||||||||||||||||||
508 | |||||||||||||||||||||||||||||||||||
509 | |||||||||||||||||||||||||||||||||||
510 | |||||||||||||||||||||||||||||||||||
511 | |||||||||||||||||||||||||||||||||||
512 | |||||||||||||||||||||||||||||||||||
513 | |||||||||||||||||||||||||||||||||||
514 | |||||||||||||||||||||||||||||||||||
515 | |||||||||||||||||||||||||||||||||||
516 | |||||||||||||||||||||||||||||||||||
517 | |||||||||||||||||||||||||||||||||||
518 | |||||||||||||||||||||||||||||||||||
519 | |||||||||||||||||||||||||||||||||||
520 | |||||||||||||||||||||||||||||||||||
521 | |||||||||||||||||||||||||||||||||||
522 | |||||||||||||||||||||||||||||||||||
523 | |||||||||||||||||||||||||||||||||||
524 | |||||||||||||||||||||||||||||||||||
525 | |||||||||||||||||||||||||||||||||||
526 | |||||||||||||||||||||||||||||||||||
527 | |||||||||||||||||||||||||||||||||||
528 | |||||||||||||||||||||||||||||||||||
529 | |||||||||||||||||||||||||||||||||||
530 | |||||||||||||||||||||||||||||||||||
531 | |||||||||||||||||||||||||||||||||||
532 | |||||||||||||||||||||||||||||||||||
533 | |||||||||||||||||||||||||||||||||||
534 | |||||||||||||||||||||||||||||||||||
535 | |||||||||||||||||||||||||||||||||||
536 | |||||||||||||||||||||||||||||||||||
537 | |||||||||||||||||||||||||||||||||||
538 | |||||||||||||||||||||||||||||||||||
539 | |||||||||||||||||||||||||||||||||||
540 | |||||||||||||||||||||||||||||||||||
541 | |||||||||||||||||||||||||||||||||||
542 | |||||||||||||||||||||||||||||||||||
543 | |||||||||||||||||||||||||||||||||||
544 | |||||||||||||||||||||||||||||||||||
545 | |||||||||||||||||||||||||||||||||||
546 | |||||||||||||||||||||||||||||||||||
547 | |||||||||||||||||||||||||||||||||||
548 | |||||||||||||||||||||||||||||||||||
549 | |||||||||||||||||||||||||||||||||||
550 | |||||||||||||||||||||||||||||||||||
551 | |||||||||||||||||||||||||||||||||||
552 | |||||||||||||||||||||||||||||||||||
553 | |||||||||||||||||||||||||||||||||||
554 | |||||||||||||||||||||||||||||||||||
555 | |||||||||||||||||||||||||||||||||||
556 | |||||||||||||||||||||||||||||||||||
557 | |||||||||||||||||||||||||||||||||||
558 | |||||||||||||||||||||||||||||||||||
559 | |||||||||||||||||||||||||||||||||||
560 | |||||||||||||||||||||||||||||||||||
561 | |||||||||||||||||||||||||||||||||||
562 | |||||||||||||||||||||||||||||||||||
563 | |||||||||||||||||||||||||||||||||||
564 | |||||||||||||||||||||||||||||||||||
565 | |||||||||||||||||||||||||||||||||||
566 | |||||||||||||||||||||||||||||||||||
567 | |||||||||||||||||||||||||||||||||||
568 | |||||||||||||||||||||||||||||||||||
569 | |||||||||||||||||||||||||||||||||||
570 | |||||||||||||||||||||||||||||||||||
571 | |||||||||||||||||||||||||||||||||||
572 | |||||||||||||||||||||||||||||||||||
573 | |||||||||||||||||||||||||||||||||||
574 | |||||||||||||||||||||||||||||||||||
575 | |||||||||||||||||||||||||||||||||||
576 | |||||||||||||||||||||||||||||||||||
577 | |||||||||||||||||||||||||||||||||||
578 | |||||||||||||||||||||||||||||||||||
579 | |||||||||||||||||||||||||||||||||||
580 | |||||||||||||||||||||||||||||||||||
581 | |||||||||||||||||||||||||||||||||||
582 | |||||||||||||||||||||||||||||||||||
583 | |||||||||||||||||||||||||||||||||||
584 | |||||||||||||||||||||||||||||||||||
585 | |||||||||||||||||||||||||||||||||||
586 | |||||||||||||||||||||||||||||||||||
587 | |||||||||||||||||||||||||||||||||||
588 | |||||||||||||||||||||||||||||||||||
589 | |||||||||||||||||||||||||||||||||||
590 | |||||||||||||||||||||||||||||||||||
591 | |||||||||||||||||||||||||||||||||||
592 | |||||||||||||||||||||||||||||||||||
593 | |||||||||||||||||||||||||||||||||||
594 | |||||||||||||||||||||||||||||||||||
595 | |||||||||||||||||||||||||||||||||||
596 | |||||||||||||||||||||||||||||||||||
597 | |||||||||||||||||||||||||||||||||||
598 | |||||||||||||||||||||||||||||||||||
599 | |||||||||||||||||||||||||||||||||||
600 | |||||||||||||||||||||||||||||||||||
601 | |||||||||||||||||||||||||||||||||||
602 | |||||||||||||||||||||||||||||||||||
603 | |||||||||||||||||||||||||||||||||||
604 | |||||||||||||||||||||||||||||||||||
605 | |||||||||||||||||||||||||||||||||||
606 | |||||||||||||||||||||||||||||||||||
607 | |||||||||||||||||||||||||||||||||||
608 | |||||||||||||||||||||||||||||||||||
609 | |||||||||||||||||||||||||||||||||||
610 | |||||||||||||||||||||||||||||||||||
611 | |||||||||||||||||||||||||||||||||||
612 | |||||||||||||||||||||||||||||||||||
613 | |||||||||||||||||||||||||||||||||||
614 | |||||||||||||||||||||||||||||||||||
615 | |||||||||||||||||||||||||||||||||||
616 | |||||||||||||||||||||||||||||||||||
617 | |||||||||||||||||||||||||||||||||||
618 | |||||||||||||||||||||||||||||||||||
619 | |||||||||||||||||||||||||||||||||||
620 | |||||||||||||||||||||||||||||||||||
621 | |||||||||||||||||||||||||||||||||||
622 | |||||||||||||||||||||||||||||||||||
623 | |||||||||||||||||||||||||||||||||||
624 | |||||||||||||||||||||||||||||||||||
625 | |||||||||||||||||||||||||||||||||||
626 | |||||||||||||||||||||||||||||||||||
627 | |||||||||||||||||||||||||||||||||||
628 | |||||||||||||||||||||||||||||||||||
629 | |||||||||||||||||||||||||||||||||||
630 | |||||||||||||||||||||||||||||||||||
631 | |||||||||||||||||||||||||||||||||||
632 | |||||||||||||||||||||||||||||||||||
633 | |||||||||||||||||||||||||||||||||||
634 | |||||||||||||||||||||||||||||||||||
635 | |||||||||||||||||||||||||||||||||||
636 | |||||||||||||||||||||||||||||||||||
637 | |||||||||||||||||||||||||||||||||||
638 | |||||||||||||||||||||||||||||||||||
639 | |||||||||||||||||||||||||||||||||||
640 | |||||||||||||||||||||||||||||||||||
641 | |||||||||||||||||||||||||||||||||||
642 | |||||||||||||||||||||||||||||||||||
643 | |||||||||||||||||||||||||||||||||||
644 | |||||||||||||||||||||||||||||||||||
645 | |||||||||||||||||||||||||||||||||||
646 | |||||||||||||||||||||||||||||||||||
647 | |||||||||||||||||||||||||||||||||||
648 | |||||||||||||||||||||||||||||||||||
649 | |||||||||||||||||||||||||||||||||||
650 | |||||||||||||||||||||||||||||||||||
651 | |||||||||||||||||||||||||||||||||||
652 | |||||||||||||||||||||||||||||||||||
653 | |||||||||||||||||||||||||||||||||||
654 | |||||||||||||||||||||||||||||||||||
655 | |||||||||||||||||||||||||||||||||||
656 | |||||||||||||||||||||||||||||||||||
657 | |||||||||||||||||||||||||||||||||||
658 | |||||||||||||||||||||||||||||||||||
659 | |||||||||||||||||||||||||||||||||||
660 | |||||||||||||||||||||||||||||||||||
661 | |||||||||||||||||||||||||||||||||||
662 | |||||||||||||||||||||||||||||||||||
663 | |||||||||||||||||||||||||||||||||||
664 | |||||||||||||||||||||||||||||||||||
665 | |||||||||||||||||||||||||||||||||||
666 | |||||||||||||||||||||||||||||||||||
667 | |||||||||||||||||||||||||||||||||||
668 | |||||||||||||||||||||||||||||||||||
669 | |||||||||||||||||||||||||||||||||||
670 | |||||||||||||||||||||||||||||||||||
671 | |||||||||||||||||||||||||||||||||||
672 | |||||||||||||||||||||||||||||||||||
673 | |||||||||||||||||||||||||||||||||||
674 | |||||||||||||||||||||||||||||||||||
675 | |||||||||||||||||||||||||||||||||||
676 | |||||||||||||||||||||||||||||||||||
677 | |||||||||||||||||||||||||||||||||||
678 | |||||||||||||||||||||||||||||||||||
679 | |||||||||||||||||||||||||||||||||||
680 | |||||||||||||||||||||||||||||||||||
681 | |||||||||||||||||||||||||||||||||||
682 | |||||||||||||||||||||||||||||||||||
683 | |||||||||||||||||||||||||||||||||||
684 | |||||||||||||||||||||||||||||||||||
685 | |||||||||||||||||||||||||||||||||||
686 | |||||||||||||||||||||||||||||||||||
687 | |||||||||||||||||||||||||||||||||||
688 | |||||||||||||||||||||||||||||||||||
689 | |||||||||||||||||||||||||||||||||||
690 | |||||||||||||||||||||||||||||||||||
691 | |||||||||||||||||||||||||||||||||||
692 | |||||||||||||||||||||||||||||||||||
693 | |||||||||||||||||||||||||||||||||||
694 | |||||||||||||||||||||||||||||||||||
695 | |||||||||||||||||||||||||||||||||||
696 | |||||||||||||||||||||||||||||||||||
697 | |||||||||||||||||||||||||||||||||||
698 | |||||||||||||||||||||||||||||||||||
699 | |||||||||||||||||||||||||||||||||||
700 | |||||||||||||||||||||||||||||||||||
701 | |||||||||||||||||||||||||||||||||||
702 | |||||||||||||||||||||||||||||||||||
703 | |||||||||||||||||||||||||||||||||||
704 | |||||||||||||||||||||||||||||||||||
705 | |||||||||||||||||||||||||||||||||||
706 | |||||||||||||||||||||||||||||||||||
707 | |||||||||||||||||||||||||||||||||||
708 | |||||||||||||||||||||||||||||||||||
709 | |||||||||||||||||||||||||||||||||||
710 | |||||||||||||||||||||||||||||||||||
711 | |||||||||||||||||||||||||||||||||||
712 | |||||||||||||||||||||||||||||||||||
713 | |||||||||||||||||||||||||||||||||||
714 | |||||||||||||||||||||||||||||||||||
715 | |||||||||||||||||||||||||||||||||||
716 | |||||||||||||||||||||||||||||||||||
717 | |||||||||||||||||||||||||||||||||||
718 | |||||||||||||||||||||||||||||||||||
719 | |||||||||||||||||||||||||||||||||||
720 | |||||||||||||||||||||||||||||||||||
721 | |||||||||||||||||||||||||||||||||||
722 | |||||||||||||||||||||||||||||||||||
723 | |||||||||||||||||||||||||||||||||||
724 | |||||||||||||||||||||||||||||||||||
725 | |||||||||||||||||||||||||||||||||||
726 | |||||||||||||||||||||||||||||||||||
727 | |||||||||||||||||||||||||||||||||||
728 | |||||||||||||||||||||||||||||||||||
729 | |||||||||||||||||||||||||||||||||||
730 | |||||||||||||||||||||||||||||||||||
731 | |||||||||||||||||||||||||||||||||||
732 | |||||||||||||||||||||||||||||||||||
733 | |||||||||||||||||||||||||||||||||||
734 | |||||||||||||||||||||||||||||||||||
735 | |||||||||||||||||||||||||||||||||||
736 | |||||||||||||||||||||||||||||||||||
737 | |||||||||||||||||||||||||||||||||||
738 | |||||||||||||||||||||||||||||||||||
739 | |||||||||||||||||||||||||||||||||||
740 | |||||||||||||||||||||||||||||||||||
741 | |||||||||||||||||||||||||||||||||||
742 | |||||||||||||||||||||||||||||||||||
743 | |||||||||||||||||||||||||||||||||||
744 | |||||||||||||||||||||||||||||||||||
745 | |||||||||||||||||||||||||||||||||||
746 | |||||||||||||||||||||||||||||||||||
747 | |||||||||||||||||||||||||||||||||||
748 | |||||||||||||||||||||||||||||||||||
749 | |||||||||||||||||||||||||||||||||||
750 | |||||||||||||||||||||||||||||||||||
751 | |||||||||||||||||||||||||||||||||||
752 | |||||||||||||||||||||||||||||||||||
753 | |||||||||||||||||||||||||||||||||||
754 | |||||||||||||||||||||||||||||||||||
755 | |||||||||||||||||||||||||||||||||||
756 | |||||||||||||||||||||||||||||||||||
757 | |||||||||||||||||||||||||||||||||||
758 | |||||||||||||||||||||||||||||||||||
759 | |||||||||||||||||||||||||||||||||||
760 | |||||||||||||||||||||||||||||||||||
761 | |||||||||||||||||||||||||||||||||||
762 | |||||||||||||||||||||||||||||||||||
763 | |||||||||||||||||||||||||||||||||||
764 | |||||||||||||||||||||||||||||||||||
765 | |||||||||||||||||||||||||||||||||||
766 | |||||||||||||||||||||||||||||||||||
767 | |||||||||||||||||||||||||||||||||||
768 | |||||||||||||||||||||||||||||||||||
769 | |||||||||||||||||||||||||||||||||||
770 | |||||||||||||||||||||||||||||||||||
771 | |||||||||||||||||||||||||||||||||||
772 | |||||||||||||||||||||||||||||||||||
773 | |||||||||||||||||||||||||||||||||||
774 | |||||||||||||||||||||||||||||||||||
775 | |||||||||||||||||||||||||||||||||||
776 | |||||||||||||||||||||||||||||||||||
777 | |||||||||||||||||||||||||||||||||||
778 | |||||||||||||||||||||||||||||||||||
779 | |||||||||||||||||||||||||||||||||||
780 | |||||||||||||||||||||||||||||||||||
781 | |||||||||||||||||||||||||||||||||||
782 | |||||||||||||||||||||||||||||||||||
783 | |||||||||||||||||||||||||||||||||||
784 | |||||||||||||||||||||||||||||||||||
785 | |||||||||||||||||||||||||||||||||||
786 | |||||||||||||||||||||||||||||||||||
787 | |||||||||||||||||||||||||||||||||||
788 | |||||||||||||||||||||||||||||||||||
789 | |||||||||||||||||||||||||||||||||||
790 | |||||||||||||||||||||||||||||||||||
791 | |||||||||||||||||||||||||||||||||||
792 | |||||||||||||||||||||||||||||||||||
793 | |||||||||||||||||||||||||||||||||||
794 | |||||||||||||||||||||||||||||||||||
795 | |||||||||||||||||||||||||||||||||||
796 | |||||||||||||||||||||||||||||||||||
797 | |||||||||||||||||||||||||||||||||||
798 | |||||||||||||||||||||||||||||||||||
799 | |||||||||||||||||||||||||||||||||||
800 | |||||||||||||||||||||||||||||||||||
801 | |||||||||||||||||||||||||||||||||||
802 | |||||||||||||||||||||||||||||||||||
803 | |||||||||||||||||||||||||||||||||||
804 | |||||||||||||||||||||||||||||||||||
805 | |||||||||||||||||||||||||||||||||||
806 | |||||||||||||||||||||||||||||||||||
807 | |||||||||||||||||||||||||||||||||||
808 | |||||||||||||||||||||||||||||||||||
809 | |||||||||||||||||||||||||||||||||||
810 | |||||||||||||||||||||||||||||||||||
811 | |||||||||||||||||||||||||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | |||||
3 | Gastroenteritis Escherichia Coli | ETEC | dmLT | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT01147445 | Completed | NIAID | Government | Phase 1 | 2010-09-01 | 2012-06-01 | 2012-06-01 | Adult | 36 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 20-Nov.-2013 | ClinicalTrials.gov | |||||||||||||
4 | Gastroenteritis Escherichia Coli | ETEC | dmLT | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT02052934 | Completed | NIAID | Government | Phase 1 | 2014-03-10 | 2016-11-02 | 2016-11-02 | Adult | 80 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
5 | Gastroenteritis Escherichia Coli | ETEC | dmLT | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT02531685 | Open, recruiting | NIAID | Government | Phase 1 | 2016-06-02 | 2018-07-07 | 2018-12-29 | Adut | 99 | USA | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
6 | Gastroenteritis Escherichia Coli | ETEC | ACE527 | Active candidate / in development | Live, attenuated target organism | Protein: specify | CFA/I, CS1-3, CS5, CS6, B subunit | Novel other: specify | dmLT | NCT00901654 | Completed | TD Vaccines A/S | Industry | Phase 1 | 2009-06-01 | 2009-11-01 | 2009-11-01 | Adult | 36 | USA | Results not yet reported | ClinicalTrials.gov | ||||||||||||||
7 | Gastroenteritis Escherichia Coli | ETEC | ACE527 | Active candidate / in development | Live, attenuated target organism | Protein: specify | CFA/I, CS1-3, CS5, CS6, B subunit | Novel other: specify | dmLT | NCT01060748 | Completed | TD Vaccines A/S | Industry | Phase 2 | 2010-03-01 | 2010-10-01 | 2010-10-01 | Adult | 70 | USA | Results not yet reported | ClinicalTrials.gov | ||||||||||||||
8 | Gastroenteritis Escherichia Coli | ETEC | ACE527 | Active candidate / in development | Live, attenuated target organism | Protein: specify | CFA/I, CS1-3, CS5, CS6, B subunit | Novel other: specify | dmLT | NCT01739231 | Completed | PATH | Other | Other: Phase1/2 | 2012-09-01 | 2013-10-01 | 2014-01-01 | Adult | 57 | USA | Results not yet reported | ClinicalTrials.gov | Submission Cylce 2: Results submitted 23 May 2016; Results returned after QCR 26 Jun 2016 | |||||||||||||
9 | Gastroenteritis Escherichia Coli | ETEC | ETVAX | Active candidate / in development | Inactivated whole target organism | Protein: specify | CFA/I, CS3, CS5, CS6, B subunit | Novel other: specify | dmLT | ISRCTN23764070 | Completed | University of Gothenburg | Academic | Phase 1 | 2010-12-05 | 2011-01-06 | 2011-01-06 | Adult | 60 | SWE | Results not yet reported | isrctn.com | ||||||||||||||
10 | Gastroenteritis Escherichia Coli | ETEC | ETVAX | Active candidate / in development | Inactivated partial (split) target organism | Protein: specify | CFA/I, CS3, CS5, CS6, B subunit | Novel other: specify | dmLT | ISRCTN91363076 | Completed | University of Gothenburg | Academic | Phase 1 | 2012-03-08 | 2013-03-01 | 2013-03-01 | Adult | 120 | SWE | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 12-Dez.-2014 | isrctn.com | ||||||||||||
11 | Gastroenteritis Escherichia Coli | ETEC | ETVAX | Active candidate / in development | Inactivated whole target organism | Protein: specify | LCTBA, CFA/I, CS3, CS5, CS6 | Novel other: specify | dmLT | ISRCTN27096290 | Completed | University of Gothenburg | Academic | Phase 1 | 2013-12-01 | 2014-06-01 | 2014-06-01 | Adult | 60 | SWE | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 9-Feb.-2018 | isrctn.com | https://www.ncbi.nlm.nih.gov/pubmed/27133878 | |||||||||||
12 | Gastroenteritis Escherichia Coli | ETEC | ETVAX | Active candidate / in development | Inactivated whole target organism | Protein: specify | CFA/I, CS3, CS5, CS6, B subunit | Novel other: specify | dmLT | NCT02531802 | Completed | PATH | Other | Other: Phase1/2 | 2015-10-01 | 2017-07-29 | 2017-07-29 | Child, Adult | 475 | BGD | Results not yet reported | Peer-reviewed publication or journal | 13-Juli-2017 | ClinicalTrials.gov | ||||||||||||
13 | Gastroenteritis Escherichia Coli | ETEC | ETVAX | Active candidate / in development | Inactivated whole target organism | Protein: specify | CFA/I, CS3, CS5, CS6, B subunit | Novel other: specify | dmLT | Open, recruiting | Scandinavian Biopharma AB | Industry | Phase 2b | Adult | 800 | BEN; FIN | Results not yet reported | Study start date unknown. | ||||||||||||||||||
14 | Gastroenteritis Escherichia Coli | ETEC | ETEC/rCTB | Inactive / no longer in development | Inactivated whole target organism | Protein: specify | CFA/I, CS1, CS2, CS3, CS4, CS5 | None | NCT02556996 | Completed | US Army Medical Research and Material Commad | Government | Phase 3 | 1998-10-01 | 2001-03-01 | 2002-04-01 | Child | 356 | EGY | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
15 | Gastroenteritis Escherichia Coli | ETEC | dscCfaE | Active candidate / in development | Recombinant subunit VLP (fusion) | Protein: specify | CFA/I | Novel other: specify | mLT | NCT01382095 | Completed | US Army Medical Research and Material Commad | Government | Phase 1 | 2011-07-01 | 2012-08-01 | 2013-04-01 | Adult | 40 | USA | Results not yet reported | ClinicalTrials.gov | ||||||||||||||
16 | Gastroenteritis Escherichia Coli | ETEC | dscCfaE | Active candidate / in development | Recombinant subunit VLP (fusion) | Protein: specify | CFA/I | Novel other: specify | mLT | NCT01922856 | Completed | US Army Medical Research and Material Commad | Government | Phase 2 | 2013-09-19 | 2016-02-06 | 2016-07-14 | Adult | 56 | USA | Results not yet reported | ClinicalTrials.gov | ||||||||||||||
17 | Gastroenteritis Escherichia Coli | ETEC | dsc14CfaE-sCTA2/LTB5 | Active candidate / in development | Recombinant subunit VLP (fusion) | Protein: specify | CFA/I | Novel other: specify | mLT | NCT01644565 | Unknown | US Army Medical Research and Material Commad | Government | Phase 1 | 2012-08-01 | 2016-11-01 | 2017-11-01 | Adult | 57 | USA | Results not yet reported | ClinicalTrials.gov | Last verified October 2015 by US Army Medical Research and Material Command; Recruitment status was "Active, not recruiting" | |||||||||||||
18 | Gastroenteritis Escherichia Coli | ETEC | Peru-15-pCTB | Inactive / no longer in development | Live, attenuated target organism | Carbohydrate: specify | LPS | None | NCT00654108 | Completed | NIAID | Government | Phase 1 | 2008-06-01 | 2010-05-01 | 2010-12-01 | Adult | 62 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 22-Jan.-2015 | ClinicalTrials.gov | Cholera vaccine, vectoring cross-reactive ETEC antigen (rCTB) | ||||||||||||
19 | Gastroenteritis Escherichia Coli | ETEC | BB01 | Inactive / no longer in development | Live, attenuated target organism | Protein: specify | CFA/I | None | ISRCTN05087777 | Completed | Berna Biotech Ltd. | Industry | Phase 1 | 2005-05-13 | 2006-01-13 | 2006-01-13 | Adult | 50 | CHE | Results not yet reported | isrctn.com | |||||||||||||||
20 | Gastroenteritis Escherichia Coli | ETEC | Dukoral | Registered | Inactivated whole target organism | Protein: specify | CTB | None | ISRCTN11806026 | Completed | University of Gothenburg | Academic | Phase 2 | 2016-03-01 | 2017-06-01 | 2017-06-01 | Adult | 60 | SWE | Results not yet reported | isrctn.com | Cholera vaccine, vectoring cross-reactive ETEC antigen (rCTB); Publication anticipated 2018-06-30 | ||||||||||||||
21 | Gastroenteritis Escherichia Coli | ETEC | LT patch | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT01040325 | Completed | Intercell USA, Inc. | Industry | Phase 2 | 2009-12-01 | 2010-06-01 | 2010-12-01 | Adult | 723 | GER, IND, GBR | Results not yet reported | ClinicalTrials.gov | |||||||||||||||
22 | Gastroenteritis Escherichia Coli | ETEC | LT patch | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT00993681 | Completed | Intercell USA, Inc. | Industry | Phase 3 | 2009-10-01 | 2010-11-01 | 2011-04-01 | Adult | 2036 | GER, GTM, MEX, GBR | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1-März-2014 | ClinicalTrials.gov | |||||||||||||
23 | Gastroenteritis Escherichia Coli | ETEC | LT patch | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | Completed | Intercell USA, Inc. | Industry | Phase 3 | 2009-06-16 | 2011-04-12 | 2011-04-12 | Adult | 2400 | GER; GTM; MEX; GBR | Results reported in registry | Clinical Study Report | 15-Jan.-2017 | |||||||||||||||
24 | Gastroenteritis Escherichia Coli | ETEC | LT Patch | Inactive / no longer in development | Recombinant subunit (non VLP) | Protein: specify | LT | None | NCT00516659 | Completed | Intercell USA, Inc. | Industry | Phase 2 | 2006-05-01 | 2007-01-01 | 2007-12-01 | Adult | 201 | USA, GTM, MEX | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 14-Juni-2008 | ClinicalTrials.gov | |||||||||||||
25 | Gastroenteritis Escherichia Coli | ETEC | CssBA ± dmLT | Active candidate / in development | Recombinant subunit (non VLP) | Protein: specify | CssBA | Novel other: specify | dmLT | NCT03404674 | Open, recruiting | PATH | Other | Phase 1 | 2018-01-01 | 2019-10-31 | 2019-10-31 | Adult | 50 | USA | Results not yet reported | ClinicalTrials.gov | ||||||||||||||
26 | ||||||||||||||||||||||||||||||||||||
27 | ||||||||||||||||||||||||||||||||||||
28 | ||||||||||||||||||||||||||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | ||||
3 | MERS | Middle East Respiratory Syndrome Coronavirus | GLS-5300 | Active candidate / in development | DNA | Protein: specify | S glycoprotein | None | Open, not recruiting | GeneOne Life Science, Inc | Industry | Phase 1 | 01/01/2016 | 01/05/2017 | 01/09/2017 | Adult | 75 | USA | |||||||||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Publication Information | Other | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Primary Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Submitted Date | Registry Publication Date | Registry Publication Link | Notes | |
3 | Ebola | EBOV | Ad5-EBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02326194 | Completed, published | Jiangsu Province CDCP | Government | Phase 1 | 2014-12-01 | 2015-02-01 | 2015-07-01 | Adult | 120 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-03-25 | https://www.ncbi.nlm.nih.gov/pubmed/25817373 | Peer-reviewed publication or journal | 2016-12-22 | https://www.ncbi.nlm.nih.gov/pubmed/28017642 | clinicaltrials.gov | This is the original trial, the extended booster study is below (NCT02533791) | |||||
4 | Ebola | EBOV | Ad5-EBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02401373 | Completed, published | First Affiliated Hospital of Zhejiang University | Academic | Phase 1 | 2015-03-01 | 2015-07-01 | 2015-07-01 | Adult | 61 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-07-14 | http://www.tandfonline.com/doi/abs/10.1080/21645515.2017.1342021?journalCode=khvi20 | clinicaltrials.gov | Other Study ID Numbers: GR2015VCT001 | ||||||||
5 | Ebola | EBOV | Ad5-EBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02533791 | Completed, published | Jiangsu Province CDCP | Government | Phase 1 | 2015-07-01 | 2015-09-01 | 2015-10-01 | Adult | 110 | China | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-12-22 | https://www.ncbi.nlm.nih.gov/pubmed/28017642?dopt=Abstract | clinicaltrials.gov | |||||||||
6 | Ebola | EBOV | Ad5-EBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02575456 | Completed, published | Jiangsu Province CDCP | Government | Phase 2 | 2015-10-01 | 2016-06-01 | 2016-07-01 | Adult | 500 | Sierra Leone | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-12-22 | http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32617-4/fulltext | clinicaltrials.gov | Other Study ID Numbers: JSVCT024, also registered as PACTR201509001259869 | ||||||||
7 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02876328 | Open, recruiting | NIAID | Government | Phase 2 | 2017-03-31 | 2019-03-01 | 2019-03-01 | Child, Adult | 5500 | Guinea, Liberia | Results not yet reported | clinicaltrials.gov | ||||||||||||
8 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02269423 | Completed, published | Merck | Industry | Phase 1 | 2014-10-01 | 2015-08-01 | 2015-08-01 | Adult | 39 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | https://www.ncbi.nlm.nih.gov/pubmed/25830322 | Peer-reviewed publication or journal | 2017-01-26 | https://www.ncbi.nlm.nih.gov/pubmed/25830322 | clinicaltrials.gov | Initial interim publication in April 2015. Links to this publication now replaced with full 2017 publication. April 2015 publication noted in PubMed record and article PDF. other numbers: V920-001; NLG0307 (WRAIR #2163) | |||||
9 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02280408 | Completed, published | Merck | Industry | Phase 1 | 2014-10-01 | 2015-12-01 | 2015-12-01 | Adult | 39 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | https://www.ncbi.nlm.nih.gov/pubmed/25830322 | Peer-reviewed publication or journal | 2017-01-26 | https://www.ncbi.nlm.nih.gov/pubmed/25830322 | clinicaltrials.gov | Initial interim publication in April 2015. Links to this publication now replaced with full 2017 publication. April 2015 publication noted in PubMed record and article PDF. Exploratory results linked to this trial and NCT02269423 : https://www.ncbi.nlm.nih.gov/pubmed/27323685 | |||||
10 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02283099 | Completed, published | Universitätsklinikum Hamburg-Eppendorf | Academic | Phase 1 | 2014-11-01 | 2015-11-01 | 2015-11-01 | Adult | 30 | Germany | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | https://www.ncbi.nlm.nih.gov/pubmed/25830326 | Peer-reviewed publication or journal | 2017-04-05 | http://www.ebiomedicine.com/article/S2352-3964(17)30141-X/fulltext | clinicaltrials.gov | Interim publication from April 2015 was later published in April 2016 along with results from a number of other trials. Full results solely from this trial were published in April 2017. other study number: UKE-DZIF2-VSV{Delta}G/ZEBOVGP. Exploratory results linked to this trial and NCT02280408: https://www.ncbi.nlm.nih.gov/pubmed/27323685 | |||||
11 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02287480 | Completed, prelim results published | University of Geneva | Academic | Phase1/2 | 2014-11-01 | 2015-04-01 | 2016-01-01 | Adult | 115 | Switzerland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-08-04 | http://www.ncbi.nlm.nih.gov/pubmed/26248510 | Peer-reviewed publication or journal | 2018-04-04 | https://www.sciencedirect.com/science/article/pii/S1473309918301658?via%3Dihub | clinicaltrials.gov | Interim results also reported in: http://www.nejm.org/doi/full/10.1056/NEJMoa1502924 Unable to find a final publication. Preliminary data from linked study NCT02933931 is published. other study number: CCER 14-221 | |||||
12 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02296983 | Completed, published | University of Oxford | Academic | Phase 1 | 2014-12-01 | 2016-02-01 | 2016-09-01 | Adult | 40 | Kenya | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | http://www.nejm.org/doi/pdf/10.1056/NEJMoa1502924 | Peer-reviewed publication or journal | 2018-04-04 | https://www.sciencedirect.com/science/article/pii/S1473309918301658?via%3Dihub | clinicaltrials.gov | Pan African Clinical Trials Registry number, PACTR201411000919191. | |||||
13 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02314923 | Completed, prelim results published | Merck | Industry | Phase 1 | 2014-12-05 | 2016-06-23 | 2016-06-23 | Adult | 512 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-06-09 | http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30313-4/fulltext | clinicaltrials.gov | Other Study ID Numbers: V920-004; NLG0507 ( Other Identifier: NewLink Genetics Corp. ). preliminary data from linked study NCT02933931 is published | ||||||||
14 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02374385 | Completed, published | Dalhousie University | Academic | Phase 1 | 2014-11-01 | 2015-03-01 | 2015-06-01 | Adult | 40 | Canada | Results reported in peer-reviewed journal | Non-peer reviewed publication or journal | 2015-04-01 | https://drive.google.com/file/d/1W6nA-6FvmXuFrQJLMbw80GdyYvfCa_-AYSTq0F7lbnkITgZtBxIkZA8BBMStxp7L4wrSzJHwiBd9fjp4/view | Peer-reviewed publication or journal | 2017-06-19 | https://www.ncbi.nlm.nih.gov/pubmed/28630358 | clinicaltrials.gov | ||||||
15 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02378753 | Completed, published | CDC | Government | Phase 2/3 | 2015-04-01 | 2016-11-08 | 2016-12-05 | Adult | 8651 | Sierra Leone | Results reported in registry and peer-reviewed journal | Non-peer reviewed publication or journal | 2016-07-08 | https://www.ncbi.nlm.nih.gov/pubmed/27387395 | Peer-reviewed publication or journal | 2018-05-18 | https://academic.oup.com/jid/article/217/suppl_1/S6/4999145 | clinicaltrials.gov | 2018-09-22 | 2018-04-05 | https://clinicaltrials.gov/ct2/show/results/NCT02378753 | Other Study ID Numbers: CDC-NCIRD-6689 | ||
16 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | PACTR201411000919191 | Open, not recruiting | Universitaetsklinikum Tuebingen | Academic | Phase 1 | 2014-11-21 | 2016-07-31 | Adult | 155 | Gabon | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-04-01 | http://www.nejm.org/doi/pdf/10.1056/NEJMoa1502924 | Peer-reviewed publication or journal | 2017-10-06 | http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002402 | www.pactr.org | Secondary ID: LA- BPSC1001-01 | ||||||
17 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | PACTR201503001057193 | Completed, published | WHO | Other | Phase 3 | 2015-03-07 | 2016-01-20 | Child, Adult | 8851 | Guinea | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-07-31 | http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)61117-5.pdf | Peer-reviewed publication or journal | 2016-12-22 | http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)61117-5.pdf | www.pactr.org | Secondary ID: RPC 721AB | ||||||
18 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02368119 | Completed, unpublished | University of Maryland | Academic | Phase 1 | 2015-03-01 | 2016-09-27 | 2016-09-27 | Adult | 60 | Mali | Results not yet reported | clinicaltrials.gov | Other Study ID Numbers: HP-00062548 | |||||||||||
19 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02408913 | Completed, unpublished | NIAID | Government | Phase 1 | 2015-03-26 | 2017-04-06 | 2017-04-06 | Adult | 140 | USA | Results not yet reported | clinicaltrials.gov | ||||||||||||
20 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02451891 | Open, not recruiting | University of Oxford | Academic | Phase 1 | 2015-04-01 | 2017-08-01 | 2017-08-01 | Adult | 38 | UK | Interim results reported | Abstract / Poster / Conference proceedings | 2016-04-12 | https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=44903 | clinicaltrials.gov | Other Study ID Numbers: EBL04 | ||||||||
21 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02240875 | Open, not recruiting | University of Oxford | Academic | Phase 1 | 2014-09-17 | 2017-08-01 | 2017-08-01 | Adult | 92 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-01-28 | https://www.ncbi.nlm.nih.gov/pubmed/25629663?dopt=Abstract | Peer-reviewed publication or journal | 2016-04-28 | https://www.ncbi.nlm.nih.gov/pubmed/25629663 | clinicaltrials.gov | Other Study ID Numbers: EBL01; 2014-003518-10 (EudraCT No.) VA-BN Filo: Recombinant viral vector | |||||
22 | Ebola | EBOV | ChAd3-EBO-Z, VRC-EBOADC069-00-VP (ChAd3) and VRC-EBOMVA079-00-VP (MVA-EbolaZ) boost | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP or EBOV GP, SUDV GP | Glycoprotein | None | NCT02354404 | Completed, unpublished | NIAID | Government | Phase 1 | 2015-01-27 | 2017-04-19 | 2017-04-19 | Adult | 90 | Uganda | Results not yet reported | clinicaltrials.gov | Other Study ID Numbers: PACTR201412000957310, RV422 | |||||||||||
23 | Ebola | EBOV | ChAd3-EBO-Z | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02289027 | Completed, published | Centre Hospitalier Universitaire Vaudois | Academic | Phase 1/2 | 2014-10-01 | 2015-06-01 | 2015-06-01 | Adult | 120 | Switzerland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-12-22 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT02289027 | clinicaltrials.gov | 4/27/2018 | https://clinicaltrials.gov/ct2/show/results/NCT02289027 | other study number: cAd3-EBOZ Lau | ||||||
24 | Ebola | EBOV | ChAd3-EBO-Z | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02231866 | Completed, published | NIAID/ NIH CC | Government | Phase 1 | 2014-08-27 | 2017-04-05 | 2017-04-05 | Adult | 50 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-11-03 | https://www.ncbi.nlm.nih.gov/pubmed/26546548 | Peer-reviewed publication or journal | 2017-03-09 | https://www.ncbi.nlm.nih.gov/pubmed/25426834 | clinicaltrials.gov | ||||||
25 | Ebola | EBOV | VRC-EBOADC069-00-VP (ChAd3) | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP | Glycoprotein | None | NCT02231866 | Completed, published | NIAID/ NIH CC | Government | Phase 1 | 2014-08-27 | 2017-04-05 | 2017-04-05 | Adult | 50 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-11-03 | https://www.ncbi.nlm.nih.gov/pubmed/26546548 | Peer-reviewed publication or journal | 2017-03-09 | https://www.ncbi.nlm.nih.gov/pubmed/25426834 | clinicaltrials.gov | ||||||
26 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein | None | NCT02267109 | Completed, published | University of Maryland | Academic | Phase 1 | 2014-10-01 | 2016-04-01 | 2018-06-01 | Adult | 91 | Mali | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2015-11-03 | https://www.ncbi.nlm.nih.gov/pubmed/26546548 | clinicaltrials.gov | |||||||||
27 | Ebola | EBOV | ChAd3-EBO-Z and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02485912 | Completed, unpublished | University of Oxford | Academic | Phase 1 | 2015-07-01 | 2016-01-01 | 2016-01-01 | Adult | 40 | Senegal | Results not yet reported | clinicaltrials.gov | ||||||||||||
28 | Ebola | EBOV | ChAd3-EBO-Z | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02485301 | Completed, published | GSK | Industry | Phase 2 | 2015-07-15 | 2016-12-23 | 2016-12-23 | Adult | 3024 | Cameroon, Mali, Nigeria, Senegal | Results reported in registry | Non-peer reviewed publication or journal | 2017-05-16 | https://www.gsk-clinicalstudyregister.com/files2/202091%20-%20Clinical-Study-Result-Summary.pdf | clinicaltrials.gov | 5/16/2017 | 2018-01-04 | https://clinicaltrials.gov/ct2/show/results/NCT02485301 | other ID: 202091 | |||||
29 | Ebola | EBOV | ChAd3-EBO-Z | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02548078 | Completed, unpublished | GSK | Industry | Phase 2 | 2015-11-09 | 2017-05-15 | 2017-05-15 | Child | 600 | Mali, Senegal | Results submitted to registry | clinicaltrials.gov | 3/30/2018 | https://clinicaltrials.gov/ct2/show/results/NCT02548078 | other studies: 202090, PACTR201507001154522, PACTR201504001092179 | |||||||||
30 | Ebola | EBOV | ChAd3-EBO-Z and Ad26-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02495246 | Open, not recruiting | University of Oxford | Academic | Phase 1 | 2015-09-21 | 2017-08-22 | 2017-08-22 | Adult | 32 | UK | Results not yet reported | clinicaltrials.gov | other ID: EBL05 | |||||||||||
31 | Ebola | EBOV | EBOV GP nanoparticle | Active candidate / in development | Recombinant subunit (VLP) | Protein: EBOV GP | Glycoprotein | Licensed other: specify | Matrix-M | NCT02370589 | Completed, unpublished | Novavax | Industry | Phase 1 | 2015-02-01 | 2016-04-01 | 2016-04-01 | Adult | 230 | Australia | Interim results reported | Non-peer reviewed publication or journal | 2015-07-21 | https://drive.google.com/file/d/0B2ccvtjUol6La1BkQzJVMVZqV0E/view | clinicaltrials.gov | ||||||||
32 | Ebola | EBOV | HPIV3-EbovZ | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02564575 | Completed, unpublished | NIAID | Government | Phase 1 | 2015-08-01 | 2016-11-01 | 2016-11-01 | Adult | 30 | USA | Interim results reported | Abstract / Poster / Conference proceedings | 2016-11-13 | https://www.astmh.org/ASTMH/media/Documents/Abstracts-1001-1500-ASTMH-2016-Annual-Meeting-Abstract-Book.pdf | clinicaltrials.gov | Other Study ID Numbers: CIR 305 | ||||||||
33 | Ebola | EBOV | HPIV3-EbovZ | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT03462004 | Open, recruiting | NIAID | Government | Phase 1 | 2018-03-05 | 2019-10-01 | 2019-12-01 | Adult | 30 | USA | Results not yet reported | clinicaltrials.gov | two doses of the HPIV3/ΔHNF/EbovZ GP vaccine | |||||||||||
34 | Ebola | EBOV | INO-4212, with and without INO-9012 | Active candidate / in development | DNA | Protein: EBOV GP | Glycoprotein | None | NCT02464670 | Open, not recruiting | Inovio Pharmaceuticals | Industry | Phase 1 | 2015-05-01 | 2018-05-01 | 2018-07-01 | Adult | 240 | USA | Interim results reported | Other | 2016-03-30 | http://ir.inovio.com/news/news-releases/news-releases-details/2016/Inovio-Ebola-Vaccine-Generates-Robust-Immune-Responses-in-Humans/default.aspx | clinicaltrials.gov | used electroporation | ||||||||
35 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02876328 | Open, recruiting | NIAID | Government | Phase 2 | 2017-03-31 | 2019-03-01 | 2019-03-01 | Child, Adult | 5500 | Guinea, Liberia | Results not yet reported | clinicaltrials.gov | ||||||||||||
36 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02860650 | Open, not recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 1 | 2016-08-01 | 2017-05-01 | 2018-01-01 | Adult | 72 | USA | Results not yet reported | clinicaltrials.gov | ||||||||||||
37 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02313077 | Completed, published | Crucell Holland BV | Industry | Phase 1 | 2014-10-01 | 2016-04-20 | 2016-04-20 | Adult | 87 | UK | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2016-04-19 | https://www.ncbi.nlm.nih.gov/pubmed/27092831?dopt=Abstract | clinicaltrials.gov | |||||||||
38 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02325050 | Completed, unpublished | Janssen Vaccines & Prevention B.V. | Industry | Phase 1 | 2015-01-08 | 2015-07-02 | 2017-05-08 | Adult | 164 | USA | Interim results reported | Abstract / Poster / Conference proceedings | 2016-05-25 | http://viruseradication.com/abstract-details.php?abstract_id=539 | clinicaltrials.gov | |||||||||
39 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02376400 | Completed, unpublished | Crucell Holland BV | Industry | Phase 1 | 2015-04-01 | 2015-12-01 | 2016-09-01 | Adult | 78 | Tanzania, Uganda | Results not yet reported | clinicaltrials.gov | Other Study ID Numbers: CR106459 VAC52150EBL1004 ( Other Identifier: Crucell Holland BV ) | |||||||||||
40 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02376426 | Completed, unpublished | Crucell Holland BV | Industry | Phase 1 | 2015-03-01 | 2015-09-01 | 2016-06-01 | Adult | 72 | Kenya | Interim results reported | Abstract / Poster / Conference proceedings | 2016-11-06 | http://www.ijidonline.com/article/S1201-9712(16)31298-X/fulltext | clinicaltrials.gov | Other Study ID Numbers: CR106458 VAC52150EBL1003 ( Other Identifier: Crucell Holland BV ) | ||||||||
41 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02416453 | Open, not recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2015-06-15 | 2017-11-17 | 2017-11-17 | Adult | 408 | France, UK | Results not yet reported | clinicaltrials.gov | Secondary ID: CR107227, VAC52150EBL2001, 2015-000596-27 | |||||||||||
42 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02509494 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 3 | 2015-09-30 | 2019-05-03 | 2019-05-13 | Child, Adult | 1019 | Sierra Leone | Results not yet reported | clinicaltrials.gov | Other ID: PACTR201506001147964 | |||||||||||
43 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02543268 | Completed, unpublished | Crucell Holland BV | Industry | Phase 3 | 2015-09-01 | 2016-01-01 | 2016-07-01 | Adult | 329 | USA | Results not yet reported | clinicaltrials.gov | ||||||||||||
44 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02543567 | Completed, unpublished | Janssen Vaccines & Prevention B.V. | Industry | Phase 3 | 2015-09-21 | 2016-06-07 | 2016-11-29 | Adult | 525 | USA | Results not yet reported | clinicaltrials.gov | ||||||||||||
45 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02564523 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2015-11-06 | 2019-01-21 | 2019-07-21 | Child, Adult | 1056 | Burkina Faso, Cote D'Ivoire, Kenya, Uganda | Results not yet reported | clinicaltrials.gov | Other Study ID Numbers: CR107249; VAC52150EBL2002 | |||||||||||
46 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02598388 | Open, not recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 2 | 2015-12-10 | 2018-08-03 | 2018-12-28 | Adult | 575 | USA, Kenya, Mozambique, Nigeria, Tanzania, Uganda | Results not yet reported | clinicaltrials.gov | Other study numbers: CR108062; VAC52150EBL2003. Other registry ID: PACTR201608001734218 | |||||||||||
47 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02661464 | Open, recruiting | Janssen Vaccines & Prevention B.V. | Industry | Phase 3 | 2016-07-01 | 2022-05-01 | 2023-04-11 | Child, Adult | 922 | USA, Kenya, UK, Burkina Fasa, Cote d'Ivoire, France, Kenya, Mozambique, Nigeria, Tanzania, Uganda, Sierra Leone | Results not yet reported | clinicaltrials.gov | ||||||||||||
48 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT02891980 | Open, not recruiting | NIAID | Government | Phase 1 | 2017-03-24 | 2019-03-15 | 2019-03-15 | Adult | 65 | USA | Results not yet reported | clinicaltrials.gov | ||||||||||||
49 | Ebola | EBOV | Ad26-ZEBOV and MVA-BN-Filo | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP, MARV GP, TAFV NP | Glycoprotein, nucleoprotein | None | NCT03140774 | Open, not recruiting | University of Oxford | Academic | Phase 1 | 2017-05-17 | 2017-10-31 | 2018-10-31 | Adult | 56 | UK | Results not yet reported | clinicaltrials.gov | ||||||||||||
50 | Ebola | EBOV | rVSVN4CT1-EBOVGP1 | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02718469 | Completed, unpublished | Profectus Biosciences | Industry | Phase 1 | 2015-12-22 | 2016-09-15 | 2016-09-15 | Adult | 38 | USA | Interim results reported | Other | 2016-12-04 | http://www.profectusbiosciences.com/pdfs/publications/2016%2012%20Profectus%20Keystone%20Symposia%20on%20Hemorrhagic%20Fever%20Viruses-presentation.pdf | clinicaltrials.gov | Other Study ID Numbers: rVSV-EBOV-01 | ||||||||
51 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02788227 | Open, recruiting | NIAID/ NIH CC | Government | Phase 2 | 2016-01-12 | 2021-10-31 | 2022-10-21 | Adult | 18 | USA | Results not yet reported | clinicaltrials.gov | Other Study ID Numbers: CR108144 | |||||||||||
52 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02503202 | Completed, published | Merck | Industry | Phase 3 | 2015-08-17 | 2016-05-02 | 2017-09-29 | Adult | 1198 | Canada, Spain, US | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-05-26 | https://www.ncbi.nlm.nih.gov/pubmed/28549145?dopt=Abstract | clinicaltrials.gov | Other Study ID Numbers: V920-012, 2015-001658-14 ( EudraCT Number ) | ||||||||
53 | Ebola | EBOV, SUDV | VRC-EBOADV018-00-VP | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP, SUDV GP | Glycoprotein | None | NCT00374309 | Completed, published | NIAID/ NIH CC | Government | Phase 1 | 2006-09-05 | 2009-05-05 | Adult | 48 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2010-10-27 | http://www.sciencedirect.com/science/article/pii/S0264410X10015070 | clinicaltrials.gov | secondary registry ID: VRC 205 (06-I-0237) | |||||||||
54 | Ebola | EBOV, SUDV | VRC-EBODNA012-00-VP | Active candidate / in development | DNA | Protein: EBOV GP, SUDV GP, EBOV NP | Glycoprotein, nucleoprotein | None | NCT00072605 | Completed, published | NIAID/ NIH CC | Government | Phase 1 | 2003-10-30 | 2007-08-01 | Adult | 27 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2006-09-20 | https://www.ncbi.nlm.nih.gov/pubmed/16988008 | clinicaltrials.gov | secondary registry ID VRC 204 (04-I-0028) | |||||||||
55 | Ebola | EBOV, SUDV | VRC-EBODNA023-00-VP | Active candidate / in development | DNA | Protein: EBOV GP, SUDV GP | Glycoprotein | None | NCT00605514 | Completed, published | NIAID/ NIH CC | Government | Phase 1 | 2008-01-25 | 2010-06-21 | 2010-06-21 | Adult | 20 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-09-14 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318920/ | clinicaltrials.gov | VRC-MARDNA025-00-VP: plasmid DNA | ||||||||
56 | Marburg | MARV | VRC-MARDNA025-00-VP | Active candidate / in development | DNA | Protein: MARV GP | Glycoprotein | None | NCT00605514 | Completed, published | NIAID/NIH CC | Government | Phase 1 | 2008-01-25 | 2010-06-21 | 2010-06-21 | Adult | 20 | USA | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-09-14 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318920/ | clinicaltrials.gov | |||||||||
57 | Ebola & Marburg | EBOV, SUDV, MARV | VRC-EBODNA023-00-VP and VRC-MARDNA025-00-VP | Active candidate / in development | DNA | Protein: EBOV GP, SUDV GP, MARV GP | Glycoprotein | None | NCT00997607 | Completed, published | NIAID | Government | Phase 1 | 2010-02-01 | 2012-04-01 | 2012-04-01 | Adult | 108 | Uganda | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-12-23 | http://www.sciencedirect.com/science/article/pii/S0140673614623850 | clinicaltrials.gov | other study ID number: RV 247 | ||||||||
58 | Ebola | EBOV, SUDV | VRC-EBODNA023-00-VP | Active candidate / in development | DNA | Protein: EBOV GP, SUDV GP | Glycoprotein | None | NCT00997607 | Completed, published | NIAID | Government | Phase 1 | 2010-02-01 | 2012-04-01 | 2012-04-01 | Adult | 108 | Uganda | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-12-23 | http://www.sciencedirect.com/science/article/pii/S0140673614623850 | clinicaltrials.gov | other study ID number: RV 247 | ||||||||
59 | Marburg | MARV | VRC-MARDNA025-00-VP | Active candidate / in development | DNA | Protein: MARV GP | Glycoprotein | None | NCT00997607 | Completed, published | NIAID | Government | Phase 1 | 2010-02-01 | 2012-04-01 | 2012-04-01 | Adult | 108 | Uganda | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2014-12-23 | http://www.sciencedirect.com/science/article/pii/S0140673614623850 | clinicaltrials.gov | other study ID number: RV 247 | ||||||||
60 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02344407 | Open, not recruiting | NIAID | Government | Phase 2 | 2015-01-20 | 2016-06-01 | 2020-06-01 | Adult | 1500 | Liberia | Results reported in both peer-reviewed journal and registry | Abstract / Poster / Conference proceedings | 2016-02-22 | http://www.croiwebcasts.org/console/player/29571?mediaType=slideVideo& | Peer-reviewed publication or journal | 2017-10-13 | https://www.ncbi.nlm.nih.gov/pubmed/29020589?dopt=Abstract | clinicaltrials.gov | 2017-05-25 | https://clinicaltrials.gov/ct2/show/results/NCT02344407?term=NCT02344407&rank=1 | ||||
61 | Ebola | EBOV | ChAd3-EBO-Z | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02344407 | Open, not recruiting | NIAID | Government | Phase 2 | 2015-01-20 | 2016-06-01 | 2020-06-01 | Adult | 1500 | Liberia | Results reported in both peer-reviewed journal and registry | Abstract / Poster / Conference proceedings | 2016-02-22 | http://www.croiwebcasts.org/console/player/29571?mediaType=slideVideo& | Peer-reviewed publication or journal | 2017-10-13 | https://www.ncbi.nlm.nih.gov/pubmed/29020589?dopt=Abstract | clinicaltrials.gov | 2017-05-25 | 2017-08-01 | https://clinicaltrials.gov/ct2/show/results/NCT02344407?term=NCT02344407&rank=1 | |||
62 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02933931 | Open, recruiting | University Hospital, Geneva | Other | Phase 1 | 2016-11-01 | 2020-01-01 | 2020-04-01 | Adult | 100 | Switzerland | Interim results reported | Peer-reviewed publication or journal | 2018-04-04 | https://www.sciencedirect.com/science/article/pii/S1473309918301658?via%3Dihub | clinicaltrials.gov | Follow-up study to NCT02287480. Partial follow-up results reported in that paper. | ||||||||
63 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT03161366 | Suspended | Epicentre | Other | Phase 3 | 2018-12-01 | 2019-06-01 | 2019-03-31 | Adult | 500 | Uganda | Results not yet reported | clinicaltrials.gov | ||||||||||||
64 | Ebola | EBOV | rVSV-ZEBOV | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT03031912 | Open, recruiting | Dalhousie University | Academic | Phase 2 | 2017-08-01 | 2019-01-01 | 2019-12-01 | Child, Adult | 200 | Canada, Burkina Faso, Senegal | Results not yet reported | clinicaltrials.gov | ||||||||||||
65 | Ebola | EBOV | GamEvac-Combi (VSV-GP and Ad5-GP) | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT03072030 | Open, recruiting | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Government | Phase 4 | 2017-08-03 | 2019-12-01 | 2019-12-31 | Adult | 2000 | Guinea, Russia | Results not yet reported | clinicaltrials.gov | Other registry ID: PACTR201702002053400 | |||||||||||
66 | Ebola | EBOV | GamEvac-Combi (VSV-GP and Ad5-GP) | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | No. 0373100043215000055 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Government | Phase 1/2 | 2015-09-16 | 2015-11-30 | Adult | 84 | Russia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 2017-02-02 | https://www.ncbi.nlm.nih.gov/pubmed/28152326 | www.pactr.org | Other registry ID: grls.rosminzdrav.ru (No. 495*) "zakupki.gov.ru (No. 0373100043215000055)" | |||||||||
67 | Ebola | EBOV | GamEvac-Combi (VSV-GP and Ad5-GP) | Active candidate / in development | Recombinant viral vector | Protein: EBOV GP | Glycoprotein | None | NCT02911415 | Completed, unpublished | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Government | Phase 4 | 2016-10-01 | 2017-12-25 | 2017-12-25 | Adult | 60 | Russia | Results not yet reported | clinicaltrials.gov | Other registry ID: NCT02911428 | |||||||||||
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Publication Information | Other | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication PMID | Full Publication Link | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | |||
3 | Pneumococcal Infections | S. Pneumoniae | PCV 13 (Prevnar 13) |dTpa | MCV4 | Active candidate / registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | ACTRN12613000536763 | Completed | Children's Hospital, Westmead | Academic | Phase 2 | 7/8/2013 | Unspecified | Unspecified | Adult | 227 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 11/21/2016 | 27780630 | https://www.ncbi.nlm.nih.gov/pubmed/?term=ACTRN12613000536763 | Schedule | ||||||||||
13 | Pneumococcal Infections | S. Pneumoniae | Influenza vaccination|Pneumococcal polysaccharide vaccination | Active candidate / in development | NCT00380679 | Unknown | Louisiana State University Health Sciences Center in New Orleans | Other | Government | Phase 2 | 12/1/2005 | 3/1/2006 | Unspecified | Adult | null | United States | Results not yet reported | Acceptance and receipt of vaccinations | ||||||||||||||||||
24 | Pneumococcal Infections | S. Pneumoniae | PCV 7 (PncCRM and PncOMPC) | Active candidate / registered | Subunit conjugate | Conjugate: specify antigen & carrier to CRM197 or OMPC | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00378417 | Completed | National Institute for Health and Welfare, Finland | Other | Industry | Phase 3 | 3/1/1995 | 3/1/1999 | Unspecified | Child | 3075 | Finland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 5/13/2013 | 23658394 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00378417 | |||||||||||
26 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Nucovac) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | Yes | CTRI/2014/04/004543 | Completed | Panacea Biotec Ld | Industry | Phase 1 | 19/04/2014 | Unspecified | Unspecified | Child | 72 | India | Results not yet reported | |||||||||||||||
27 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Nucovac) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | Yes | CTRI/2013/05/003711 | Completed | Panacea Biotec Ld | Industry | Phase 1|Phase 2 | 04/06/2013 | Unspecified | Unspecified | Adult | 48 | India | Results not yet reported | |||||||||||||||
29 | Pneumococcal Infections | S. Pneumoniae | PCV10 (SIILPCV10) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | CTRI/2015/12/006456 | Completed | Serum Institute of India | Other | Phase 2 | 1/7/2016 | Unspecified | Unspecified | Child | 112 | India | Results not yet reported | |||||||||||||||
30 | Pneumococcal Infections | S. Pneumoniae | PCV10 (SIILPCV10) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | CTRI/2013/09/003961 | Completed | Serum Institute of India | Other | Phase 1 | 6/18/2014 | Unspecified | Unspecified | Adult | 34 | India | Results not yet reported | |||||||||||||||
33 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00370227 | Completed | GlaxoSmithKline | Industry | Phase 3 | 10/1/2006 | 3/1/2007 | Unspecified | Child | 390 | Finland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 6/1/2010 | 20508478 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00370227 | |||||||||||
54 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00333450 | Completed | GlaxoSmithKline | Industry | Phase 3 | 8/1/2006 | 12/1/2006 | Unspecified | Child | 120 | Germany | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/1/2012 | 21909049 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00333450 | |||||||||||
55 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00307541 | Completed | GlaxoSmithKline | Industry | Phase 3 | 10/1/2005 | 4/1/2006 | Unspecified | Child | 120 | Germany | United States | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 1/1/2012 | 21909049 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00333450 | |||||||||||
57 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00307554 | Completed | GlaxoSmithKline | Industry | Phase 3 | 11/1/2005 | 6/1/2006 | Unspecified | Child | 1600 | Finland | France | Poland | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/1/2009 | 19325447 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00307554 | |||||||||||
67 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | ACTRN12609000515291 | Completed | Royal Children's Hospital | Government | Phase 3 | 6/1/2009 | Unspecified | Unspecified | Child | 100 | Australia | Results not yet reported | |||||||||||||||
68 | Pneumococcal Infections | S. Pneumoniae | PCV10 (Synflorix ) | Infanrix | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00338351 | Completed | GlaxoSmithKline | Industry | Phase 2 | 4/1/2006 | 10/1/2006 | Unspecified | Child | 240 | Chile | Results not yet reported | |||||||||||||||
71 | Pneumococcal Infections, Rotavirus Infections | S. Pneumoniae | PCV10 (Synflorix ) | Infanrix Hexa | Rotarix | Paracetamol | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | None | NCT00370318 | Completed | GlaxoSmithKline | Industry | Phase 3 | 9/1/2006 | 4/1/2007 | Unspecified | Child | 400 | Czech Republic | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 17/10/2009 | 19837254 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00370318 | Prophylactic Antipyretic Treatment | ||||||||||
78 | Pneumococcal Infections | S. Pneumoniae | PCV11 | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F | None | NCT00327522 | Completed | GlaxoSmithKline | Industry | Phase 2 | 6/1/2006 | Unspecified | Unspecified | Adult | 10 | Belgium | Results not yet reported | |||||||||||||||
88 | Pneumococcal Infections | S. Pneumoniae | PCV13 (GBP411) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | TCTR20170109002 | Not yet open | SK Chemicals Co.,Ltd. | Industry | Phase 3 | 4/14/2017 | 4/23/2018 | Unspecified | Child | 100 | Tailand | Results not yet reported | |||||||||||||||
96 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT00205803 | Completed | Pfizer | Industry | Phase 1|Phase 2 | 9/1/2004 | 5/1/2007 | Unspecified | Child | 249 | United States | Results reported in both peer-reviewed journal and registry | Peer-reviewed publication or journal | 5/1/2010 | 20435707 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00205803 | 3/26/2010 | https://clinicaltrials.gov/ct2/show/results/NCT00205803 | |||||||||
133 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT00656409 | Completed | Institute of Child Health | Other | Phase 3 | 6/1/2006 | 3/1/2008 | Unspecified | Child, Adult | 30 | United Kingdom | Results not yet reported | |||||||||||||||
140 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | ACTRN12614001003662 | Open, recruiting | Hunter Medical Research Institute | Other | Phase 1 | 6/1/2016 | Unspecified | Unspecified | Adult | 100 | Australia | Results not yet reported | |||||||||||||||
141 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | JPRN-UMIN000010576 | Open, recruiting | National Cancer Center Hospital | Academic | Phase 2 | 4/23/2013 | Unspecified | Unspecified | Child, Adult | 73 | Japan | Results not yet reported | allogeneic hematopoietic stem cell transplantation recipients | ||||||||||||||
142 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | Novel other: specify | B.lactis Bi-07 | ACTRN12613000368730 | Not yet open | Individual Associate Professor Mimi Tang | Other | Phase 1 | 4/16/2013 | Unspecified | Unspecified | Child | 30 | Australia | Results not yet reported | ||||||||||||||
143 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | ACTRN12613000264785 | Open, recruiting | Individual Te-Yu Hung | Other | Phase 2|Phase 3 | 3/6/2013 | Unspecified | Unspecified | Child | 100 | Australia | Results not yet reported | |||||||||||||||
150 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | PCV10 (Synflorix) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | ACTRN12610000544077 | Open, recruiting | University Menzies School of Health Research | Academic | Phase 3 | Phase 4 | 8/29/2011 | Unspecified | Unspecified | Child | 425 | Australia | Results not yet reported | |||||||||||||||
158 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT02255227 | Open, recruiting | Centre Hospitalier Universitaire de Saint Etienne | Academic | Industry | Phase 2 | 4/1/2015 | 12/1/2020 | 12/1/2020 | Adult | 150 | France | Results not yet reported | Chronic Inflammatory Bowel Disease | ||||||||||||||
159 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | PPV-23 (Pneumovax 23) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier CRM197 | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT00137605 | Completed | CIHR Canadian HIV Trials Network | Other | Industry | Phase 1|Phase 2 | 9/1/2004 | 10/1/2007 | Unknown | Adult | 79 | Canada | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 3/24/2013 | 23535358 | https://www.ncbi.nlm.nih.gov/pubmed/23535358?dopt=Abstract | |||||||||||
180 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00488826 | Completed | Pfizer | Industry | Phase 1 | 10/1/2005 | 5/1/2007 | Unspecified | Child | 800 | China | Results reported in registry | 3/31/2009 | https://clinicaltrials.gov/ct2/show/results/NCT00488826 | |||||||||||||
182 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00000829 | Completed | NIAID | Government | Industry | Phase 1 | Unspecified | 10/1/1999 | Unspecified | Child | 60 | United States | Puerto Rico | Results not yet reported | |||||||||||||||
183 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00142389 | Completed | Johns Hopkins Bloomberg School of Public Health | Academic | Government | Industry | Phase 1|Phase 2 | 8/1/2004 | 12/1/2006 | Unspecified | Adult | 680 | Bangladesh | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/1/2013 | 23300160 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00142389 | |||||||||||
185 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00213265 | Unknown | The Hospital for Sick Children | Academic | Phase 3 | 7/1/2002 | Unspecified | Unspecified | Child, Adult | 150 | Canada | Results not yet reported | |||||||||||||||
188 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | ACTRN12607000387426 | Completed | Individual Professor C Raina MacIntyre | Other | Phase 3 | Phase 4 | 5/16/2005 | Unspecified | Unspecified | Senior | 315 | Australia | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/23/2014 | 24760002 | https://www.ncbi.nlm.nih.gov/pubmed/?term=ACTRN12607000387426 | |||||||||||
189 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | EUCTR2017-001529-41-Outside-EU/EEA | Unknown | Pfizer | Industry | Phase 4 | Unspecified | Unspecified | Unspecified | Child | 100 | Russian Federation | Results not yet reported | |||||||||||||||
192 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00153543 | Completed | CDC | Government | Phase 1 | 5/1/2002 | 6/1/2003 | Unspecified | Adult | 90 | United States | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 7/15/2009 | https://academic.oup.com/cid/article/49/2/241/404324/Immunogenicity-and-Reactogenicity-of-Pneumococcal | ||||||||||||
194 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Active candidate / registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00148824 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | Other | Industry | Phase 2 | 2/1/2003 | 1/1/2006 | Unspecified | Adult | 212 | France | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/15/2010 | 20210645 | https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00148824 | |||||||||||
197 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | RBR-3p7577 | Completed | Hospital das Clínicas da Faculdade de Medicina da USP | Academic | Phase 1 | 1/1/2011 | Unspecified | Unspecified | Adult | 330 | Brazil | Results not yet reported | |||||||||||||||
198 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | IRCT201110116660N3 | Completed | Mazandaran University of Medical Sciences | Academic | Phase 2 | 7/27/2011 | Unspecified | Unspecified | Child, Adult | 50 | Iran | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 11/1/2017 | PMC5412244 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412244/ | |||||||||||
199 | Pneumococcal Infections | S. Pneumoniae | PCV7 (Prevnar 7) | PPV-23 (Pneumovax 23) | Tetanus-diphtheria toxoids (Td) | Active candidate / registered | Subunit conjugate | Conjugate: specify antigen & carrier | 4, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00164411 | Completed | CDC | Other | Academic | Phase 1 | 1/1/2004 | 3/1/2005 | Unspecified | Adult | 30 | United States | Results not yet reported | |||||||||||||||
201 | Pneumococcal Infections | S. Pneumoniae | PCV7 (VCN7-T) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier tetanus toxoid | 4, 6B, 9V, 14, 18C, 19F and 23F | None | RPCEC00000243 | Not yet open | Finlay Institute | Other | Phase 1|Phase 2 | 5/24/2017 | 4/28/2017 | Unspecified | Child | 880 | Cuba | Results not yet reported | |||||||||||||||
202 | Pneumococcal Infections | S. Pneumoniae | PCV7 (VCN7-T) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier tetanus toxoid | 4, 6B, 9V, 14, 18C, 19F and 23F | None | RPCEC00000182 | Completed | Biomolecular Chemistry Center (CQB) | Other | Phase 2|Phase 3 | 6/9/2014 | Unspecified | Unspecified | Child | 1140 | Cuba | Results not yet reported | |||||||||||||||
203 | Pneumococcal Infections | S. Pneumoniae | PCV7 (VCN7-T) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier Tetanus toxoid | 4, 6B, 9V, 14, 18C, 19F and 23F | None | RPCEC00000173 | Completed | Biomolecular Chemistry Center (CQB) | Other | Phase 1 | 5/1/2013 | Unspecified | Unspecified | Child | 45 | Cuba | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 9/15/2014 | 25068497 | https://www.ncbi.nlm.nih.gov/pubmed/?term=RPCEC00000173 | |||||||||||
204 | Pneumococcal Infections | S. Pneumoniae | PCV7 (VCN7-T) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier tetanus toxoid | 4, 6B, 9V, 14, 18C, 19F and 23F | None | RPCEC00000133 | Completed | Biomolecular Chemistry Center (CQB) | Other | Phase 1 | 6/17/2012 | Unspecified | Unspecified | Adult | 40 | Cuba | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 10/1/2015 | 26947279 | https://www.ncbi.nlm.nih.gov/pubmed/?term=RPCEC00000133 | |||||||||||
205 | Pneumococcal Infections | S. Pneumoniae | PCV9 | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F | None | NCT00197769 | Completed | Public Health England | Academic | Phase 2 | 9/1/2000 | 1/1/2004 | Unspecified | Child | null | United Kingdom | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | 4/1/2006 | 16567982 | https://www.ncbi.nlm.nih.gov/pubmed/16567982?dopt=Abstract | |||||||||||
220 | Pneumococcal Infections | S. Pneumoniae | PPV-23 (Pneumovax 23) | Registered | Polysaccharides | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | None | NCT00310349 | Unknown | University of Melbourne | Other | Phase 3 | 3/1/2006 | 1/1/2009 | Unspecified | Child, Adult | 210 | Australia | Results not yet reported | Maternal immunization | |||||||||||||||
230 | Pneumococcal Infections | S. Pneumoniae | PPV-23 (Pneumovax 23) | Registered | Polysaccharides | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | None | ACTRN12615000536561 | Open, recruiting | University of Newcastle | Academic | Phase 3 | 2/23/2016 | 12/31/2017 | Unspecified | Adult | 4500 | Australia | Results not yet reported | ||||||||||||||||
232 | Pneumococcal Infections | S. Pneumoniae | PPV-23 (Pneumovax 23) | PCV10 (Synflorix ) | Registered | Polysaccharides | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | None | NCT00307567 | Completed | GlaxoSmithKline | Industry | Phase 2 | 11/1/2005 | 3/1/2006 | Unspecified | Child | 689 | Germany | Results not yet reported | ||||||||||||||||
239 | Pneumococcal Infections | S. Pneumoniae | PCV (LBVE) | PCV13 (Prevnar 13) | Active candidate / in development | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT03467984 | Open, not yet recruiting | LG Chem | Industry | Phase 2 | 4/1/2018 | 10/1/2018 | 3/1/2019 | Child | 230 | Results not yet reported | ||||||||||||||||
240 | Pneumococcal Infections | S. Pneumoniae | PCV15 (V114) + PPV-23 (Pneumovax 23) | PCV13 (Prevnar 13) | Active candidate / in development | Polysaccharides | Conjugate: specify antigen & carrier | 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F | Aluminum salts (alum) | aluminum phosphate | NCT03480802 | Open, not yet recruiting | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 7/9/2018 | 4/13/2020 | 4/13/2020 | Adult | 300 | Results not yet reported | |||||||||||||||
241 | Pneumococcal Infections | S. Pneumoniae | PCV13 (Prevnar 13) | Registered | Subunit conjugate | Conjugate: specify antigen & carrier | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | None | NCT03384589 | Open, not yet recruiting | University of British Columbia | Other | Phase 2 | Phase 3 | 1/1/2018 | 12/1/2020 | 12/1/2020 | Child | 248 | Canada | Results not yet reported | |||||||||||||||
242 | Pneumococcal Infections | S. Pneumoniae | PCV15 (V114) + PPV-23 (Pneumovax 23) | PCV13 (Prevnar 13) | Active candidate / in development | Polysaccharides | Conjugate: specify antigen & carrier | 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F | Aluminum salts (alum) | aluminum phosphate | NCT03480763 | Open, not yet recruiting | Merck Sharp & Dohme Corp. | Industry | Phase 3 | 6/25/2018 | 10/29/2019 | 10/29/2019 | Adult | 600 | Results not yet reported | |||||||||||||||
243 | |||||||||||||||||||||||||||||||||||
244 | |||||||||||||||||||||||||||||||||||
245 | |||||||||||||||||||||||||||||||||||
246 | |||||||||||||||||||||||||||||||||||
247 | |||||||||||||||||||||||||||||||||||
248 | |||||||||||||||||||||||||||||||||||
249 | |||||||||||||||||||||||||||||||||||
250 | |||||||||||||||||||||||||||||||||||
251 | |||||||||||||||||||||||||||||||||||
252 | |||||||||||||||||||||||||||||||||||
253 | |||||||||||||||||||||||||||||||||||
254 | |||||||||||||||||||||||||||||||||||
255 | |||||||||||||||||||||||||||||||||||
256 | |||||||||||||||||||||||||||||||||||
257 | |||||||||||||||||||||||||||||||||||
258 | |||||||||||||||||||||||||||||||||||
259 | |||||||||||||||||||||||||||||||||||
260 | |||||||||||||||||||||||||||||||||||
261 | |||||||||||||||||||||||||||||||||||
262 | |||||||||||||||||||||||||||||||||||
263 | |||||||||||||||||||||||||||||||||||
264 | |||||||||||||||||||||||||||||||||||
265 | |||||||||||||||||||||||||||||||||||
266 | |||||||||||||||||||||||||||||||||||
267 | |||||||||||||||||||||||||||||||||||
268 | |||||||||||||||||||||||||||||||||||
269 | |||||||||||||||||||||||||||||||||||
270 | |||||||||||||||||||||||||||||||||||
271 | |||||||||||||||||||||||||||||||||||
272 | |||||||||||||||||||||||||||||||||||
273 | |||||||||||||||||||||||||||||||||||
274 | |||||||||||||||||||||||||||||||||||
275 | |||||||||||||||||||||||||||||||||||
276 | |||||||||||||||||||||||||||||||||||
277 | |||||||||||||||||||||||||||||||||||
278 | |||||||||||||||||||||||||||||||||||
279 | |||||||||||||||||||||||||||||||||||
280 | |||||||||||||||||||||||||||||||||||
281 | |||||||||||||||||||||||||||||||||||
282 | |||||||||||||||||||||||||||||||||||
283 | |||||||||||||||||||||||||||||||||||
284 | |||||||||||||||||||||||||||||||||||
285 | |||||||||||||||||||||||||||||||||||
286 | |||||||||||||||||||||||||||||||||||
287 | |||||||||||||||||||||||||||||||||||
288 | |||||||||||||||||||||||||||||||||||
289 | |||||||||||||||||||||||||||||||||||
290 | |||||||||||||||||||||||||||||||||||
291 | |||||||||||||||||||||||||||||||||||
292 | |||||||||||||||||||||||||||||||||||
293 | |||||||||||||||||||||||||||||||||||
294 | |||||||||||||||||||||||||||||||||||
295 | |||||||||||||||||||||||||||||||||||
296 | |||||||||||||||||||||||||||||||||||
297 | |||||||||||||||||||||||||||||||||||
298 | |||||||||||||||||||||||||||||||||||
299 | |||||||||||||||||||||||||||||||||||
300 | |||||||||||||||||||||||||||||||||||
301 | |||||||||||||||||||||||||||||||||||
302 | |||||||||||||||||||||||||||||||||||
303 | |||||||||||||||||||||||||||||||||||
304 | |||||||||||||||||||||||||||||||||||
305 | |||||||||||||||||||||||||||||||||||
306 | |||||||||||||||||||||||||||||||||||
307 | |||||||||||||||||||||||||||||||||||
308 | |||||||||||||||||||||||||||||||||||
309 | |||||||||||||||||||||||||||||||||||
310 | |||||||||||||||||||||||||||||||||||
311 | |||||||||||||||||||||||||||||||||||
312 | |||||||||||||||||||||||||||||||||||
313 | |||||||||||||||||||||||||||||||||||
314 | |||||||||||||||||||||||||||||||||||
315 | |||||||||||||||||||||||||||||||||||
316 | |||||||||||||||||||||||||||||||||||
317 | |||||||||||||||||||||||||||||||||||
318 | |||||||||||||||||||||||||||||||||||
319 | |||||||||||||||||||||||||||||||||||
320 | |||||||||||||||||||||||||||||||||||
321 | |||||||||||||||||||||||||||||||||||
322 | |||||||||||||||||||||||||||||||||||
323 | |||||||||||||||||||||||||||||||||||
324 | |||||||||||||||||||||||||||||||||||
325 | |||||||||||||||||||||||||||||||||||
326 | |||||||||||||||||||||||||||||||||||
327 | |||||||||||||||||||||||||||||||||||
328 | |||||||||||||||||||||||||||||||||||
329 | |||||||||||||||||||||||||||||||||||
330 | |||||||||||||||||||||||||||||||||||
331 | |||||||||||||||||||||||||||||||||||
332 | |||||||||||||||||||||||||||||||||||
333 | |||||||||||||||||||||||||||||||||||
334 | |||||||||||||||||||||||||||||||||||
335 | |||||||||||||||||||||||||||||||||||
336 | |||||||||||||||||||||||||||||||||||
337 | |||||||||||||||||||||||||||||||||||
1 | Active candidate / in development | DNA | Protein: specify | None | Not yet open | Industry | Phase 0 | Results not yet reported | Abstract / Poster / Conference proceedings | Clinical Study Report |
|---|---|---|---|---|---|---|---|---|---|---|
2 | Registered | Inactivated partial (split) target organism | Carbohydrate: specify | Aluminum salts (alum) | Open, recruiting | Academic | Phase 1 | Interim results reported | Non-peer reviewed publication or journal | Non-peer reviewed publication or journal |
3 | Inactive / no longer in development | Inactivated whole target organism | Conjugate: specify antigen & carrier | Licensed other: specify | Open, not recruiting | Government | Phase 2 | Results reported in peer-reviewed journal | Peer-reviewed publication or journal | Peer-reviewed publication or journal |
4 | Research Tool | Live, attenuated target organism | Other: specify | Novel other: specify | Completed | Product Development Partner | Phase 2b | Results reported in registry | Other | Other |
5 | mRNA | Withdrawn | Other | Phase 3 | Results reported in both peer-reviewed journal and registry | |||||
6 | Peptide | Unknown | Phase 4 | |||||||
7 | Prime-boost: specify | Other: specify | ||||||||
8 | Recombinant bacterial vector | |||||||||
9 | Recombinant subunit (non VLP) | |||||||||
10 | Recombinant subunit VLP (fusion) | |||||||||
11 | Recombinant subunit VLP (non-fusion) | |||||||||
12 | Recombinant viral vector | |||||||||
13 | Subunit (e.g., toxoid, carbohydrate) from target organism | |||||||||
14 | Subunit conjugate | |||||||||
15 | Other: specify |
1 | Disease & Pathogen | Vaccine Candidate | Clinical Trial Information | Results Reporting Information | Other | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | Disease | Pathogen | Candidate Vaccine | Candidate Vaccine Status | Platform | Immunogen Type | Immunogen | Adjuvant Type | Adjuvant | Registry ID | Trial Status | Sponsor Name | Sponsor Type | Phase | Study Start date | Primary Completion Date (anticipated or actual) (see notes) | Completion Date (anticipated or actual) (see notes) | Age | Sample Size, Enrollment | Location | Results Reporting Status | Interim Publication Type | Interim Publication Date | Interim Publication Link | Full Publication Type | Full Publication Date | Full Publication Link / PMID | Clinical Trials Registry | Registry Publication Date | Registry Publication Link | Notes | |